

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, 14/52, C12N 15/12, 15/19, 15/63, A61K 38/16, 38/19, 48/00		A1	(11) International Publication Number: WO 99/29728
			(43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/US98/26291			(74) Agent: BARRETT, William, A.; Intellectual Property/Technology Law, P.O. Box 14329, Research Triangle Park, NC 27709 (US).
(22) International Filing Date: 11 December 1998 (11.12.98)			
(30) Priority Data: 60/069,281 11 December 1997 (11.12.97) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/069,281 (CON) Filed on 11 December 1997 (11.12.97)			
(71) Applicant (for all designated States except US): UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE [US/US]; 4321 Hartwick Road, College Park, MD 20740 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): GALLO, Robert, C. [US/US]; 8513 Thornden Terrace, Bethesda, MD 02817 (US). DEVICO, Anthony, L. [US/US]; 4533 Peacock Avenue, Alexandria, VA 22304 (US). GARZINO-DEMO, Alfredo [IT/US]; 601 North Eutaw Street, Baltimore, MD 21201 (US).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>			
(54) Title: METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES			
(57) Abstract The present invention relates to a method to enhance the efficacy of a vaccine in a subject treated with the vaccine comprising administering to the subject in combination with the vaccine a one or more chemokines. The present invention also relates to compositions of vaccines containing chemokines.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES

1. CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Application Serial No. 60/069,281 filed December 11, 1997.

2. BACKGROUND OF THE INVENTION

The present invention relates to a method to enhance the efficacy of a vaccine by administration of a chemokine, such as macrophage derived chemokine (MDC), in conjunction with the vaccine. The present invention also relates to compositions useful in the method.

2.1. GENERATION OF AN IMMUNE RESPONSE

The introduction of a foreign antigen into an individual elicits an immune response consisting of two major components, the cellular and humoral immune responses, mediated by two functionally distinct populations of lymphocytes known as T and B cells, respectively (see generally Coutinho, 1991, Immune System, *Encyclopedia of Human Biology*, Vol. 4, Ed. Dulbecco, Academic Press, Inc.). A subset of T cells responds to antigen stimulation by producing lymphokines which "help" or activate various other cell types in the immune system.

Another T cell subset is capable of developing into antigen-specific cytotoxic effector cells, which can directly kill antigen-positive target cells. On the other hand, the B cell response is primarily carried out by secretory proteins, antibodies, which directly bind and neutralize antigens.

Helper T cells (TH) can be distinguished from classical cytotoxic T lymphocytes (CTL) and B cells by their cell surface expression of the glycoprotein marker CD4. Although the mechanism by which CD4⁺ TH function has not been fully elucidated, the existence of functionally distinct subsets within the CD4⁺ T cell compartment has been reported (Mosmann and Coffman, 1989, *Ann. Rev. Immunol.*

7:145-173). In the mouse, type 1 helper T cells (TH1) produce interleukin-2 (IL-2) and τ -interferon (τ -IFN) upon activation, while type 2 helper T cells (TH2) produce IL-4 and IL-5. Based on the profile of lymphokine production, TH1 appear to be involved in promoting the activation and proliferation of other T cell subsets including CTL, whereas TH2 specifically regulate B cell proliferation and differentiation, antibody synthesis, and antibody class switching.

A second T cell subpopulation is the classical CTL which express the CD8 surface marker. Unlike most TH, these cells display cytolytic activity upon direct contact with target cells, rather than through the production of lymphokines. *In vivo*, CTL function is particularly important in situations where an antibody response alone is inadequate. Significant experimental evidence indicates that CTL rather than B cells and their antibody products play a principal role in the defense against viral infections and cancer.

A salient feature of both T and B cell responses is their exquisite specificity for the immunizing antigen; however, the mechanisms for antigen recognition differ between these two cell types. B cells recognize antigens by antibodies, either acting as cell surface receptors or as secreted proteins, which bind directly to antigens on a solid surface or in solution, whereas T cells only recognize antigens that have been processed or degraded into small fragments and presented on a solid phase such as the surface of antigen-presenting cells (APC). Additionally, antigenic fragments must be presented to T cells in association with major histocompatibility complex (MHC)-encoded class I or class II molecules. The MHC refers to a cluster of genes that encode proteins with diverse immunological functions. In man, the MHC is known as HLA. Class I gene products are found on all somatic cells, and they were originally discovered as targets of major transplantation rejection responses. Class II gene products are mostly expressed on cells of various hematopoietic lineages, and they are involved in cell-cell interactions in the immune system. Most importantly, MHC-encoded proteins have been shown to function as receptors for processed antigenic fragments on the surface of APC (Bjorkman et al., 1987, *Nature* 329:506-512).

Another level of complexity in the interaction between a T cell and an antigenic fragment is that it occurs only if the MHC molecules involved are the same on the APC and the responding T cells. In other words, a T cell specific for a particular antigenic epitope expresses a receptor having low affinity for self MHC

proteins, which when such MHC proteins on APC are occupied by the epitope, engage the T cell in a stronger interaction leading to antigen-specific T cell activation. The phenomenon of a T cell reacting with a processed antigen only when presented by cells expressing a matching MHC is known as MHC-restriction.

The specificity of T cell immune responses for antigens is a function of the unique receptors expressed by these cells. The T cell receptor (TCR) is structurally homologous to an antibody; it is a heterodimer composed of disulfide-linked glycoproteins. Four TCR polypeptide chains known as α , β , τ , and δ have been identified, although the vast majority of functional T cells express the $\alpha\beta$ heterodimeric TCR. Transfer of α and β genes alone into recipient cells was shown to be both necessary and sufficient to confer antigen specificity and MHC-restriction (Dembic et al., 1986, *Nature* 320:232-238). Thus, the $\alpha\beta$ TCR appears to be responsible for recognizing a combination of antigenic fragment and MHC determinants.

The apparent basis of MHC restriction is that $CD4^+$ T cells express $\alpha\beta$ TCR which recognize antigenic fragments physically associated with MHC class II proteins, while the TCR on $CD8^+$ CTL recognize MHC class I-associated fragments. Thus, $CD4^+$ T cells can recognize only a restricted class of APC that are class II⁺, whereas $CD8^+$ CTL can interact with virtually any antigen-positive cells, since all cells express class I molecules. $CD4^+$ CTL have been identified, and they are MHC class II restricted, and lyse target cells only if the latter express self-MHC class II determinants associated with specific antigenic fragments. Both CD4 and CD8 molecules also contribute to this interaction by binding to monotypic determinants on the MHC class II and I molecules, respectively.

A second type of TCR composed of $\tau\delta$ heterodimers is expressed by a small percentage of T cells, but the involvement of $\tau\delta$ T cells in antigen-specific recognition is still poorly understood. Some studies have shown that functionally active $\tau\delta$ T cells can be cytolytic in a MHC non-restricted manner.

In summary, the generation of an immune response begins with the sensitization of $CD4^+$ and $CD8^+$ T cell subsets through their interaction with APC that express MHC-class I or class II molecules associated with antigenic fragments. The sensitized or primed $CD4^+$ T cells produce lymphokines that participate in the activation of B cells as well as various T cell subsets. The sensitized $CD8^+$ T cells increase in numbers in response to lymphokines and are capable of destroying any

cells that express the specific antigenic fragments associated with matching MHC-encoded class I molecules. For example, in the course of a viral infection, CTL eradicate virally-infected cells, thereby limiting the progression of virus spread and disease development.

2.2. ANTIGEN PRESENTING CELLS

The presentation of antigens to T cells is carried out by specialized cell populations referred to as antigen presenting cells (APC). Typically, APC include macrophages/monocytes, B cells, and bone marrow-derived dendritic cells (DC). APC are capable of internalizing exogenous antigens, cleaving them into smaller fragments in enzyme-rich vesicles, and coupling the fragments to MHC-encoded products for expression on the cell surface (Goldberg and Rock, 1992, *Nature* 357:375-379). Since APC express both MHC-encoded class I and class II glycoproteins, they can present antigenic fragments to both CD4⁺ and CD8⁺ T cells for the initiation of an immune response.

By definition, APC not only can present antigens to T cells with antigen-specific receptors, but can provide all the signals necessary for T cell activation. Such signals are incompletely defined, but probably involve a variety of cell surface molecules as well as cytokines or growth factors. Further, the factors necessary for the activation of naive or unprimed T cells may be different from those required for the re-activation of previously primed memory T cells. The ability of APC to both present antigens and deliver signals for T cell activation is commonly referred to as an accessory cell function. Although monocytes and B cells have been shown to be competent APC, their antigen presenting capacities *in vitro* appear to be limited to the re-activation of previously sensitized T cells. Hence, they are not capable of directly activating functionally naive or unprimed T cell populations.

Although it had been known for a long time that APC process and present antigens to T cells, it was not shown until relatively recently that small antigenic peptides could directly bind to MHC-encoded molecules (Babbitt et al., 1985, *Nature* 317:359; Townsend et al., 1986, *Cell* 44:959). However, it is believed that, normally, complex antigens are proteolytically processed into fragments inside the APC, and become physically associated with the MHC-encoded proteins intracellularly prior to

trafficking to the cell surface as complexes. Two distinct pathways for antigen presentation have been proposed (Braciale et al., 1987, *Immunol. Rev.* 98:95-114). It was thought that exogenous antigens were taken up by APC, processed and presented by the exogenous pathway to class II restricted CD4⁺ T cells, while the endogenous pathway processed intracellularly synthesized proteins, such as products of viral genes in virally-infected cells, for association with MHC class I proteins and presentation to CD8⁺ CTL. However, although the two pathways in antigen processing and presentation may still be correct in some respects, the distinction is blurred in light of recent findings that exogenously added antigens may also be presented to class I-restricted CTL (Moore et al., 1988, *Cell* 54:777).

The term "dendritic cells" (DC) refers to a diverse population of morphologically similar cell types found in a variety of lymphoid and non-lymphoid tissues (Steinman, 1991, *Ann. Rev. Immunol.* 9:271-296). These cells include lymphoid DC of the spleen, Langerhans cells of the epidermis, and veiled cells in the blood circulation. Although they are collectively classified as a group based on their morphology, high levels of surface MHC-class II expression, and absence of certain other surface markers expressed on T cells, B cells, monocytes, and natural killer cells, it is presently not known whether they derive from a common precursor or can all function as APC in the same manner. Further, since the vast majority of published reports have utilized DC isolated from the mouse spleen, results from these studies may not necessarily correlate with the function of DC obtained from other tissue types. (Inaba et al., 1997, *J. Exp. Med.* 166:182-194; Hengel et al., 1987, *J. Immunol.*, 139:4196-4202; Kaut et al., 1988, *J. Immunol.*, 140:3186-3193; Romani et al., 1989, *J. Exp. Med.* 169:1169-1178; Macatonia et al., 1989, *J. Exp. Med.* 169:1255-1264; Inaba et al., 1990, *J. Exp. Med.* 172:631-6640). For example, despite high levels of MHC-class II expression, mouse epidermal Langerhans cells, unlike splenic DC, are not active APC in mixed leucocyte reaction (MLR), unless cultured with granulocyte-macrophage colony stimulating factor (GM-CSF) (Witmer-Pock et al., 1987, *J. Exp. Med.* 166:1484-1498; Heufler et al., 1988, *J. Exp. Med.* 167:700-705). Most human Langerhans cells express the CD1 and CD4 markers, while blood DC do not. Additionally, it has not been established the extent to which the functional characteristics observed with mouse DC are applicable to human DC, especially the DC obtained from non-splenic tissues; in part, due to inherent differences between the

human and murine immune systems.

Recently, a few studies have described the isolation of human DC from the peripheral blood, which involves the use of sheep red blood cells and/or fetal calf serum (Young and Steinman, 1990, *J. Exp. Med.* 171:1315-1332; Freudenthal and Steinman, 1990, *Proc. Natl. Acad. Sci. USA* 87:7698-7702; Macatonia et al., 1989 *Immunol.* 67:285-289; Markowicz and Engleman, 1990, *J. Clin. Invest.* 85:955-961). Engleman et al. described a partial purification procedure of DC from human blood, which does not involve the use of sheep red blood cells and/or fetal calf serum, and showed that the partially purified human DC can, in fact, present exogenous antigens to naive T cells (PCT Publication WO 94/02156 dated February 3, 1994 at page 9, lines 5-32).

Recent studies have indicated that DCs are superior APCs as compared to other APCs such as macrophages and monocytes. First, the potent accessory cell function of DCs provides for an antigen presentation system for virtually any antigenic epitopes which T and B cells are capable of recognizing through their specific receptors. For example, Engleman et al. demonstrate that human DCs can present both complex protein antigens and small peptides to CD4⁺ T cells as well as to CD8⁺ CTL (PCT Publication WO 94/02156 dated February 3, 1994, Example 7, from page 29, line 10 to page 34, line 16). Engleman et al. also show that the *in vitro* priming effect of DCs does not require the addition of exogenous lymphokines, indicating that DCs produce all of the necessary signals in antigen presentation leading to the activation of T cells (PCT Publication WO 94/02156 dated February 3, 1994, from page 32, line 36 to page 33, line 2). More importantly, DCs can induce a primary CD4⁺ T cell-mediated proliferative response when similarly prepared monocytes can not induce such a response (PCT Publication WO 94/02156 dated February 3, 1994 at page 31, lines 23-30). Similarly, when DCs and monocytes were compared for their ability to present antigens for re-activating secondary T cell response, it was observed that DCs were capable of stimulating a stronger response than monocytes (PCT Publication WO 94/02156 dated February 3, 1994 at page 32, lines 12-16).

2.3. CHEMOKINES

Chemokines, or chemoattractant cytokines, are a subgroup of immune factors

that have been shown to mediate chemotactic and other pro-inflammatory phenomena (see, Schall, 1991, *Cytokine* 3:165-183). Chemokines are small molecules of approximately 70-80 residues in length and can generally be divided into two subgroups, α which have two N-terminal cysteines separated by a single amino acid (CxC) and β which have two adjacent cysteines at the N terminus (CC). RANTES, MIP-1 α and MIP-1 β are members of the β subgroup (reviewed by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633; Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

MCP-1 has been shown to attract monocytes but not neutrophils. MCP-1, MCP-2, and MCP-3 share a pyroglutamate proline NH₂-terminal motif and are structurally closely related to each other and to eotaxin (56% to 71% amino acid sequence identity). MCP-1, MCP-2, and MCP-3 attract monocytes, CD4⁺ and CD8⁺ T lymphocytes (Loetscher et al. *FAESB J.* 1994, 8:1055-60), as well as basophil leukocytes. MCP-2, MCP-3, and MCP-4 (but not MCP-1) attracts eosinophil leukocytes. All four MCPs attract activated T lymphocytes, natural killer (NK) cells, and dendritic cells (see Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

Eotaxin acts on eosinophils and is inactive on neutrophils and monocytes, but has weak-to-moderate chemotactic activity toward IL-2-conditioned T lymphocytes (see Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705). Due to its preferential, powerful action on eosinophils and its occurrence in different species, eotaxin is considered to be an important chemokine in the pathophysiology of allergic conditions and asthma (See Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

IP10 is a CXC chemokine attracts human monocytes, T lymphocytes, and NK cells, and Mig attracts tumor-infiltrating T lymphocytes. It has been suggested that IP10 and Mig may also be involved in the regulation of lymphocyte recruitment and the formation of the lymphoid infiltrates observed in autoimmune inflammatory lesions, delayed-type hypersensitivity, some viral infections, and certain tumors (Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

SDF-1 (stromal cell-derived factor 1), including SDF-1 and SDF-1 β stimulates the proliferation of B cell progenitors, and attracts mature dendritic cells (Finkel et al. *Immunobiology* 1998, 198:490-500). Synthetic human SDF-1 stimulates monocytes, neutrophils, and peripheral blood lymphocytes, as is indicated by [Ca²⁺]_i changes and chemotaxis. SDF-1 is also a powerful HIV-suppressive factor (See Baggiolini et al.

Annu. Rev. Immunol. 1997, 15:675-705).

The amino terminus of the β chemokines RANTES, MCP-1, and MCP-3 has been implicated in the mediation of cell migration and inflammation induced by these chemokines. This involvement is suggested by the observation that the deletion of the amino terminal 8 residues of MCP-1, amino terminal 9 residues of MCP-3, and amino terminal 8 residues of RANTES and the addition of a methionine to the amino terminus of RANTES, antagonize the chemotaxis, calcium mobilization and/or enzyme release stimulated by their native counterparts (Gong et al., 1996, *J. Biol. Chem.* 271:10521-10527; Proudfoot et al., 1996 *J. Biol. Chem.* 271:2599-2603). Additionally, α chemokine-like chemotactic activity has been introduced into MCP-1 via a double mutation of Tyr 28 and Arg 30 to leucine and valine, respectively, indicating that internal regions of this protein also play a role in regulating chemotactic activity (Beall et al., 1992, *J. Biol. Chem.* 267:3455-3459).

The monomeric forms of all chemokines characterized thus far share significant structural homology, although the quaternary structures of α and β groups are distinct. While the monomeric structures of the β and α chemokines are very similar, the dimeric structures of the two groups are completely different. An additional chemokine, lymphotactin, which has only one N terminal cysteine has also been identified and may represent an additional subgroup (γ) of chemokines (Yoshida et al., 1995, *FEBS Lett.* 360:155-159; and Kelner et al., 1994, *Science* 266:1395-1399).

Receptors for chemokines belong to the large family of G-protein coupled, 7 transmembrane domain receptors (GCR's) (See, reviews by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; and Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633). Competition binding and cross-desensitization studies have shown that chemokine receptors exhibit considerable promiscuity in ligand binding. Examples demonstrating the promiscuity among β chemokine receptors include: CCR-1, which binds RANTES and MIP-1 α (Neote et al., 1993, *Cell* 72:415-425), CCR-4, which binds RANTES, MIP-1 α , and MCP-1 (Power et al., 1995, *J. Biol. Chem.* 270:19495-19500), and CCR-5, which binds RANTES, MIP-1 α , and MIP-1 β (Alkhatib et al., 1996, *Science* 272:1955-1958 and Dragic et al., 1996, *Nature* 381:667-674). Erythrocytes possess a receptor (known as the Duffy antigen) which binds both α and β chemokines (Horuk et al., 1994, *J. Biol. Chem.* 269:17730-17733; Neote et al., 1994, *Blood* 84:44-52; and Neote et al., 1993, *J. Biol. Chem.* 268:12247-12249). Thus the sequence and

structural homologies evident among chemokines and their receptors allow some overlap in receptor-ligand interactions.

Godiska et al. identified and described the nucleic acid and amino acid sequences of an additional β chemokine designated macrophage derived chemokine (MDC) (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). PCT publication WO 96/40923 further provides materials and methods for the recombinant production of the chemokine, the purified and isolated chemokine protein, and polypeptide analogues thereof. The PCT publication WO 96/40923 does not disclose that the human MDC has chemotactic activity upon DC. While Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604) showed that, in a microchamber migration assay, monocyte-derived DC migrated toward the human MDC, the reference fails to teach that MDC can enhance an immune response to an antigen *in vivo*.

Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237), isolated a stimulated T cell chemotactic protein (STCP-1) from an activated macrophage cDNA library. The nucleotide sequence of the STCP-1 is identical to that of the MDC isolated by Godiska et al. (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). However, unlike the results observed by Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604), Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237) showed that although the STCP-1 acted as a mild chemoattractant for primary activated T lymphocytes and a potent chemoattractant for chronically activated T lymphocytes, the STCP-1 has no chemoattractant activity for monocytes, neutrophils, eosinophils and resting T lymphocytes. Chang et al. further showed that the STCP-1 does not induce Ca^{2+} mobilization in monocytes, dendritic cells, neutrophils, eosinophils, lipopolysaccharide-activated B lymphocytes, and freshly isolated resting T lymphocytes.

2.4. HIV VACCINES

Human immunodeficiency virus (HIV) induces a persistent and progressive infection leading, in the vast majority of cases, to the development of the acquired immunodeficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983, *Science* 220:868-870; Gallo et al., 1984, *Science* 224:500-503). The HIV envelope surface glycoproteins are

synthesized as a single 160 kilodalton precursor protein which is cleaved by a cellular protease during viral budding into two glycoproteins, gp41 and gp120. gp41 is a transmembrane glycoprotein and gp120 is an extracellular glycoprotein which remains non-covalently associated with gp41, possibly in a trimeric or multimeric form (Hammerskjold, M. and Rekosh, D., 1989, *Biochem. Biophys. Acta* 989:269-280). The V3 loop of gp120 is the major determinant of sensitivity to chemokine inhibition of infection or replication (Cocchi et al., 1996, *Nature Medicine* 2:1244-1247; and Oravec et al., 1996, *J. Immunol.* 157:1329-1332).

Although considerable effort is being put into the design of effective therapeutics, currently no curative anti-retroviral drugs against AIDS exist. The HIV-1 envelope proteins (gp160, gp120, gp41) have been shown to be the major antigens for neutralizing anti-HIV antibodies present in AIDS patients (Barin et al., 1985, *Science* 228:1094-1096). Thus far, therefore, these proteins seem to be the most promising candidates to act as antigens for anti-HIV vaccine development. Several groups have begun to use various portions of gp160, gp120, and/or gp41 as immunogenic targets for the host immune system (see, for example, Ivanoff et al., U.S. Pat. No. 5,141,867; Saith et al., PCT publication WO 92/22654; Shafferman, A., PCT publication WO 91/09872; Formoso et al., PCT publication WO 90/07119). Therefore, methods to increase the efficacy of vaccines against HIV, especially vaccines using gp120 as the antigen, are needed.

Additionally a novel vaccine technology, designated genetic vaccination, nucleic acid vaccination or DNA vaccination, has been explored to induce immune responses *in vivo*. Injection of cDNA expression cassettes results in *in vivo* expression of the encoded proteins (Dubensky et al., 1984, *Proc. Natl. Acad. Sci. USA* 81:7529-7533; Raz et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4523; Wolff et al., 1990, *Science* 247:1465-1468), with the concomitant development of specific cellular and humoral immune responses directed against the encoded antigen(s) (Wang et al., 1995, *Hum. Gene Ther.* 6:407-418; Ulmer et al., 1993, *Science* 259:1745-1749; Tang et al., 1992, *Nature* 356:152-154; Michel et al., 1995, *Proc. Natl. Acad. Sci. USA* 92:5307-5311; and Lowrie et al., 1994, *Vaccine* 12:1537-1540). Humoral and cellular responses have been induced to HIV-1 and SIV antigens through various applications of this technology in macaques (Wang et al., 1995, *Virology* 221:102-112; Wang et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4156-4160; and Boyer et al., 1996, *J. Med.*

Primatol. 25:242-250) as well as mice (Wang et al., 1995, *Virology* 221:102-112; Lu et al., 1995, *Virology* 209:147-154; Haynes et al., 1994, *AIDS Res. Hum. Retroviruses* 10 (Suppl. 2):S43-S45; Okuda et al., 1995, *AIDS Res. Hum. Retroviruses* 11:933-943).

Recently, Lekutis et al. (1997, *J. Immunol.* 158:4471-4477), assessed the TH cell response elicited by an HIV-1 gp120 DNA vaccine in rhesus monkeys by isolation of gp120-specific, MHC class II-restricted CD4⁺ T cell lines from the vaccinated animals. Lekutis et al. showed that the isolated cell lines proliferated in response to APC in the presence of recombinant gp120, as well as to APC expressing HIV encoded env protein. Lekutis et al. further showed that these cell lines responded to env by secreting IFN- γ and IFN- α without appreciable IL-4 production. These results demonstrate that the animals exhibited a cellular immune response to the DNA vaccine.

Boyer et al. (1997, *Nature Medicine* 3:625-532), inoculated chimpanzees with an HIV-1 DNA vaccine encoding env, rev, and gag/pol, and found that the immunized animals developed specific cellular and humoral immune responses to these proteins. After challenging the immunized animals with a heterologous chimpanzee titrated stock of HIV-1 SF2, Boyer et al. further found, using a Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay, that those animals vaccinated with the DNA vaccine were protected against infection whereas the control animals were not so protected.

Kim et al., (1997 *J. Immunol.* 158:816-826), investigated the role of co-delivery of genes for IL-12 and GM-CSF along with DNA vaccine formulation for HIV-1 antigens env and gag/pol in mice. Kim et al. observed a dramatic increase in specific CTL response from the mice immunized with the HIV-1 DNA vaccine and IL-12. Kim et al. also observed that the co-delivery of IL-12 genes resulted in the reduction of specific antibody response, whereas the codelivery of GM-CSF genes resulted in the enhancement of specific antibody response. Kim et al. further observed that co-delivery of IL-12 gene with a HIV DNA vaccine results in splenomegaly (Kim et al. 1997, *J. Immunol.*, 158:816-826), which has been shown in mice to have toxic effects such as weight reduction or even death (Eng et al., 1995, *J. Exp. Med.* 181:1893; Stevensen et al., 1995, *J. Immunol.* 155:2545; and Orange et al., 1995, *J. Exp. Med.* 181:901).

Notwithstanding the recent developments of the HIV DNA vaccine, there still

exists a need for a method to enhance the efficacy of a vaccine, especially an HIV DNA vaccine. For instance, for efficacious vaccine against HIV-1 one preferably induces both cellular and humoral immune responses to control the infection (Boyer et al., 1997, *Nature Medicine* 3:625-532). The induction of both cellular and humoral immune response by the Berjer et al. method is still quite low because only one of the three immunized chimpanzees developed both cellular and humoral responses. Similarly, although co-delivery of an IL-12 encoding gene with a HIV DNA vaccine, as described in Kim et al. (1997, *J. Immun.* 158:816-826), may have enhanced the cellular immune response, this co-delivery also decreased the humoral response.

Citation of a reference hereinabove shall not be construed as an admission that such reference is prior art to the present invention.

3. SUMMARY OF THE INVENTION. SUMMARY OF THE INVENTION. . SUMMARY OF THE INVENTION

The present invention is based upon the ability of chemokines, such as MDC, Rantes, MIP-1d, MIP-1B, and I-309, to enhance the immune response to an antigen, particularly a vaccine. Accordingly, in a first aspect, the present invention provides a method for enhancing the efficacy of a vaccine, which method comprises administration to a subject of one or more purified chemokines, or biologically active fragments, analogues or derivatives thereof, either concurrently with one or more purified antigens against which an immune response is desired or within a time period either before or after administration of the antigens such that the immune response against the antigens is enhanced.

In a second aspect, the present invention provides a method to enhance the efficacy of a vaccine, which method comprises administration to a subject of a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments, derivatives, analogues, and/or truncation isoforms thereof, and a second purified nucleic acid comprising a nucleotide sequence encoding one or more antigens against which an immune response is desired, such that, the one or more chemokine(s) and the antigen(s) are expressed in a coordinated manner upon introduction into a suitable cell. Alternatively, the nucleotide sequences encoding one or more chemokines, or

fragments, derivatives, and/or analogues thereof, and the antigens against which an immune response is desired are present on the same nucleic acid.

In a preferred embodiment, the invention provides a method to enhance the efficacy of an HIV vaccine.

In yet another aspect, the present invention provides a composition comprising an immunogenic amount of one or more purified antigens, an amount of one or more purified chemokines, or a fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response to the antigen. In another aspect, the present invention provides a composition comprising a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, fragments, derivatives analogues and or truncation isoforms thereof, and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens against which an immune response is desired, such that, the chemokine(s) and the antigen are expressed in a coordinated manner upon introduction into a suitable cell. In a preferred embodiment, the antigen is an HIV antigen. In another preferred embodiment, the chemokine is selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha

chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

4. DESCRIPTION OF FIGURES

Figures 1A and 1B. The nucleotide and amino acid sequences of MDC. 1A depicts the nucleotide sequence of MDC (SEQ ID NO:1), with the coding region indicated by the appearance of the amino acid sequence in the line below; and 1B depicts the amino acid of MDC (SEQ ID NO:2) from GenBank accession no. U83171 (Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604).

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method for enhancing the efficacy of a vaccine in a subject comprising administering to the subject one or more purified antigens in conjunction with one or more purified chemokines, or more purified fragments, derivatives or analogues and/or truncation isoforms thereof.

While any chemokine may be employed according to the present invention, the chemokine is preferably selected from the following table:

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines	Macrophage-derived chemokine	MDC/STCP-1	u83171; u83239
	Monocyte chemotactic protein 1	MCP-1	x14768
	Monocyte chemotactic protein 2	MCP-2	X99886
	Monocyte chemotactic protein 3	MCP-3	x72308; s57464
	Monocyte chemotactic protein 4	MCP-4	u46767
	activated macrophage specific chemokine 1	AMAC-1	Y13710
	Macrophage inflammatory protein 1 alpha	MIP-1 α	AF043339; X03754; D90144

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Macrophage inflammatory protein 1 beta	MIP-1 β	j04130; d90145
	Macrophage inflammatory protein 1 gamma	MIP-1 γ	
	Macrophage inflammatory protein 1 delta	MIP-1 δ	AF031587
	Macrophage inflammatory protein 2 alpha	MIP-2 α	AF043340
	Macrophage inflammatory protein 3 alpha	MIP-3 α	u77035
	Macrophage inflammatory protein 3 beta	MIP-3 β	u77180
	Regulated upon activation, normal T cell expressed and secreted (and its variants)	RANTES	M21211
	I-309		M57502
	EBI1-ligand chemokine	ELC	AB000887
	Pulmonary and activation-regulated chemokine	PARC/DC-CK-1/MIP4	AB000221
	Liver and activation-regulated chemokine	LARC	D86955
	Thymus and activation regulated chemokine	TARC	D43767
	Eotaxin (and variants)		D49372; Z69291; Z75669; Z75668
	Human chemokine 1	HCC1; NCC2	Z49270; z49269
	Human chemokine 2	HCC2; NCC3, MIP-5, MIP-1 δ	Z70292
	Human chemokine 3	HCC3	Z70293
	IL-10-inducible chemokine	HCC4	U91746
	liver-expressed chemokine	LEC; HCC4; NCC4	AB007454
	6Ckine		AF001979
	Exodus 1		u64197
	Exodus 2		U88320
	Exodus 3		U88321
	thymus-expressed chemokine	TECK	U86358
	Secondary Lymphoid tissue chemokine	SLC	AB002409

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Lymphocyte and Monocyte chemoattractant; Monotactin	LMC	AF055467
	Activation-induced, chemokine-related molecule	ATAC	x86474
	Myeloid progenitor inhibitory factor-1	MPIF-1; MIP-3 or ckbeta8	u85767
	Myeloid progenitor inhibitory factor-2	MPIF-2	u85768
	Stromal cell-derived factor 1 alpha	SDF-1 α ; PBSF	L36034
CXC chemokines	Stromal cell-derived factor 1 beta	SDF-1 β ; PBSF	L36033
	B-cell-attracting chemokine 1	BLC	AJ002211
	HuMIG		x72755 s60728
	H174		AF002985
	Interferon-stimulated T-cell alpha chemoattractant	I-TAC	AF030514
	Interleukin-8	IL-8	m17017; y00787
	IP-10		X02530
	platelet factor 4	PF4	M20901
	growth-regulated gene-alpha	GRO- α	J03561
	growth-regulated gene-beta	GRO- β	M36820
	growth-regulated gene-gamma	GRO- γ	M36821
	Neutrophil-activating protein 2	NAP-2; CTAP-3	M54995; M38441
	ENA-78		L37036
	granulocyte chemotactic protein 2	GCP-2	Y08770
C-CHEMOKINES	LYMPHOTACTIN	SCM-1	D63789 D63790
CX3C-CHEMOKINES	Fractalkine/neurotactin		U91835 U84487

The present invention also relates to the use of fragments, analogues and derivatives of the foregoing chemokines, as well as truncation isoforms of such chemokines which are known in the art.

The present invention also relates to therapeutic compositions comprising one or more chemokines, nucleic acids encoding one or more chemokines, derivatives, analogues, and/or truncation isoforms thereof, and nucleic acids encoding the same, that are effective to enhance the immune response of a subject to a vaccine.

In another preferred embodiment of the invention, nucleic acids comprising

nucleotide sequences encoding one or more chemokines or fragments or derivatives, including truncation isoforms, thereof, and encoding one or more antigens against which an immune response is desired, which coding sequences are operatively linked to gene regulatory sequences capable of directing the expression of the one or more chemokines and the one or more antigens upon introduction into a suitable cell, for example, but not limited to, the cell (of a subject), are administered to a subject such that the one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, and one or more antigens, are expressed in the subject.

For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections which follow.

5.1. METHODS AND COMPOSITIONS TO ENHANCE THE EFFICACY OF A VACCINE

The present invention provides methods for enhancing the efficacy of a vaccine in a subject, which methods comprise administering to a subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject in conjunction with an amount of one or more purified chemokines, or fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response against the antigen. In one aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered to the subject concurrently with (e.g., in the same composition with) the purified antigen or antigens against which an immune response is desired. In another, aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered either before or after the administration of one or more purified antigens against which immunity is desired in the subject, but is administered within such time that the chemokine(s) enhance the immune response to the one or more antigens. For example, but not by way of limitation, the purified chemokine(s) are administered during the time that the subject mounts an immune response against the administered one or more antigens, or, the purified MDC is administered within, for example, but not limited to, 30 minutes, 1 hour, 5 hours, 10 hours, 1 day, 2 days of (preferably, after) administration of the one or more purified antigens against which immunity is desired.

In a preferred embodiment, the present invention provides compositions comprising an immunogenic amount of one or more purified antigens and an amount of purified MDC, or one or more fragments, derivatives or analogues thereof, effective to enhance the immune response to said antigen and, preferably, the composition further comprises a pharmaceutically acceptable carrier.

A preferred chemokine for use in the methods and compositions of the present invention is any MDC protein, fragment or derivative thereof, that is capable of enhancing the efficacy of a vaccine (for example, but not limited to, as determined by the assays described in Section 5.4, *infra*). In one specific embodiment, the MDC is purified full length MDC, preferably full length MDC having the amino acid sequence of SEQ ID NO: 2 (Figure 1B). In another embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 2-69 of SEQ ID NO: 2 (Figure 1B). In another specific embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 3-69 of SEQ ID NO: 2 (Figure 1B). In still another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (SEQ ID NO:2), which derivative has activity to enhance the efficacy of the vaccine. In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (SEQ ID NO:2), which derivative has activity to enhance the efficacy of the vaccine.

In yet another specific embodiment, the chemokine is a purified derivative of the protein, which derivative has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. In yet another specific

embodiment, the chemokine is a purified derivative of the protein that has only one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. The chemokines useful in the present invention may be derived from any suitable source and obtained by any method known in the art, for example but not limited to the methods described in Section 5.2 *infra*.

Preferably, the chemokine(s) are of the same species as the subject to which the vaccine is administered. In a preferred embodiment, one or more human chemokines are administered to a human subject, e.g., human MDC is administered to a human subject, alone or in combination with another chemokine.

The present invention also provides a method to enhance the efficacy of a vaccine in a subject, which method comprises administering to a subject a purified first nucleic acid comprising a nucleotide sequence encoding an antigen against which an immune response is desired in a subject and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragment(s), derivative(s) or analogue(s) thereof, where the expression of the encoded antigen(s) and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are under control of one or more appropriate gene regulatory elements (which regulatory elements can be any regulatory element known in the art, for example, but not limited to, those regulatory elements described in Section 5.2 *supra*), such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are coordinately expressed, *i.e.*, are expressed either at the same time or within an appropriate time period (*i.e.*, sufficient for the chemokine(s) to enhance the immune response against the antigen relative to a corresponding immune response in the absence of the chemokine) and the antigen(s) are expressed in an immunogenic amount and the chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are expressed in an amount sufficient to enhance the immune response against the antigen(s). In a specific embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen are present on separate nucleic acids. In another embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen(s) are present on the same nucleic acid.

The present invention also provides compositions to enhance the

efficacy of a vaccine in a subject, which compositions comprise a purified first nucleic acid comprising a nucleotide sequence encoding one or more antigen(s) and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, wherein the nucleotide sequences encoding the antigens and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens and a purified second set of one or more purified nucleic acids comprising a nucleotide sequence encoding one or more chemokines, or fragments, analogues, derivatives, (including truncation isoforms) thereof, wherein the nucleotide sequence(s) encoding the antigen(s) and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second sets of nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified nucleic acid comprising a first set of one or more nucleotide sequences encoding one or more antigens and a second set of one or more nucleotide sequence encoding one or more chemokines, or fragments, derivatives, or analogues thereof (including truncation isoforms), wherein the first and second sets of nucleotide sequences are operably linked to one or more gene regulatory elements such that, upon introduction into a suitable cell, the antigen(s) and the chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are

expressed in an amount effective to enhance the immune response against the antigen(s).

Any nucleic acid comprising a nucleotide sequence encoding one or more chemokine proteins, or fragments or derivatives, thereof (including truncation isoforms), that are capable of enhancing the immune response to the antigen (for example, but not limited to, as determined by any of the assays described in Section 5.2., *infra*) can be used in the methods and compositions of the present invention.

In a preferred embodiment, the nucleotide sequence encodes MDC. In another embodiment, the MDC-encoding nucleotide consists of the nucleotide sequence of SEQ ID NO:1 (Figure 1A). In another specific embodiment, the method or composition of the invention uses a nucleic acid encoding an MDC derivative having deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the immune response against an antigen in a subject.

Such compositions of nucleic acids encoding an antigen are often referred to as DNA vaccines.

Such DNA vaccines are produced by any method known in the art for constructing an expression plasmid vector containing the nucleotide sequences of the antigen(s) and/or chemokine(s) to be expressed which vector is suitable for expression of the encoded proteins in the subject or in cells recombinant for the expression vector, which cells are to be provided to the subject. Such expression vectors may contain various promoters, terminators and polyadenylation coding regions to control the expression of the encoded protein.

The DNA vaccine can be administered by any method known in the art for administration of DNA. The DNA vaccine may be delivered either directly, in which case the subject is directly exposed to the DNA vaccine such that the DNA enters and is expressed in cells of the subject, or indirectly, in which case, the DNA vaccine is first introduced into suitable cells by any method known in the art *in vitro*, then the cells containing the DNA vaccine are transplanted into the subject.

In a specific embodiment, the DNA vaccine is directly administered *in vivo*, where it is expressed to produce the encoded antigens and chemokine(s). This can be accomplished by any of numerous methods known in the art, e.g., by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or

other viral vector (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see e.g., Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In a preferred embodiment, the nucleic acid of a DNA vaccine is injected into the muscle of the subject to be immunized.

Another approach is to introduce the nucleic acid of the DNA vaccine into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign nucleic acid into cells (see e.g., Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen et al., *Meth. Enzymol.* 217:618-644 (1993); Cline, *Pharmac. Ther.* 29:69-92 (1985)) and may be used in accordance with the present invention. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene.

Cells into which a DNA vaccine can be introduced for purposes of immunization encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

The resulting recombinant cells can be delivered to a subject by various

methods known in the art. In a preferred embodiment, the recombinant cells are injected, e.g., subcutaneously. In another embodiment, recombinant skin cells may be applied as a skin graft onto the patient. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The cells can also be encapsulated in a suitable vehicle and then implanted in the subject (see, e.g., Dionne et al. PCT Publication WO 92/19195, dated November 12, 1992). The amount of cells envisioned for use depends on the desired effect, subject state, etc., and can be determined by one skilled in the art.

By way of example, and not by way of limitation a DNA vaccine may be generated as described by Lekutis et al. for an HIV DNA vaccine (1997, *J. Immunol.* 158:4471-4477). Briefly, an expression vector is constructed with the promoter, enhancer and intron A of human cytomegalovirus (CMV) and the termination and polyadenylation sequences of bovine growth hormone in a plasmid backbone. Additionally, the nucleotide sequence for signal sequence of tissue plasminogen activator is either substituted for the signal sequence of the antigen, if the antigen has a signal sequence or is added onto the amino-terminus of the antigen, thereby eliminating the dependence on viral proteins for expression (e.g., in the case of gp120 expression, rev and env proteins are required unless the HIV-1 signal sequence is so substituted). The resulting formulation is then injected intra-muscularly.

Further examples of DNA vaccines are set forth in Boyer et al. (1996, *J. Med. Primatol.*, 25:242-250), which describes the construction of a plasmid encoding the HIV-1 gp160 envelope glycoprotein as well as the rev-tax region cloned into pMAMneoBlue vector (Clontech, Inc., Palo Alto, CA), and a vector encoding the envelope glycoprotein and rev from HIV-1 strain MN under the control of the CMV promoter. Another vector which can be used in the present invention is as described in Boyer et al. (1997, *Nature Medicine* 3:526-532) and contains expression cassettes encoding the envelope and Rev proteins of HIV-1 strain MN, and encoding the Gag/Pol proteins of HIV-1 strain IIIB.

For the practice of the present invention, the nucleotide sequence for the one or more chemokines, or fragments, derivatives, or analogues thereof, can either be incorporated into the same expression vector containing the nucleotide sequence encoding the antigen in such a manner that the chemokine(s) are expressed. Alternatively, the nucleotide sequence encoding the chemokine(s), or fragment(s),

derivative(s) or analogue(s) thereof, can be cloned into a separate expression vector (e.g., as described above for the expression vector containing the sequences coding for antigen) and the expression vector that expresses the antigen(s) mixed with the expression vector that expresses the chemokine(s). The mixture of the two expression vectors can then be administered to the subject.

The methods and compositions of the present invention may be used as a vaccine in a subject in which immunity for the antigen(s) is desired. Such antigens can be any antigen known in the art to be useful in a vaccine formulation. The methods and compositions of the present invention can be used to enhance the efficacy of any vaccine known in the art. The vaccine of the present invention may be used to enhance an immune response to infectious agents and diseased or abnormal cells, such as but not limited to bacteria, parasites, fungi, viruses, tumors and cancers. The compositions of the invention may be used to either treat or prevent a disease or disorder amenable to treatment or prevention by generating an immune response to the antigen provided in the composition. In one preferred embodiment, the antigen(s) are proteins, fragments or derivatives, including truncation isoforms, thereof, encoded by any genes of the HIV genome including the *env*, *gag*, *pol*, *nef*, *vif*, *rev*, and *tat* genes. In a more preferred embodiment, the antigen is an HIV-associated gp120 protein.

The methods and compositions of the present invention may be used to elicit a humoral and/or a cell-mediated response against the antigen(s) of the vaccine in a subject. In one specific embodiment, the methods and compositions elicit a humoral response against the administered antigen in a subject. In another specific embodiment, the methods and compositions elicit a cell-mediated response against the administered antigen in a subject. In a preferred embodiment, the methods and compositions elicit both a humoral and a cell-mediated response.

The subjects to which the present invention is applicable may be any mammalian or vertebrate species, which include, but are not limited to, cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats, monkeys, rabbits, chimpanzees, and humans. In a preferred embodiment, the subject is a human. The compositions and methods of the invention can be used to either prevent a disease or disorder, or to treat a particular disease or disorder, where an immune response against a particular antigen or antigens is effective to treat or prevent the

disease or disorder. Such diseases and disorders include, but are not limited to, viral infections, such as HIV, CMV, hepatitis, herpes virus, measles, etc, bacterial infections, fungal and parasitic infections, cancers, and any other disease or disorder amenable to treatment or prevention by eliciting an immune response against a particular antigen or antigens. In another preferred embodiment, the subject is infected or at risk of being infected with HIV virus.

In another preferred embodiment the invention provides methods and compositions to enhance the efficacy of an HIV vaccine, such a vaccine can be administered to either prevent or treat HIV.

5.2. CHEMOKINE GENES AND PROTEINS

Chemokine proteins and nucleic acids can be obtained by any method known in the art. Chemokine nucleotide and amino acid sequences are available in public databases such as Genbank and are also published in various references known to those of skill in the art. The gene bank accession numbers for the preferred chemokines of the present invention are provided in Table I, in Section 5 above. The ensuing discussion uses MDC by way of example, but applies equally to other chemokines as well.

The MDC nucleotide and amino acid sequences for, *inter alia*, human, are available in the public databases (e.g. Genbank accession No. U83171) also published in Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604. The nucleotide sequence and the amino acid sequence for the human MDC are provided in Figures 1A and B (SEQ ID NOS:1 and 2, respectively).

Chemokines used herein include, but are not limited to, chemokines from mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, and human. In one preferred embodiment, the chemokine is of human origin.

Any vertebrate cell potentially can serve as the nucleic acid source for the isolation of chemokine nucleic acids. The nucleic acid sequences encoding the chemokine(s) can be isolated from vertebrate, mammalian, human, porcine, bovine, feline, avian, equine, canine, as well as additional primate sources, etc. The DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a

DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (see, for example, Sambrook et al., 1989, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

In the molecular cloning of the gene from cDNA, cDNA is generated from totally cellular RNA or mRNA by methods that are well known in the art. The gene may also be obtained from genomic DNA, where DNA fragments are generated (e.g. using restriction enzymes or by mechanical shearing), some of which will encode the desired gene. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once the DNA fragments are generated, identification of the specific DNA fragment containing all or a portion of the chemokine gene may be accomplished in a number of ways.

A preferred method for isolating a chemokine gene is by the polymerase chain reaction (PCR), which can be used to amplify the desired chemokine sequence in a genomic or cDNA library or from genomic DNA or cDNA that has not been incorporated into a library. Oligonucleotide primers which would hybridize to chemokine sequences can be used as primers in PCR.

Additionally, a portion of the chemokine (of any species) gene or its specific RNA, or a fragment thereof, can be purified (or an oligonucleotide synthesized) and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton, W. and Davis, R., 1977, *Science* 196:180; Grunstein, M. And Hogness, D., 1975, *Proc. Natl. Acad. Sci. U.S.A.* 72:3961). Those DNA fragments with substantial homology to the probe will hybridize. Chemokine nucleic acids can be also identified and isolated by expression cloning using, for example, anti-chemokine antibodies for selection.

Alternatives to obtaining the chemokine DNA by cloning or amplification

include, but are not limited to, chemically synthesizing the gene sequence itself from the known chemokine sequence or making cDNA to the mRNA which encodes the chemokine protein. Other methods are possible and within the scope of the invention. Once a clone has been obtained, its identity can be confirmed by nucleic acid sequencing (by any method well known in the art) and comparison to known chemokine sequences. DNA sequence analysis can be performed by any techniques known in the art, including but not limited to the method of Maxam and Gilbert (1980, Meth. Enzymol. 65:499-560), the Sanger dideoxy method (Sanger, F., et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463), the use of T7 DNA polymerase (Tabor and Richardson, U.S. Patent No. 4,795,699), use of an automated DNA sequenator (e.g., Applied Biosystems, Foster City, CA) or the method described in PCT Publication WO 97/ 15690.

Nucleic acids which are hybridizable to a chemokine nucleic acid, or to a nucleic acid encoding a chemokine derivative can be isolated, by nucleic acid hybridization under conditions of low, high, or moderate stringency (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. USA 78:6789-6792). For example, the nucleic acid of SEQ ID No: 1 is hybridizable to an MDC nucleic acid.

Chemokine proteins and derivatives, analogs and fragments of chemokine proteins can be obtained by any method known in the art, including but not limited to recombinant expression methods, purification from natural sources, and chemical synthesis.

For example, chemokines can be obtained by recombinant protein expression techniques. For recombinant expression, the chemokine gene or portion thereof is inserted into an appropriate cloning vector for expression in a particular host cell. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives or the Bluescript vector (Stratagene). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site

desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and chemokine gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionation, can be done before insertion into the cloning vector.

In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated chemokine gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

The nucleotide sequence coding for a chemokine protein or a functionally active analog or fragment or other derivative thereof, can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals can also be supplied by the native chemokine gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein

coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of nucleic acid sequence encoding a chemokine protein or peptide fragment may be regulated by a second nucleic acid sequence so that the chemokine protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a chemokine protein may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control chemokine expression include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42); prokaryotic expression vectors such as the β -lactamase promoter (Villa-Komaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25); see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), beta-globin gene control region

which is active in myeloid cells (Mogam et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).

For example, a vector can be used that comprises a promoter operably linked to an chemokine-encoding nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene).

In a specific embodiment, an expression construct is made by subcloning a chemokine coding sequence into the *EcoRI* restriction site of each of the three pGEX vectors (Glutathione S-Transferase expression vectors; Smith and Johnson, 1988, Gene 7:31-40). This allows for the expression of the chemokine protein product from the subclone in the correct reading frame.

Expression vectors containing chemokine gene inserts can be identified by three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a chemokine gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted chemokine gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of a chemokine gene in the vector. For example, if the chemokine gene is inserted within the marker gene sequence of the vector, recombinants containing the chemokine insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the chemokine protein in *in vitro* assay systems, e.g., binding with anti-chemokine antibody or the chemokine's receptor.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host

system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered protein may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation of proteins). Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions to different extents.

In other specific embodiments, the chemokine protein(s), fragment(s), analogue(s), or derivative(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer. In a specific embodiment, a chimeric protein containing all or a portion of the chemokine is joined via a peptide bond to all or a portion of an antigen against which immunity is desired.

Both cDNA and genomic sequences can be cloned and expressed.

The chemokine protein(s) may also be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column

chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. The functional properties may be evaluated using any suitable assay (see Section 5.5). Alternatively, the protein can be synthesized by standard chemical methods known in the art (e.g., see Hunkapiller, M., et al., 1984, *Nature* 310:105-111). The chemokine-encoding nucleic acid sequence(s) can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions. Any technique for mutagenesis known in the art can be used, including, but not limited to, *in vitro* site-directed mutagenesis (Hutchinson et al., 1978, *J. Biol. Chem.* 253:6551), use of TAB linkers (Pharmacia), mutation-containing PCR primers, etc.

The experimentation involved in mutagenesis consists primarily of site-directed mutagenesis followed by phenotypic testing of the altered gene product. Some of the more commonly employed site-directed mutagenesis protocols take advantage of vectors that can provide single stranded as well as double stranded DNA, as needed. Generally, the mutagenesis protocol with such vectors is as follows. A mutagenic primer, i.e., a primer complementary to the sequence to be changed, but consisting of one or a small number of altered, added, or deleted bases, is synthesized. The primer is extended *in vitro* by a DNA polymerase and, after some additional manipulations, the now double-stranded DNA is transfected into bacterial cells. Next, by a variety of methods, the desired mutated DNA is identified, and the desired protein is purified from clones containing the mutated sequence. For longer sequences, additional cloning steps are often required because long inserts (longer than 2 kilobases) are unstable in those vectors. Protocols known to those skilled in the art and kits for site-directed mutagenesis are widely available from biotechnology supply companies, for example from Amersham Life Science, Inc. (Arlington Heights, IL) and Stratagene Cloning Systems (La Jolla, CA).

In other specific embodiments, the chemokine derivative(s) or analogue(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analogue, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art.

In addition, chemokine proteins, derivatives (including fragments and chimeric proteins), and analogues can be chemically synthesized. See, e.g., Clark-Lewis et al., 1991, *Biochem.* 30:3128-3135 and Merrifield, 1963, *J. Amer. Chem. Soc.* 85:2149-2156. For example, chemokines, derivatives and analogues can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 50-60). Chemokines, derivatives and analogues that are proteins can also be synthesized by use of a peptide synthesizer. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 34-49).

The chemokine proteins, derivatives, or analogues of the invention may be synthesized in their entirety by the sequential addition of amino acid residues or alternatively as fragment subcomponents which may be combined using techniques well known in the art, such as, for example, fragment condensation (Shin et al., 1992, *Biosci. Biotech. Biochem.* 56:404-408; Nyfeler et al., 1992, *Peptides*, Proc. 12th Amer. Pep. Soc., Smith and Rivier (eds), Leiden, pp 661-663); and Nokihara et al., 1990, *Protein Research Foundation*, Yanaihara (ed), Osaka, pp 315-320).

In a less preferred embodiment, chemokine derivatives can be obtained by proteolysis of the protein followed by purification using standard methods such as those described above (e.g., immunoaffinity purification).

In another alternate embodiment, native chemokine proteins can be purified from natural sources, by standard methods such as those described above (e.g., immunoaffinity purification).

5.3. COMPOSITION FORMULATIONS AND METHODS OF ADMINISTRATION

The composition formulations of the invention comprise an effective immunizing amount of an immunologically active ingredient, i.e., one or more antigens, and an amount of one or more chemokine(s), or fragment(s) or derivative thereof, effective to enhance the immune response against the antigen in a subject, and a pharmaceutically acceptable carrier or excipient. In a specific embodiment, the

chemokines are selected from the group consisting of Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EB1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

Pharmaceutically acceptable carriers or excipients are well known in the art and include but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, sterile isotonic aqueous buffer, and combinations thereof. One example of such an acceptable carrier is a physiologically balanced culture medium containing one or more stabilizing agents such as stabilized, hydrolyzed proteins, lactose, etc. The carrier is preferably sterile. The formulation should suit the mode of administration.

In addition, if desired, the vaccine or composition preparation may also include minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine or composition. Suitable adjuvants may include, but are not limited to: mineral gels,

e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; oil emulsions; alum, MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine. The effectiveness of an adjuvant may be determined by comparing the induction of antibodies directed against a MDC-containing composition in the presence and in the absence of various adjuvants.

In instances where the recombinant antigen is a hapten, i.e., a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response, the hapten may be covalently bound to a carrier or immunogenic molecule; for instance, a large protein such as serum albumin will confer immunogenicity to the hapten coupled to it. The hapten-carrier may be formulated for use as a vaccine.

The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.

The chemokinè(s), or fragment(s) or derivative(s) thereof, and/or the antigen(s) may be formulated into the composition as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may also be derived from inorganic bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

An effective dose (immunizing amount) is that amount sufficient to produce an immune response to the antigen(s) in the host to which the vaccine preparation is administered. The precise dose of the composition to be employed in the formulation will depend on the route of administration, and the nature of the subject to be

immunized, and should be decided by the practitioner according to standard clinical techniques. Effective doses of the vaccines or compositions of the present invention may also be extrapolated from dose-response curves derived from animal model test systems.

The invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the composition formulations of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is administered by injection, an ampoule of sterile diluent can be provided so that the ingredients may be mixed prior to administration.

In a specific embodiment, a lyophilized immunologically active ingredient and one or more chemokine polypeptide(s) of the invention are provided in a first container; a second container comprises diluent consisting of an aqueous solution of 50% glycerin, 0.25% phenol, and an antiseptic (e.g., 0.005% brilliant green).

Many methods may be used to introduce the composition formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle).

The DNA vaccines of the invention can be administered by any method known in the art for delivery of DNA to subject (for example, as described in Section 5.3 supra)

5.4. DETERMINATION OF COMPOSITION EFFICACY

The activity of one or more chemokines, or a fragment, derivative or analogue thereof, to enhance immune response to an antigen can be determined by monitoring the immune response in test animals following immunization with a composition containing the chemokine(s) and an antigen and comparing the response to that following immunization with the antigen in the absence of the chemokine(s). Generation of a humoral (antibody) response and/or cell-mediated immunity, may be taken as an indication of an immune response. Test animals may include mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, etc., and eventually human subjects. Assays for humoral and cell-mediated immunity are well known in the art.

Methods of introducing the composition may include oral, intracerebral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal or any other standard routes of immunization. The immune response of the test subjects can be analyzed by various approaches well known in the art, such as but not limited to: testing the reactivity of the resultant immune serum to the antigen of the chemokine-containing vaccine, as assayed by known techniques, e.g., immunosorbant assay (ELISA), immunoblots, radioimmunoprecipitations, etc.

As one example of suitable animal testing, a composition of the present invention may be tested in mice for the ability to enhance an antibody response to an antigen (using for example, but not limited to, the method as described in Section 6, *infra*) and the delayed-type hypersensitivity (DTH) response (also described in Section 6 *infra*), measured by an increase in footpad swelling after inoculation in the footpad of the test animal, as compared to the measurements in animals administered the antigen in a composition not containing chemokine. For example, as test animals BALB/c mice may be used. The test group each receives an inoculation with fixed amount of antigen and varying amount of one or more chemokines. The control group receives an inoculation of comparable amount of antigen alone.

Serum samples may be drawn from the mice after the final inoculation (for example every one or two weeks after inoculation), and serum is analyzed for antibodies against the antigen using known methods in the art, e.g., using an ELISA. DTH responses to the antigen may be measured after the final inoculation (e.g. within 1-7 days). An increase in the serum titer of antibodies recognizing the antigen and/or

an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokine(s) as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing the chemokine(s), indicates that the chemokine(s) enhance the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokines as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing chemokine(s), indicates that the chemokine(s) enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen.

6. EXAMPLE: IMMUNIZATION WITH MDC-CONTAINING COMPOSITION

The following experiment illustrates the evaluation of whether MDC will act as an adjuvant for a protein antigen and enhance the efficacy of a vaccine. However, it will be appreciated that the description applies equally to other chemokines and combinations of chemokines.

6.1. MATERIALS AND METHODS

6.1.1. ANIMALS AND REAGENTS

BALB/c mice are purchased from Harlan-Sprague-Dawley (Indianapolis, IN).

Human MDC (hMDC) was obtained from CD8⁺ T cell clones immortalized *in vitro* prepared as previously described (Markham et al., 1983 *Int. J. Cancer* 31:413; Markham et al. 1984, *Int. J. Cancer* 33:13). One such immortalized CD8⁺ T cell clone, F3b Clone 19, was adapted to growth in serum-free medium by the following procedure and used for further studies. F3b Clone 19 cells were grown in complete medium containing rIL-2 (16 ng/ml) at 37°C in a CO₂ incubator. After expanding the culture to 200 ml, the cells were pelleted and resuspended in RPMI medium containing HB101 (Irvine Scientific) supplemented with 16 ng/ml of rIL-2, 1% glutamine and 1% penicillin/streptomycin. The cells were grown to full confluence and the medium harvested by centrifugation at 670 x g for 10 minutes.

Human MDC (hMDC) was purified from F3b Clone 19 as described in Pal et al., 1997, *Science* 278:695-698. Briefly, the cell free culture supernatant from F3b Clone 19 was clarified by high speed centrifugation and fractionated by heparin affinity chromatography, taking advantage of the heparin binding characteristics of chemokines (Witt and Lander, 1994, *Current Biology* 4:394; Proost et al., 1996, *Method: A Companion to Methods in Enzymology* 10:82). Culture supernatant (1200 ml) from F3b Clone 19, grown to high cell density in serum-free medium supplemented with rIL-2 was clarified by high speed centrifugation (100,000 x g for 60 minutes at 4°C) and applied to a 5 ml HiTrap heparin affinity FPLC column (Pharmacia) equilibrated in 10 mM Tris-HCl, pH 7.6 containing 0.1 M NaCl (column buffer). The column was then washed extensively with column buffer and the bound proteins eluted from the column with 10 mM Tris-HCl, pH 7.6 containing 2.0 M NaCl at a flow rate of 0.5 to 1 ml/minute. Virtually all of the HIV suppressive activity effective against primary NSI and SI isolates and HIV-1_{IIIb} was recovered in the column eluate (data not shown). The heparin affinity column eluate was brought to pH 2.0 by addition of trifluoroacetic acid (TFA) and subjected to reversed phase HPLC on a PEEK C-18 column (Waters Instruments) equilibrated in H₂O containing 0.1 % TFA. Proteins bound to the column were eluted with a 5 minute linear gradient of aqueous acetonitrile (0 to 35 %) containing 0.1% TFA. After 10 minutes at 35% acetonitrile, the column was further developed with a 60 minute linear gradient of 35-70% aqueous acetonitrile in TFA. The flow rate was maintained at 0.5 to 1 ml/minute. The fractions obtained were then tested for suppressor activity in the acute infectivity assay using HIV-1_{IIIb}. Active fractions were pooled, diluted twofold in H₂O with 0.1 % TFA

and reapplied to the column. The column was then developed with a 30 minute linear aqueous acetonitrile gradient (0-60%) containing 0.1% TFA at a flow rate of 0.5 to 1 ml/minute. The fractions obtained were assayed as above. Active fractions were pooled, diluted with H₂O/0.1 % TFA and fractionated under the same conditions to obtain a single protein peak. The fraction corresponding to the peak and flanking fractions were tested in the infectivity assay to verify that suppressor activity was cofractionated with the protein.

Suppressive activity against HIV-1_{IIIb} in the absence of cytotoxic effects consistently copurified with a single protein peak that appeared as a homogeneous 8 kDa band when analyzed by SDS-polyacrylamide gel electrophoresis. This protein was not reactive in ELISAs for RANTES, MIP-1 α or MIP-1 β (R&D Systems).

Recombinant gp120 protein derived from HIV-1 IIIB isolate is purchased from Intracel (Foster City, CA).

6.1.2 IMMUNIZATION OF MICE

The hMDC and the gp120 is resuspended in a total volume of 50 μ l of phosphate-buffered saline (PBS). Mice are divided into 5 groups with 3-4 mice in each group. Groups 1-4 are inoculated with 10 μ g gp120 and 0.3 μ g, 0.1 μ g, 0.03 μ g, and 0.01 μ g of hMDC, respectively. As a control, group 5 is inoculated with 10 μ g of gp120 in the absence of hMDC. For primary inoculation, each group of mice is inoculated with 10 μ l of the hMDC and gp120 solution via footpad. Two to three weeks after the primary inoculation, each mouse is given the same dose of hMDC/gp120 that is used in primary inoculation.

6.1.3 ELISA ASSAY

Serum samples are collected one week after the second inoculation via tail vein bleed. gp120 serum responses are measured using standard gp120 antibody ELISA assays.

6.1.4 DTH ASSAY

The delayed-type hypersensitivity (DTH) response is measured from 1-7 days after the second inoculation. A caliper is to be used to measure footpad swelling.

6.2. RESULTS

Mice inoculated with hMDC/gp120 are expected to have greater serum antibody and DTH responses than mice inoculated with gp120 alone. The improved responses will be reflected in either increased titers of serum antibody responses or increased footpad swelling. A dose response effect is expected - increasing the dose of hMDC used is expected to cause a corresponding improvement in the serum and DHT gp120-specific responses.

7. EXAMPLE: OTHER CHEMOKINES AND COMBINATIONS OF CHEMOKINES

The foregoing experiments can be repeated using other chemokines and combinations of chemokines. For example, the experiments are preferably repeated using one or more chemokines selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EB11-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine., 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

THE CLAIMS:

1. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject and an amount of one or more chemokines, or purified fragments or derivatives thereof, effective to enhance the efficacy of said vaccine.
2. The method of claim 1, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
3. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-

- regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.
4. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
 5. The method of claim 1 wherein the fragment(s) or derivative(s) are truncation isoforms.
 6. The method of claim 1, wherein the one or more chemokines include MDC comprising the amino acid sequence of SEQ ID NO: 2.
 7. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.
 8. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2., which derivative has activity to enhance the efficacy of the vaccine.
 9. The method of claim 1, wherein the one or more chemokine derivatives has one or more insertions or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
 10. The method of claim 1, including a chemokine derivative having one or more conservative substitutions in sequence relative a wildtype MDC, which derivative has activity to enhance the efficacy of the vaccine.
 11. The method of claim 1, wherein the one or more chemokines include a human chemokine.

12. The method of claim 1, wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof is/are administered concurrently with the purified antigen(s).
13. The method of claim 1 wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof, are administered within a time period before or after administration of the purified antigen, which time period permits the purified MDC or purified fragment or derivative thereof MDC to enhance the efficacy of the vaccine.
14. The method of claim 1, wherein the antigen is an HIV antigen.
15. The method of claim 14, wherein the HIV antigen is HIV-associated gp120 protein.
16. The method of claim 1, wherein the subject is a human.
17. The method of claim 1, wherein the subject is infected or at risk of being infected with HIV virus.
18. The method of claim 1, wherein the vaccine elicits a humoral response against the antigen in the subject.
19. The method of claim 1, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.
20. The method of claim 1, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.
21. The method of claim 1, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.

22. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject a first amount of a first set of one or more purified nucleotide sequences encoding one or more antigens against which an immune response is desired in the subject and a second second set of one or more purified nucleic acids, each comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner upon introduction into a suitable cell, said first amount is immunogenic and said second amount is effective in enhancing the efficacy of the vaccine.
23. The method of claim 22, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
24. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EB11-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine

- 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.
25. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
26. The method of claim 22 wherein the fragment(s) or derivative(s) are truncation isoforms.
27. The method of claim 22, wherein the nucleotide sequence encoding one or more chemokines comprises the nucleotide sequence of SEQ ID NO:1.
28. The method of claim 22, wherein one or more of the chemokine derivative(s) have deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the efficacy of the vaccine.
29. The method of claim 22, wherein the vaccine elicits a humoral response against the antigen in the subject.
30. The method of claim 22, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.
31. The method of claim 22, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.
32. The method of claim 22, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.
33. A composition comprising: an immunogenic amount of one or more purified antigens and an amount of one or more purified chemokines, or purified

fragments or derivatives thereof, effective to enhance the immune response to said antigen(s); and a pharmaceutically acceptable carrier.

34. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
35. The composition of claim 33, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
36. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating

- protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.
- 37. The composition of claim 33, wherein the fragment(s) or derivative(s) are truncation isoforms.
- 38. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.
- 39. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2, which derivative has activity to enhance the efficacy of the vaccine.
- 40. The composition of claim 33, wherein the one or more chemokine derivatives has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
- 41. The composition of claim 33, wherein the one or more chemokine derivatives has one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
- 42. The composition of claim 33, wherein the chemokine is a human chemokine.
- 43. The composition of claim 33, wherein the antigen is an HIV antigen.
- 44. The composition of claim 43, wherein the antigen is HIV associated gp120 protein.
- 45. A composition comprising an amount of a first set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens

- and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s), or fragment(s) or derivative(s) thereof, are expressed from said first set of nucleic acid(s) and second set of nucleic acid(s) in a coordinated manner such that upon introduction into a suitable cell, the amount of said first set of nucleic acid(s) is sufficient to express an immunogenic amount of the antigen and the amount of the said second set of nucleic acid(s) is effective in enhancing the efficacy of the vaccine; and a pharmaceutically acceptable carrier.
46. The composition of claim 45, wherein the chemokine is MDC and the nucleic acid encoding the MDC comprises the nucleotide sequence of SEQ ID NO: 1.
47. The composition of claim 45, wherein the chemokine derivative(s) have deletional, insertional or substitutional mutations and/or combinations thereof, and the derivative(s) have activity to enhance the efficacy of the vaccine.
48. The composition of claim 45, further comprising pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.
49. A composition comprising a first set of purified nucleotide sequences encoding one or more antigens and a second set of purified nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner such that upon introduction into a suitable cell, the sets produce an amount of said antigen(s) that is immunogenic and an amount of chemokine(s), or fragment(s) or derivative(s) thereof, that is effective in enhancing the efficacy of the vaccine relative to a corresponding vaccine composition without such chemokine(s), fragment(s) or derivative(s) thereof.
50. The composition of claim 49, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine,

Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EB11-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

51. The method of claim 49, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
52. The method of claim 49, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
53. The composition of claim 49, wherein the fragment(s) or derivative(s) are truncation isoforms.

- 54. The composition of claim 49, wherein the nucleic acid is administered directly to the subject.
- 55. The composition of claim 49, wherein the nucleic acid is introduced into a suitable host cell and said suitable host cell is introduced into the subject.

GAGACATACA GGACAGAGC ATG GCT CGC CTA CAG ACT GCA CTC CTG GTT GTC	52
Met Ala Arg Leu Gln Thr Ala Leu Leu Val Val	-24
	-20
	-15
CTC GTC CTC CTT GCT GTG GCG CTT CAA GCA ACT GAG GCA GGC CCC TAC	100
Leu Val Leu Leu Ala Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr	
	-10
	-5
	1
GGC GCC AAC ATG GAA GAC AGC AGC GTC TGC TGC CGT GAT TAC GTC CGT TAC	148
Gly Ala Asn Met Glu Asp Ser Val Cys Cys Arg Asp Tyr Val Arg Tyr	
	5
	10
	15
CGT CTG CCC CTG CGC GTG GTG AAA CAC TTC TAC TGG ACC TCA GAC TCC	196
Arg Leu Pro Leu Arg Val Val Lys His Phe Tyr Trp Thr Ser Asp Ser	
	20
	25
	30
	35
TGC CCG AGG CCT GGC GTG GTG TTG CTA ACC TTC AGG GAT AAG GAG ATC	244
Cys Pro Arg Pro Gly Val Val Leu Leu Thr Phe Arg Asp Lys Glu Ile	
	40
	45
	50
TGT GCC GAT CCC AGA GTG CCC TGG GTG AAG ATG ATT CTC AAT AAG CTG	292
Cys Ala Asp Pro Arg Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu	
	55
	60
	65

FIG. 1A-1

AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA 348
 Ser Gln

GGAGCCCTAC CTCCCTGCCA TTATAGCTGC TCCCCGCCAG AAGCCTGTGC CAACTCTCTG 408

CATTCCCTGA TCTCCATCCC TGTGGCTGTC ACCCTTGGTC ACCTCCGTGC TGTCACCTGCC 468

ATCTCCCCCC TGACCCCTCT AACCCTATCCT CTGCCTCCCT CCCTGCAGTC AGAGGGTCCT 528

GTTCCCATCA GCGATTCCCC TGCTTAAACC CTTCCATGAC TCCCCACTGC CCTAAGCTGA 588 ^{2/6}

GGTCAGTCTC CCAAGCCTGG CATGTGGCCC TCTGGATCTG GGTTCATCT CTGTCTCCAG 648

CCTGCCCACT TCCCTTCATG AATGTTGGGT TCTAGCTCCC TGTTCTCCAA ACCCATACTA 708

CACATCCAC TTCTGGGTCT TTGCCTGGGA TGTGTCTGAC ACTCAGAAAG TCCCACCACC 768

TGCACATGTG TAGCCCCACC AGCCCTCCAA GGCATTGCTC GCCCAAGCAG CTGTAATTC 828

CATTTCATGT ATTAGATGTC CCCTGGCCCT CTGTCCCCCTC TTAATAACCC TAGTCACAGT 888

CTCCGCAGAT TCTTGGGATT TGGGGTTTT CTCCCCCACC TCTCCACTAG TTGGACCAAG 948

FIG. 1A-2

GTTTCTAGCT AAGTTACTCT AGTCTCCAAG CCTCTAGCAT AGAGCACTGC AGACAGGCC 1008
TGGCTCAGAA TCAGAGCCCA GAAAGTGGCT GCAGACAAA TCAATAAAAC TAATGTCCCT 1068
CCCCTCTCCC TGCCAAAAGG CAGTTACATA TCAATACAGA GACTCAAGGT CACTAGAAAT 1128
GGGCCAGCTG GGTCATGTG AAGCCCCAAA TTGCCCCAGA TTCACCTTTC TTCCCCCACT 1188
CCCTTTTTT TTTTTTTTTT TTTGAGATGG AGTTTCGCTC TTGTCACCCA CGCTGGAGTG 1248
CAATGGTGTG GTCTTGGCTT ATTGAAGCCT CTGCCCTCCTG GGTTC AAGTG ATTCTCTTGC 1308
CTCAGCCTCC TGAGTAGCTG GGATTACAGG TTCCTGCTAC CACGCCCAGC TAATTTTTGT 1368
ATTTT TAGTA GAGACGAGGC TTCACCATGT TGGCCAGGCT GGTCTCGAAC TCCTGTCCCTC 1428
AGGTAATCCG CCCACCTCAG CCTCCCAAAG TGCTGGGATT ACAGGCGTGA GCCACAGTGC 1488
CTGGCCTCTT CCCTCTCCCC ACTGCCCCCC CCAACTTTT TTTTTTTTT ATGGCAGGGT 1548
CTCACTCTGT CGCCCAGGCT GGAGTGCAGT GCGGTGATCT CGGCTCACTA CAACCTCGAC 1608
CTCCTGGGT CAAGTGATTC TCCCACCCCA GCCTCCCAAG TAGCTGGAT TACAGGTGTG 1668

FIG. 1A-3

4/6

<u>TGCCACTACG GCTGGCTAAT TTTTGTAATT TTAGTAGAGA CAGTTTCAC CATATTGGCC</u>	1728
AGGCTGGTCT TGAACCTCCTG ACCTCAAGTG ATCCACCTTC CTTGTGCTCC CAAAGTGCTG	1788
AGATTACAGG CGTGAGCTAT CACACCCAGC CTCCTCCCTTT TTTTCCTAAT AGGAGACTCC	1848
TGTACCTTTC TTCGTTTAC CTATGTGTCG TGTCTGCTTA CATTTCCTTC TCCCCCTCAGG	1908
CTTTTTTTGG GTGGTCCTCC AACCTCCAAT ACCCAGGCCT GGCCTCTTCA GAGTACCCCC	1968
CATTCCACTT TCCCTGCCTC CTTCCCTTAA TAGCTGACAA TCAAATTCAT GCTATGGTGT	2028
GAAAGACTAC CTTTGACTTG GTATTATAAG CTGGAGTTAT ATATGTATTT GAAAACAGAG	2088
TAAATACTTA AGAGGCCAAA TAGATGAATG GAAGAATTT AGGAACTGTG AGAGGGGGAC	2148
AAGGTGAAGC TTTCCCTGGCC CTGGGAGGAA GCTGGCTGTG GTAGCGTAGC GCTCTCTCTC	2208
TCTGTCTGTG GCAGGAGCCA AAGAGTAGGG TGTAATTGAG TGAAGGAATC CTGGGTAGAG	2268
ACCATTCTCA GGTGGTTGGG CCAGGCTAAA GACTGGGAGT TGGGTCTATC TATGCCCTTC	2328
<u>TGGCTGATTT TTGTAGAGAC GGGGTTTGC CATGTTACCC AGGCTGGTCT CAAACTCCTG</u>	2388

FIG. 1A-4

GGCTCAAGCG ATCCTCCTGG CTCAGCCTCC CAAAGTGCTG GGATTACAGG CGTGAATCAC	2448
TGCGCCTGGC TTCCTCTTCC TCTTGAGAAA TATTCTTTTC ATACAGCAAG TATGGGACAG	2508
CAGTGTCCTCA GGTAAGGAC ATAAATGTTA CAAGTGTCTG GTCCTTTCTG AGGGAGGCTG	2568
GTGCCGCTCT GCAGGGTATT TGAACCTGTG GAATTGGAGG AGGCCATTTC ACTCCCTGAA	2628
CCCAGCCTGA CAAATCACAG TGAGAATGTT CACCTTATAG GCTTGCTGTG GGGCTCAGGT	2688
TGAAAGTGTG GGGAGTGACA CTGCCTAGGC ATCCAGCTCA GTGTCATCCA GGGCCTGTGT	2748
CCCTCCCGAA CCCAGGGTCA ACCTGCCTGC CACAGGCACT AGAAGGACGA ATCTGCCCTAC	2808
TGCCCATGAA CGGGGCCCTC AAGCGTCCTG GGATCTCCTT CTCCCTCCTG TCCTGTCCTT	2868
GCCCCCTCAGG ACTGCTGGAA AATAAATCCT TTAAATAGT AAAAAAAAAA AAAA	2923

FIG. 1A-5

FIG. 1A

FIG. 1A-1
FIG. 1A-2
FIG. 1A-3
FIG. 1A-4
FIG. 1A-5

[illegible]

FIG. 18

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Gallo, Robert C.
DeVico, Anthony L.
Garzino, Alfredo
- (ii) TITLE OF THE INVENTION: METHOD AND COMPOSITION TO ENHANCE
THE EFFICACY OF A VACCINE USING MACROPHAGE DERIVED CHEMOKINE
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Pennie & Edmonds LLP
(B) STREET: 1155 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: USA
(F) ZIP: 10036/2711
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 2.0
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: To be assigned
(B) FILING DATE: Herewith
(C) CLASSIFICATION:
- (vii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Misrock, S. Leslie
(B) REGISTRATION NUMBER: 18,872
(C) REFERENCE/DOCKET NUMBER: 8769-029
- (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 212-790-9090
(B) TELEFAX: 212-869-8864
(C) TELEX: 66141 PENNIE
- (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2923 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 92..298

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAGACATACA GGACAGAGC ATG GCT CGC CTA CAG ACT GCA CTC CTG GTT GTC	52
Met Ala Arg Leu Gln Thr Ala Leu Val	
-24 -20 -15	
CTC GTC CTC CTT GCT GTG GCG CTT CAA GCA ACT GAG GCA GGC CCC TAC	100
Leu Val Leu Ala Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr	
-10 -5 1	
GGC GCC AAC ATG GAA GAC AGC GTC TGC CGT GAT TAC GTC CGT TAC	148
Gly Ala Asn Met Glu Asp Ser Val Cys Arg Asp Tyr Val Arg Tyr	
5 10 15	
CGT CTG CCC CTG CGC GTG AAA CAC TTC TAC TGG ACC TCA GAC TCC	196
Arg Leu Pro Leu Arg Val Lys His Phe Tyr Trp Thr Ser Asp Ser	
20 25 30 35	
TGC CCG AGG CCT GGC GTG TTG CTA ACC TTC AGG GAT AAG GAG ATC	244
Cys Pro Arg Pro Gly Val Leu Thr Phe Arg Asp Lys Glu Ile	
40 45 50	
TGT GCC GAT CCC AGA GTG CCC TGG GTG AAG ATG ATT CTC AAT AAG CTG	292
Cys Ala Asp Pro Arg Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu	
55 60 65	
AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA	348
Ser Gln	

GGAGCCCTAC CTCCCTGCCA TTATAGCTGC TCCCGGCCAG AAGCCTGTGC CAACTCTCTG 408
 CATTCCCTGA TCTCCATCCC TGTGGCTGTC ACCCTTGGTC ACCTCCGTGC TGTCACTGCC 468
 ATCTCCCCC TGACCCCTCT AACCCATCCT CTGCCTCCCT CCCTGCAGTC AGAGGGTCCT 528
 GTTCCCATCA GCGATTCCCC TGCTTAAACC CTTCATGAC TCCCACTGC CTTAAGCTGA 588
 GGTCACTCTC CCAAGCCTGG CATGTGGCCC TCTGGATCTG GGTTCATCT CTGTCTCCAG 648
 CCTGCCCACT TCCCTTCATG AATGTTGGGT TCTAGCTCCC TGTCTCCAA ACCCATACTA 708
 CACATCCAC TTCTGGGTCT TTGCCTGGGA TGTGCTGAC ACTCAGAAAG TCCCACCACC 768
 TGCACATGTG TAGCCCCACC AGCCCTCCAA GGCATTGCTC GCCCAAGCAG CTGGTAATTG 828
 CATTTCATGT ATTAGATGTC CCCTGGCCCT CTGTCCCTCT TTAATAACCC TAGTCACAGT 888
 CTCCGCAGAT TCTTGGGATT TGGGGGTTT CTCCCCCACC TCTCCACTAG TTGGACCAAG 948
 GTTCTAGCT AAGTTACTCT AGTCTCCAAG CCTCTAGCAT AGAGCACTGC AGACAGGCC 1008
 TGGCTCAGAA TCAGAGCCCA GAAAGTGGCT GCAGACAAA TCAATAAAC TAATGTCCCT 1068
 CCCCTCTCCC TGCCAAAAGG CAGTTACATA TCAATACAGA GACTCAAGGT CACTAGAAAT 1128
 GGGCCAGCTG GGTCAATGTG AAGCCCCAAA TTGCCCCAGA TTCACCTTC TTCCCCACT 1188
 CCCTTTTTT TTTTTTTTT TTTGAGATGG AGTTTCGCTC TTGTCACCA CGCTGGAGTG 1248
 CAATGGGTG GTCTTGGCTT ATTGAAGCCT CTGCCTCCTG GGTTCAGTG ATTCTCTTG 1308
 CTCAGCCTCC TGAGTAGCTG GGATTACAGG TTCTGTCTAC CACGCCAGC TAATTTTGT 1368
 ATTTTAGTA GAGACGAGGC TTCACCATGT TGGCCAGGT GGTCTCGAAC TCTGTCTCTC 1428
 AGGTAATCCG CCCACCTCAG CCTCCCAAAG TGCTGGGATT ACAGGCGTGA GCCACAGTGC 1488
 CTGGCCTCTT CCCTCTCCCC ACTGCCCTCT CCAACTTTT TTTTTTTTT ATGGCAGGT 1548
 CTCACCTCTG CGCCAGGCT GGAGTGCAGT GGCCTGATCT CGGCTCACTA CAACCTCGAC 1608
 CTCTGGGT CAAGTGATT TCCCACCCA GCCTCCCAAG TAGCTGGGAT TACAGGTGTG 1668
 TGCCACTACG GCTGGCTAAT TTTTGTATT TTAGTAGAGA CAGGTTTAC CATATTGGCC 1728
 AGGTGGTCT TGAACCTCTG ACCTCAAGTG ATCCACCTTC CTGTGTCTCC CAAAGTGCTG 1788
 AGATTACAGG CGTGAGCTAT CACACCCAGC CTCCCCCTT TTTTCTAAT AGGAGACTCC 1848
 TGTACCTTTC TTCGTTTAC CTATGTGTCG TGTCTGCTTA CATTTCCTTC TCCCCCTCAG 1908
 CTTTCTTGG GTGGTCTCC AACCTCCAAT ACCCAGGCT GGCCTCTCA GAGTACCCCT 1968
 CATTCCACT TCCCTGCCTC CTTCCTTAAA TAGCTGACAA TCAAAATCAT GCTATGGTGT 2028
 GAAAGACTAC CTTGACTTG GTATTATAAG CTGGAGTTAT ATATGTATT GAAAACAGAG 2088
 TAAATACTTA AGAGGCCAAA TAGATGAATG GAAGAATTTT AGGAACTGTG AGAGGGGAC 2148
 AAGGTGAAGC TTTCTGGCC CTGGGAGGAA GCTGGCTGTG GTAGCGTAGC GCTCTCTCTC 2208
 TCTGTCTGTG GCAGGAGCCA AAGAGTAGGG TGAATTTAG TGAAGGAATC CTGGGTAGAG 2268
 ACCATTCTCA GGTGGTTGGG CCAGGCTAAA GACTGGGAGT TGGGTCTATC TATGCCTTC 2328
 TGGCTGATT TTGTAGAGAC GGGGTTTTG CATGTPACCC AGGCTGGTCT CAAACTCCTG 2388
 GGCTCAAGCG ATCCTCCTGG CTCAGCCTCC CAAAGTGCTG GGATTACAGG CGTGAATCAC 2448
 TGCGCCTGGC TTCTCTTCC TCTTGAGAAA TATTCTTTT ATACAGCAAG TATGGGACAG 2508
 CAGTGTCCCA GGTAAGGAC ATAAATGTTA CAAGTGCTG GTCTTTCTG AGGGAGGCTG 2568
 GTGCCGCTCT GCAGGGTATT TGAACCTGTG GAATTGGAGG AGGCCATTTC ACTCCCTGAA 2628
 CCCAGCCTGA CAAATCACAG TGAGAATGTT CACCTTATAG GCTTGTGTG GGGCTCAGGT 2688
 TGAAAGTGTG GGGAGTGACA CTGCCTAGGC ATCCAGCTCA GTGTATCCA GGGCCTGTGT 2748
 CCCTCCCGAA CCCAGGGTCA ACCTGCCTGC CACAGGCACT AGAAGGACGA ATCTGCCTAC 2808
 TGCCCATGAA CGGGGCCCTC AAGCGTCTG GGATCTCCT CTCCCTCTG TCTGTCTCTT 2868
 GCCCCTCAGG ACTGCTGGAA AATAATCCT TTAATAAGT AAAAAA AAAA 2923

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 93 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Arg Leu Gln Thr Ala Leu Val Leu Val Leu Ala
 -24 -20 -15 -10
 Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr Gly Ala Asn Met Glu
 -5 1 5
 Asp Ser Val Cys Arg Asp Tyr Val Arg Tyr Arg Leu Pro Leu Arg
 10 15 20
 Val Lys His Phe Tyr Trp Thr Ser Asp Ser Cys Pro Arg Pro Gly
 25 30 35 40
 Val Leu Thr Phe Arg Asp Lys Glu Ile Cys Ala Asp Pro Arg
 45 50 55
 Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu Ser Gln
 60 65

C-CHEMOKINES

LYMPHOTACTIN

(SCM-1)

D63789 D63790

CX3C-chemokines

Fractalkine/neurotactin

U91835 U84487

LOCUS HSU83171 2923 bp mRNA PRI 31-MAY-1997
 DEFINITION Human macrophage-derived chemokine precursor (MDC) mRNA,
 complete cds.
 ACCESSION U83171
 NID g1931580
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae; Homo.
 REFERENCE 1 (bases 1 to 2923)
 AUTHORS Godiska, R., Chantry, D., Raport, C.J., Sozzani, S., Allavena, P.,
 Leviten, D., Mantovani, A. and Gray, P.W.
 TITLE Human macrophage-derived chemokine (MDC), a novel
 chemoattractant for monocytes, monocyte-derived dendritic cells, and natural
 killer cells
 JOURNAL J. Exp. Med. 185 (9), 1595-1604 (1997)
 MEDLINE 97296313
 REFERENCE 2 (bases 1 to 2923)
 AUTHORS Godiska, R. and Gray, P.W.
 TITLE Direct Submission
 JOURNAL Submitted (23-DEC-1996) ICOS Corporation, 22021 20th Avenue SE,
 Bothell, WA 98021, USA
 FEATURES
 source Location/Qualifiers
 1..2923
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="16"
 gene 20..301
 /gene="MDC"
 sig_peptide 20..91
 /gene="MDC"
 CDS 20..301
 /gene="MDC"
 /function="chemotactic for dendritic cells and natural
 killer cells"
 /codon_start=1
 /product="macrophage-derived chemokine precursor"
 /db_xref="PID:g1931581"
 /translation="MARLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYR
 LPLRVVKHFYWTSDSCPRPGVLLTFRDKEICADPRVPWVKMILNKLSQ"
 mat_peptide 92..298
 /gene="MDC"
 /product="macrophage-derived chemokine"
 repeat_region complement(1194..1805)
 /rpt_family="ALU"
 repeat_region complement(2335..2443)
 /rpt_family="ALU"
 BASE COUNT 605 a 861 c 669 g 788 t
 ORIGIN
 1 gagacataca ggacagagca tggctcgcct acagactgca ctcttggttg tctcgtcct
 61 ccttgctgtg gcgcttcaag caactgaggc agggccctac ggcgccaaca tggaaagacag
 121 cgtctgctgc cgtgattacg tccgttaccg tctgcccctg cgcgtggtga aacacttcta
 181 ctggacctca gactcctgcc cgaggcctgg cgtggtgttg ctaaccttca gggataagga
 241 gatctgtgcc gatccagag tgccctgggt gaagatgatt ctcaataagc tgagccaatg
 301 aagagcctac tctgatgacc gtggccttgg ctctccagg aaggctcagg agccctacct
 361 ccttgccatt atagctgctc ccgcccagaa gcctgtgcca actctctgca tctccctgac
 421 tccatccctg tggctgtcac ccttggtcac ctccgtgctg tcaactgcat cctccccctg
 481 accctctaa cccatcctct gcctccctcc ctgcagtcag agggctcctg tccatcagc
 541 gattccctcg cttaaaccct tccatgactc cccactgccc taagctgagg tcagtcctcc
 601 aagcctggca tgtggccctc tggatctggg tccatctct gtctccagcc tgcccacttc
 661 ccttcatgaa tgttgggttc tagctccttg ttctccaaac ccatactaca catcccactt
 721 ctgggtcttt gcctgggatg ttgctgacac tcagaaagtc ccaccacctg cacatgtgta
 781 gccccaccag cctccaagg cattgctcgc ccaagcagct ggtaattcca tttcatgtat
 841 tagatgtccc ctggccctct gtccctctt aataacccta gtcacagtct ccgcagattc

```

901 ttgggatttg ggggttttct cccccacctc tccactagtt ggaccaaggt ttctagctaa
961 gttactctag tctccaagcc tctagcatag agcactgcag acaggccctg gctcagaate
1021 agagcccaga aagtggctgc agacaaaatc aataaaacta atgtccctcc cctctccctg
1081 ccaaaaggca gttacatata aatacagaga ctcaagggtca ctagaaatgg gccagctggg
1141 tcaatgtgaa gccccaaatt tgcccagatt cacctttctt cccccactcc cttttttttt
1201 tttttttttt tgagatggag ttctgctctt gtcacccacg ctggagtgca atggtgtggg
1261 cttggcttat tgaagcctct gctcctggg ttcaagtgat tctcttgct cagcctcctg
1321 agtagctggg attacaggtt cctgctacca cggccagcta atttttgtat ttttagtaga
1381 gacgaggctt caccatgttg gccaggctgg tctcgaactc ctgtcctcag gtaatccgcc
1441 caccctagcc tcccaaaagt ctgggattac aggcgtgagc cacagtgcct ggcctcttcc
1501 ctctccccac tgcccccccc aacttttttt ttttttttat ggcagggtct cactctgtcg
1561 cccaggctgg agtgagctgg cgtgatctcg gctcactaca acctcgacct cctgggttca
1621 agtgattctc ccaccccagc ctcccaagta gctgggatta cagggtgtgt ccactacggc
1681 tggctaattt ttgtattttt agtagagaca ggtttcacca tattggccag gctggtcttg
1741 aactcctgac ctcaagtgat ccacctctct tgtgtctcca aagtgtgtag attacaggcg
1801 tgagctatca caccagcct cccctttttt ttcttaatag gagactcctg tacctttctt
1861 cgttttacct atgtgtctgt tctgcttaca ttctcttctc cctcagggt ttttttgggt
1921 ggtcctccaa cctccaatac ccaggcctgg cctcttcaga gtacccccca ttccactttc
1981 cctgcctcct tctttaaata gctgacaatc aaattcatgc tatggtgtga aagactacct
2041 ttgacttggg attataagct ggagtattat atgtatttga aaacagagta aatacttaag
2101 aggccaaata gatgaatgga agaatttttag gaactgtgag agggggacaa ggtgaagctt
2161 tcctggccct gggaggaagc tggtgtgtgt agcgtagcgc tctctctctc tgtctgtggc
2221 agggagccaa gagtaggggt taattgagtg aaggaatcct gggtagagac cattctcagg
2281 tgggttggcc aggctaaaga ctgggagttg ggtctatcta tgcctttctg gctgattttt
2341 gttagagacg ggttttgcca tgttaccag gctggtctca aactcctggg ctcaagcgat
2401 cctcctggct cagcctccca aagtgtctgg attacaggcg tgaatcactg cgcctggctt
2461 cctcttctct ttgagaaata ttcttttcat acagcaagta tgggacagca gtgtcccagg
2521 taaaggacat aaatgttaca agtgtctggt cctttctgag ggaggctggt gccgtctctg
2581 aggggtatttg aacctgtgga attggaggag gccatttcac tccctgaacc cagcctgaca
2641 aatcacagtg agaattgtca ccttataggc ttgctgtggg gctcagggtg aaagtgtggg
2701 gagtgcact gcctagcat ccagctcagt gtcattccagg gcctgtgtcc ctcccgaacc
2761 cagggtcaac ctgcctgcca caggcactag aaggacgaat ctgcctactg cccatgaacg
2821 gggccctcaa gcgtcctggg atctccttct cctcctgtc ctgtccttgc cctcaggac
2881 tgctggaaaa taaatccttt aaaatagtaa aaaaaaaaaa aaa

```

```

//
LOCUS      HSU83239          932 bp      mRNA          PRI          02-MAY-1997
DEFINITION Human CC chemokine STCP-1 mRNA, complete cds.
ACCESSION  U83239
NID        g2062424
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 932)
AUTHORS    Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
Grosshans,D., Meng,T., Boone,T. and Andrew,D.P.
TITLE      Molecular cloning and functional characterization of a novel CC
            chemokine STCP-1 which specifically acts on activated T
            lymphocytes
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 932)
AUTHORS    Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
Grosshans,D., Meng,T., Boone,T. and Andrew,D.P.
TITLE      Direct Submission
JOURNAL    Submitted (26-DEC-1996) Research Computing, Amgen Institute,
620        University Ave, Suite 706, Toronto, ON M5G 2C1, Canada
FEATURES   Location/Qualifiers
            source          1..932
                        /organism="Homo sapiens"
                        /note="Amgen EST program"
                        /db_xref="taxon:9606"
            CDS              15..296
                        /codon_start=1
                        /product="CC chemokine STCP-1"
                        /db_xref="PID:g2062425"

/translation="MARLQ TALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYR

```

BASE COUNT 166 a 330 c 201 g 235 t
 ORIGIN

LPLRVVKHFYWTSDSCPRPGVVLLTFRDKEICADPRVPWVKMILNKLQ*
 1 atacaggaca gagcatggct cgcctacaga ctgcactcct ggttgctctc gtcctccttg
 61 ctgtggcgct tcaagcaact gaggcaggcc cctacggcgc caacatggaa gacagcgtct
 121 gctgccgtga ttacgtccgt taccgtctgc cctgcegcgt ggtgaacac ttctactgga
 181 cctcagactc ctgcccagg cctggcgctg tgttgctaac cttcagggat aaggagatct
 241 gtgccgatcc cagagtggcc tgggtgaaga tgattctcaa taagctgagc caatgaagag
 301 cctactctga tgaccgtggc cttggctcct ccaggaaggc tcaggagccc tacctccttg
 361 ccattatagc tgctccccgc cagaagcctg tgccaactct ctgcattccc tgatctccat
 421 ccctgtggct gtcacccttg gtcacctccg tgctgtcact gccatctccc cctgacccc
 481 tctaaccat cctctgcctc cctccctgca gtcagagggt cctgttccca tcagcgattc
 541 ccctgcttaa acccttccat gactccccac tgccctaagc tgaggtcagt cttccaaagg
 601 tggcatgtgg cctctggat ctgggttcca tctctgtctc cagcctgccc acttcccttc
 661 atgaatgttg ggttctagct cctgttctc caaacccata ctacacatcc cacttctggg
 721 tctttgcctg ggatgttct gacactcaga aagtcaccac acctgcacat gtgtagcccc
 781 accagccctc caaggcattg ctgcccgaag cagctggtaa ttccatttca tgtattagat
 841 gtccctggc cctctgtccc ctcttaataa cctagtac agtctccgca gattcttggg
 901 atttgggggt tttctcccc acctctccac ta

//
 LOCUS HSMCP1 725 bp RNA PRI 03-APR-1995
 DEFINITION H.sapiens mRNA for monocyte chemoattractant protein 1 (MCP-1).
 ACCESSION X14768
 NID g34513
 KEYWORDS monocyte chemoattractant protein 1.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 725)
 AUTHORS Yoshimura, T., Yuhki, N., Moore, S.K., Appella, E., Lerman, M.I. and
 Leonard, E.J.
 TITLE Human monocyte chemoattractant protein-1 (MCP-1). Full-length
 cDNA

cloning, expression in mitogen-stimulated blood mononuclear
 leukocytes, and sequence similarity to mouse competence gene JE
 JOURNAL FEBS Lett. 244 (2), 487-493 (1989)
 MEDLINE 89153605
 COMMENT ZAPPII.

FEATURES
 source Location/Qualifiers
 1..725
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="glioma cells"
 /cell_line="U105MG"
 /clone_lib="lambda"
 sig_peptide 54..122
 /note="signal peptide (AA -23 to -1)."
 CDS 54..353
 /codon_start=1
 /product="monocyte chemoattractant preprotein"
 /db_xref="PID:g34514"
 /db_xref="SWISS-PROT:P13500"

/translation="MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKIS

VQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKWWQDSMDHLQKQTQPKT*
 mat_peptide 123..350
 /note="MCP-1 (AA 1 - 76)."
 misc_feature 162..170
 /note="pot. N-linked glycosylation site"
 misc_feature 707..712
 /note="pot. polyA signal"
 polyA_site 725
 /note="polyA site"

BASE COUNT 208 a 171 c 126 g 220 t
 ORIGIN

1 ctaaccacaga aacatccaat tctcaaactg aagctcgcac tctcgctccc agcatgaaag
 61 tctctgccgc cttctgtgct ctgctgtca tagcagccac cttcattccc caagggtctg
 121 ctacagccaga tgcaatcaat gccccagtc cctgctgtta taacttcacc aataggaaga
 181 tctcagtgca gaggctcgcg agctatagaa gaatcaccag cagcaagtgt cccaaagaag

```

241 ctgtgatctt caagaccatt gtggccaagg agatctgtgc tgacccaag cagaagtggg
301 ttcaggattc catggaccac ctggacaagc aaacccaaac tccgaagact tgaacactca
361 ctccacaacc caagaatctg cagctaactt atttcccctt agctttcccc agacaccctg
421 ttttatttta ttataatgaa ttttgtttgt tgatgtgaaa cattatgcct taagtaattgt
481 taattcttat ttaagttatt gatgttttaa gtttatcttt catggtacta gtgtttttaa
541 gatacagaga cttggggaaa ttgcttttcc tcttgaacca cagttctacc cctgggatgt
601 tttgagggtc tttgcaagaa tcattaatac aaagaatttt ttttaacatt ccaatgcatt
661 gctaaaatat tattgtggaa atgaatattt tgtaactatt acaccaaata aatatatttt
721 tgtac

```

//

```

LOCUS      HSMCP2      2991 bp      DNA      PRI      20-MAR-1997
DEFINITION H.sapiens MCP-2 gene.
ACCESSION  X99886
NID        gl905800
KEYWORDS   MCP-2 gene; monocyte chemotactic protein 2; SCYA10 gene.
SOURCE     human.
  ORGANISM Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 2991)
AUTHORS    Van Coillie, E., Fiten, P., Nomiya, H., Sakaki, Y., Miura, R.,
            Yoshie, O., Van Damme, J. and Opdenakker, G.
TITLE      The human MCP-2 gene (SCYA8): cloning, sequence analysis,
tissue     expression, and assignment to the CC chemokine gene contig on
            chromosome 17q11.2
JOURNAL     Genomics 40 (2), 323-331 (1997)
MEDLINE     97237052
REFERENCE  2 (bases 1 to 2991)
AUTHORS    Opdenakker, G.M.M.
TITLE      Direct Submission
JOURNAL     Submitted (07-AUG-1996) G.M.M. Opdenakker, Rega Institute for
            Medical Research, Minderbroedersstraat 10, B 3000 Leuven,
            BELGIUM
FEATURES   Location/Qualifiers
            source      1..2991
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="17"
                        /map="q11.2"
            repeat_region 209..219
                        /note="DR-A"
                        /rpt_type=DIRECT
            repeat_region 240..248
                        /note="DR-B"
                        /rpt_type=DIRECT
            CAAT_signal   296..300
            repeat_region 310..318
                        /note="IR-A"
                        /rpt_type=INVERTED
            repeat_region 406..415
                        /note="DR-B"
                        /rpt_type=DIRECT
            repeat_region 407..416
                        /note="IR-B"
                        /rpt_type=INVERTED
            repeat_region 425..435
                        /note="DR-A"
                        /rpt_type=DIRECT
            repeat_region 429..437
                        /note="IR-B"
                        /rpt_type=INVERTED
            repeat_region 455..465
                        /note="IR-C"
                        /rpt_type=INVERTED
            TATA_signal   467..472
            repeat_region 492..502
                        /note="IR-C"
                        /rpt_type=INVERTED
            repeat_region 492..500
                        /note="IR-A"

```

```

                /rpt_type=INVERTED
exon            534..639
                /gene="MCP-2 (SCYA10)"
                /number=1
gene            534..1969
                /gene="MCP-2 (SCYA10)"
CDS             join(534..639,1331..1448,1864..1969)
                /gene="MCP-2 (SCYA10)"
                /codon_start=1
                /product="monocyte chemotactic protein-2"
                /db_xref="PID:e279930"
                /db_xref="PID:g1905801"

```

```

/translation="MLKLTPPSKMKVSAALLCLLLMAATFSPQGLAQPDVSIPITC

```

```

CFNVINRKPIQRLSYTRITNIQCPKEAIVFKTQRGKEVCADPKERWVRDSMKHLDO

```

```

                IFQNLKP"
intron          640..1330
                /gene="MCP-2 (SCYA10)"
                /number=1
exon            1331..1448
                /gene="MCP-2 (SCYA10)"
                /number=2
intron          1449..1863
                /gene="MCP-2 (SCYA10)"
                /number=2
exon            1864..1969
                /gene="MCP-2 (SCYA10)"
                /number=3

```

```

BASE COUNT      799 a      709 c      632 g      851 t
ORIGIN

```

```

1 agattctggg gcattaagac ttagttccag gattctgtca ttctgccaac gttctgtggc
61 tgggggttcta aaggagcttg cctggccttag aactgcaagt gactctagtg tgatggagag
121 caccagcaaa gccttagggc ccattccctgg cctcctgtta cccacagagg ggtaagcctt
181 ggctctcttc cactatgacg tcagcttcca ttcttccctt cttatagaca attttccatt
241 tcaaggaaat cagagccctt aatagttcag tgagggtcact ttgtgagca caatcccata
301 cccttcagcc tctgctccac agagccctaag caaaagatag aaactcacaa cttccttggt
361 ttgttatctg gaaattatcc caggatctgg tgcttactca gcatattcaa ggaaggctct
421 acttcattct tccttgattg tgaccatgcc caggctctct gctccctata aaaggcaggc
481 agagccaccg aggagcagag aggttgagaa caaccacagaa accttcacct ctcatgctga
541 agctcacacc cttgccctcc aagatgaagg ttctgacagc gcttctgtgc ctgtgtctca
601 tggcagccac ttccagccct cagggtactg ctccagccagg taagacctct ccttttttaa
661 ggggagacca aaagaggaat taagaagagc cattatgtca cagctcatta ggaacaaaaac
721 cagaactaaa ggctcaggtc actgaggctg gtcccttga tcttccctga cccagttttt
781 gggaggagac agtggagccg ctacagcaac aaccttccca ttgtttgggg aaataatcca
841 gaacgaagaa ctgttttctc ctgtgggtgt aaaggacatt tcaggccgta gtggagaggg
901 agaaaactatt gcctgaagct tcaaattttg gtatgggttc agtgtacctt ccagaacagt
961 ggctgtgtaa agaggatgag gaccagagg aatctcagcg tatggcatag gctaactcta
1021 aagcccatga ggatgaaaga ctgggaagca aggtattgga acttatgttc ccagtgtcag
1081 aagttttggg ttagtagaca aggactagct tgttactcaa aatgtttcca aaccagtgca
1141 acaatgacgg gccgcagagt tcaatagagg aaagagactc acaggcaaca tttatctctt
1201 gggatctgga ctaagacact gaacttgga tggtgacttc ttggtcttct ccttccctct
1261 cttcttttcc ttacaaatgc acacttacgg tgggtcctaa atgtctcatt ctttgcaaaa
1321 tttctttcag attcagtttc cattccaatc acctgctgct ttaacgtgat caataggaaa
1381 attcctatcc agaggctgga gagctacaca agaataccca acatccaatg tcccaaggaa
1441 gctgtgatgt gagggtgacg tgctggcac cccattcaa aagttctgat ggacaacata
1501 gagaagtcaa gattcatgtc catatgagtc ggatgcataa aacttctatc caaaggggac
1561 ctctacccca tagagaaact cagtcctgta gaaggagtcc ataactgctc taggattccc
1621 ttctaggggc ttggtgaaac taaccaata tctgtagcca ggacctgga gggtttcacc
1681 tggacagcaa gacgagagct tccttctgga gcttcttctt ccaactcttc ccttccctcc
1741 tctcccggtt cgggttcctt cacctaagga ccaagggtgt atcagtccta gggaccaatg
1801 gcccacagtc ctgtgcagga tcttcaaagt cttccatcta attgtgacct ctctcccca
1861 cagcttcaag acccaacggg gcaaggaggt ctgtgctgac ccaaggaga gatgggtcag
1921 ggattccatg aagcatctgg accaaatatt tcaaaatctg aagccatgag ccttcataca
1981 tggactgaga gtcagagctt gaagaaaagc ttatttattt tccccacact cccccagggt
2041 cagtgtgaca ttattttatt ataacatcca caaagagatt attttttaaa aatttaaaagc
2101 ataataattt ttaaaaaagta tttaattata tttaaagtgt tgatgtttta actctatctg
2161 tcatacatcc tagtgaatgt aaaatgcaaa atcctgggtg tggtgttttt gtttttggtt
2221 tcctgtgagc tcaactaagt tcacggcaaa atgtcattgt tctccctcct acctgtctgt
2281 agtgttgtgg ggtccctcca tggatcatca aggtgaaaca ctttgggtatt ctttggcaat
2341 cagtgtctct gtaagtcaaa tgtgtgcttt gtactgctgt tgttgaaatt gatgttactg

```

```

2401 tatataacta tggaattttg aaaaaaatt tcaaaaagaa aaaaatatat ataatttaac
2461 actacttagt cttattcttc ttggggtaac atttagctgg gaggtagttt tgggcatcat
2521 ggggtgacagt ttgggcatgg acggggccatt ttcaagaat gtcttctggc tacgctggac
2581 tcaaccaagg ttctcagaga acttgggtggg accaggccag gatgttccag ctctctgact
2641 ctagtcccta acttcagcag ccctgattcg ctageccttc ttgtttctct tgtttatata
2701 ttatccagcc taagggtattt tgttatagct gcccataaag actaagataa tctccatcac
2761 tctaccccca accccaatcc caagaacttg caagcatcca tttaaaggcg tggaacctct
2821 tctttttgac agccttttaa ggtcaagatt cccctgtact tagtgagctt agctgaatct
2881 tcttacaac atgtgaccgc ccatattgag ccatacatag cgagcttatt attttccag
2941 cttattggga aaacacgtct aaggcaaca aatttattgt actgttgaac c
//LOCUS HSY16645 1368 bp mRNA PRI 25-SEP-1998
DEFINITION Homo sapiens mRNA for monocyte chemotactic protein-2.
ACCESSION Y16645
NID g2916795
KEYWORDS MCP-2 gene; monocyte chemotactic protein 2.
SOURCE human.
  ORGANISM Homo sapiens
    Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
    Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1368)
AUTHORS Van Coillie, E.
TITLE Functional comparison of two human monocyte chemotactic
protein-2 isoforms, role of the amino-terminal pyroglutamic acid and
processing by CD26/dipeptidyl peptidase IV
JOURNAL Biochemistry 37, 12672-12680 (1998)
REFERENCE 2 (bases 1 to 1368)
AUTHORS Van Coillie, E.
TITLE Direct Submission
JOURNAL Submitted (23-FEB-1998) E. Van Coillie, Rega Institute for
Medical Research, Minderbroedersstraat 10, 3000 Leuven, BELGIUM
COMMENT Related sequences: X99886, Y10802.
FEATURES
  source Location/Qualifiers
    1..1368
    /organism="Homo sapiens"
    /db_xref="taxon:9606"
    /chromosome="17"
    /tissue_type="testis"
    /clone_lib="Clontech"
    /clone="HL1142q"
    /map="ql1.2"
  gene 473..772
    /gene="MCP-2"
  sig_peptide 473..541
    /gene="MCP-2"
  CDS 473..772
    /gene="MCP-2"
    /codon_start=1
    /product="monocyte chemotactic protein-2"
    /db_xref="PID:e1253690"
    /db_xref="PID:g2916796"
/translation="MKVSAALLCLLLMAATFSPQGLAQPDVSIPITCCFNVINRKIP
IQRLESYTRITNIQCPKEAVIFKTKRGKEVCADPKERWVRDSMKHLDQIFQNLKP"
  mat_peptide 542..769
    /gene="MCP-2"
  variation 677
    /gene="MCP-2"
    /note="polymorphism, Lys -> Gln"
    /replace="c"
BASE COUNT 457 a 292 c 243 g 376 t
ORIGIN
  1 atccattgtg ctctaaagtg atggagagca ccagcaaagc cttagggccc atccctggcc
  61 tccgtgtacc cacagagggg tagggccttg gctctcttcc actatgacgt cagcttccat
  121 tcttccttcc ttatagacaa ttttccattt caaggaaatc agagccctta atagttcagt
  181 gaggtcactt tgctgagcac aatcccatac ccttcagcct ctgctccaca gagcctaagc
  241 aaaagataga aactcacaac ttccttggtt tgttatctgg aaattatccc aggatctggt
  301 gcttactcag catattcaag gaaggcttta ctccattctt ccttgattgt gaccatgccc
  361 aggcctctctg ctccctataa aaggcaggca gagccaccga ggagcagaga ggttgagaac

```



```

421 aacccagaaa ccttcacctc tcattgctgaa gctcacaccc ttgccctcca agatgaaggt
481 ttctgcagcg cttctgtgcc tgctgctcat ggcagccact ttcagccctc agggacttgc
541 tcagccagat tcagtttcca ttccaatcac ctgctgcttt aacgtgatca ataggaaaat
601 tcctatccag aggctggaga gctacacaag aatcaccaac atccaatgtc ccaaggaagc
661 tgtgatcttc aagaccaaac ggggcaagga ggtctgtgct gacccaagg agagatgggt
721 cagggattcc atgaagcatc tggaccaa atttcaaaat ctgaagccat gagccttcat
781 acatggactg agagtcatag cttgaagaaa agcttattta ttttcccaa cctccccag
841 gtgcagtgtg acattatttt attataacat ccacaaagag attattttta aataatttaa
901 agcataatat ttcttaaaaa gtatttaatt atatttaagt tgttgatgtt ttaactctat
961 ctgtcatata tcctagttaa tgtaaaatgc aaaatcctgg tgatgtgttt ttgtttttg
1021 ttttcctgtg agctcaacta agttcacggc aaaatgtcat tgttctccct cctacctgtc
1081 tgtagtgttg tggggctctc ccatggatca tcaaggtgaa acactttggt attctttggc
1141 aatcagtgtc cctgtaagtc aaatgtgtgc ttgtactgct tgttgtgaa attgatgta
1201 ctgtatataa ctatggaatt ttgaaaaaaa atttcaaaaa gaaaaaaata tatataattt
1261 aaaactaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
1321 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
//LOCUS      HSMCP3A      1085 bp      DNA      PRI      25-JUL-1994
DEFINITION   H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION    X72308 S57464
NID          g313707
KEYWORDS     monocyte chemotactic protein 3.
SOURCE       human.
ORGANISM     Homo sapiens
              Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
              Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 1085)
AUTHORS      Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
TITLE        Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of           the cDNA and comparison with other chemokines
              Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
JOURNAL      93213290
MEDLINE
REFERENCE    2 (bases 1 to 1085)
AUTHORS      Opdenakker,G.M.
TITLE        Direct Submission
JOURNAL      Submitted (27-MAY-1993) G.M. Opdenakker, Rega Institute,
University   of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
REFERENCE    3 (bases 1 to 1085)
AUTHORS      Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
              Speleman,F., Laureys,G. and Van Damme,J.
TITLE        The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
              assignment to the C-C chemokine gene cluster on chromosome
              17q11.2-q12
JOURNAL      Genomics 21 (2), 403-408 (1994)
MEDLINE      94375065
FEATURES
  source     Location/Qualifiers
             1..1085
             /organism="Homo sapiens"
             /db_xref="taxon:9606"
  gene       299..810
             /gene="MCP-3"
  CDS        299..628
             /gene="MCP-3"
             /codon_start=1
             /product="monocyte chemotactic protein-3"
             /db_xref="PID:g313708"
             /db_xref="SWISS-PROT:P80098"
/translation="MWKPMPSNMKASALLCLLLTAAAFSPQGLAQPVGINTSTTC
CYRFINKKIPKQRLESYRRTTSSHCPREAVIFKTKLDKEICADPTQKWVQDFMKHLDK
sig_peptide 299..397
             /gene="MCP-3"
mat_peptide  398..625
             /gene="MCP-3"
             /product="monocyte chemotactic protein-3"
polyA_signal 806..810
             /gene="MCP-3"
BASE COUNT  314 a    214 c    229 g    328 t

```

ORIGIN

```

1 gggtttctatt gacttgggtt aatcgtgtga ccgcggtggc tggcacgaaa ttgaccaacc
61 ctgggggttag tatagcttag ttaaactttc gtttattgct aaagggttaat cactgctggt
121 tccccgtggg gtgtgggtag gctaagcgtt ttgagctgca ttgctgcgtg cttgatgctt
181 gtcccctttg atcgtgggtga tttagagggt gaactcactg gaatggggat gcttgcatgt
241 gtaatcttac taagagctaa tagaaaggct aggaccaaac cagaaacctc caattctcat
301 gtggaagccc atgcccctac cctccaacat gaaagcctct gcagcacttc tgtgtctgct
361 gctcacagca gctgctttca gccccagggt gcttgctcag ccagttggga ttaatacttc
421 aactacctgc tgctacagat ttatcaataa gaaaatccct aagcagaggc tggagagcta
481 cagaaggacc accagtagcc actgtccccg ggaagctgta atcttcaaga ccaactgga
541 caaggagatc tgtgctgacc ccacacagaa gtgggtccag gactttatga agcacctgga
601 caagaaaacc caaactccaa agctttgaac attcatgact gaactgaaaa caagccatga
661 cttgagaaac aaataatttg tataccctgt cctttctcag agtgggtctg agattatttt
721 aatctaattc taaggaatat gagctttatg taataatgtg aatcatgggt tttcttagta
781 gattttaaaa gttattaata ttttaattta atcttccatg gattttgggt gggtttgaac
841 ataaagcctt ggatgtatat gtcattctcag tgctgtaaaa actgtgggat gctcctccct
901 tctctacctc atgggggtat tgtataagtc cttgcaagaa tcagtgcaaa gatttgcttt
961 aattgttaag atatgatgtc cctatggaag catattgtta ttatataatt acatatttgc
1021 atatgtatga ctcccaaatt ttcacataaa atagattttt gtataacaaa aaaaaaaaaa
1081 aaaaa

```

```

//
LOCUS      HSMCP3A      1085 bp      DNA      PRI      25-JUL-1994
DEFINITION H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION  X72308 S57464
NID        g313707
KEYWORDS   monocyte chemotactic protein 3.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1085)
AUTHORS    Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
TITLE      Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of         the cDNA and comparison with other chemokines
JOURNAL    Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
MEDLINE    93213290
REFERENCE  2 (bases 1 to 1085)
AUTHORS    Opdenakker,G.M.
TITLE      Direct Submission
JOURNAL    Submitted (27-MAY-1993) G.M. Opdenakker, Rega Institute,
University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
REFERENCE  3 (bases 1 to 1085)
AUTHORS    Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
            Speleman,F., Laureys,G. and Van Damme,J.
TITLE      The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
            assignment to the C-C chemokine gene cluster on chromosome
            17q11.2-q12
JOURNAL    Genomics 21 (2), 403-408 (1994)
MEDLINE    94375065
FEATURES   Location/Qualifiers
            source          1..1085
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
            gene            299..810
                        /gene="MCP-3"
            CDS              299..628
                        /gene="MCP-3"
                        /codon_start=1
                        /product="monocyte chemotactic protein-3"
                        /db_xref="PID:g313708"
                        /db_xref="SWISS-PROT:P80098"

/translation="MWKPMPSPSNMKASAALLCLLLTAAAFSPQGLAQPVGINTSTTC
CYRFINKKIPKQRLESYRRTTSSHCPREAVIFKTKLDKEICADPTQKWVQDFMKHLDK
KTQTPKL"
            sig_peptide     299..397
                        /gene="MCP-3"
            mat_peptide     398..625

```

```

        /gene="MCP-3"
        /product="monocyte chemotactic protein-3"
polyA_signal 806..810
        /gene="MCP-3"
BASE COUNT   314 a    214 c    229 g    328 t
ORIGIN
1  gggtttctatt gacttggggtt aatcgtgtga ccgcgggtggc tggcacgaaa ttgaccaacc
61  ctgggggttag tatagcttag ttaaactttc gtttattgct aaagggttaat cactgctgtt
121  tcccgtgggg gtgtggctag gctaagcgtt ttgagctgca ttgctgcgtg cttgatgctt
181  gtcccttttg atcgtgggtg tttagagggt gaactcactg gaatggggat gcttgcatgt
241  gtaatcttac taagagctaa tagaaagggt aggaccaaac cagaaacctc caattctcat
301  gtggaagccc atgccctcac cctccaacat gaaagcctct gcagcacttc tgtgtctgct
361  gctcacagca gctgctttca gcccaggg gcttgctcag ccagttggga ttaatacttc
421  aactacctgc tgctacagat ttatcaataa gaaaatccct aagcagaggc tggagagcta
481  cagaaggacc accagtagcc actgtccccg ggaagctgta atcttcaaga ccaaactgga
541  caaggagatc tgtgctgacc ccacacagaa gtgggtccag gactttatga agcacttgga
601  caagaaaacc caaactccaa agctttgaac attcatgact gaactgaaaa caagccatga
661  cttgagaaac aaataatttg tataccttgt cctttctcag agtggttctg agattatttt
721  aatctaattc taaggaatat gagctttatg taataatgtg aatcatgggt tttcttagta
781  gatttttaaaa gttattaata ttttaattta atcttccatg gattttgggt ggttttgaac
841  ataaagcctt ggatgtatat gtcattctcag tgctgtaaaa actgtgggat gctcctccct
901  tctctacctc atggggggtat tgtataagtc cttgcaagaa tcagtgcaaa gatttgcttt
961  aattgttaag atatgatgtc cctatggaag catattgtta ttatataatt acatatttgc
1021 atatgtatga ctcccaatt ttcacataaa atagattttt gtataacaaa aaaaaaaaaa
1081 aaaaaa
//LOCUS      HSU46767      825 bp      mRNA
DEFINITION   Human monocyte chemoattractant protein-4 precursor (MCP-4)
mRNA,
ACCESSION    U46767
NID          g1732122
KEYWORDS
SOURCE       human.
ORGANISM     Homo sapiens
              Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
              Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 825)
AUTHORS      Garcia-Zepeda, E.A., Combadiere, C.C., Rothenberg, M.E.,
Sarafi, M.N., Lavigne, F., Hamid, Q., Murphy, P. and Luster, A.D.
TITLE        Human monocyte chemoattractant Protein (MCP)-4: A novel CC
              chemokine with activities on monocytes, eosinophils, and
basophils
              induced in allergic and non-allergic inflammation that signals
              through the CC chemokine receptors CCR-2 and 3
JOURNAL      J. Immunol. 158 (1996) In press
REFERENCE    2 (bases 1 to 825)
AUTHORS      Garcia-Zepeda, E.A. and Luster, A.D.
TITLE        Direct Submission
JOURNAL      Submitted (22-JAN-1996) Eduardo A. Garcia-Zepeda, Infectious
              Disease Unit, Massachusetts General Hospital, 149 13th St.,
              Charlestown, MA 02129, USA
FEATURES
    source    Location/Qualifiers
              1..825
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
              /tissue_type="heart"
              /clone_lib="EG3.16"
    sig_peptide
              34..102
              /gene="MCP-4"
    CDS       34..330
              /gene="MCP-4"
              /note="small cytokine; intercrine/chemokine; C-C
subfamily    signature; chemoattractant for monocytes, eosinophils"
              /codon_start=1
              /product="monocyte chemoattractant protein-4"
precursor    /db_xref="PID:g1732123"
/translation="MKVSAVLLCLLLMTAAFNPPQGLAQPDALNVPSTCCFTFSSKKIS

```

LQRLKSYVITTSRCPQKAVIFRTKLGEICADPKEKWVQNYMKHLGRKAHTLKT*

```

gene          34..330
               /gene="MCP-4"
mat_peptide   103..327
               /gene="MCP-4"

BASE COUNT    221 a    175 c    185 g    244 t
ORIGIN
1  acattgtgaa atctccaact cttaaccttc aacatgaaag tctctgcagt gttctgtgac
61 ctgctgctca tgacagcagc ttccaacccc cagggacttg ctcagccaga tgcactcaac
121 gtcccatcta cttgctgctt cacatttagc agtaagaaga tctccttgca gaggtggaag
181 agctatgtga tcaccaccag caggtgtccc cagaaggctg tcactttcag aaccaaactg
241 ggcaaggaga tctgtgtgta cccaaaggag aagtgggtcc agaattatat gaaacacctg
301 ggccggaaag ctacacacct gaagacttga actctgttac ccctactgaa atcaagctgg
361 agtacgtgaa atgacttttc cattctcctc tggcctcctc ttctatgctt tggaatactt
421 ctaccataat ttcaaatag gatgcattcg gttttgtgat tcaaaatgta ctatgtgtta
481 agtaatatgt gctattattt gacttgttgc tggtttggag tttatttgag tattgtgat
541 cttttctaaa gcaaggcctt gagcaagtag gttgctgtct ctaagcccc ttcccttcca
601 ctatgagctg ctggcagtg gttgtattcg gttcccaggg gttgagagca tgcctgtggg
661 agtcatggac atgaagggat gctgcaatgt aggaaggaga gctctttgtg aatgtgaggt
721 tgttgctaaa ttattgttta ttgtggaaag atgaatgcaa tagtaggact gctgacattt
781 tgcagaaaat acattttatt taaaatctcc taaaaaaaaa aaaaa

//LOCUS      HSAMAC1      803 bp      RNA      PRI      10-AUG-1997
DEFINITION   Homo sapiens mRNA for alternative activated macrophage specific
CC
chemokine 1.
ACCESSION    Y13710
NID          g2326515
KEYWORDS     AMAC-1 gene; CC-chemokine 1.
SOURCE       human. ORGANISM Homo sapiens
              Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
              Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
              Hominidae;
              Homo.
REFERENCE    1 (bases 1 to 803)
AUTHORS      Politz,O.
TITLE        Direct Submission
JOURNAL      Submitted (10-JUN-1997) Politz O., Dermatology, Free University
              Benjamin Franklin Medical Center, Hindenburgdamm 30; 12200
              Berlin
              GERMANY
REFERENCE    2 (bases 1 to 803)
AUTHORS      Kodolja,V., Mueller,C., Politz,O., Hakiy,N., Orfanos,C.E. and
              Goerdts,S.
TITLE        Cloning of alternative activated macrophage associated CC
chemokine
JOURNAL      1 (AMAC-1)
              Unpublished
FEATURES     Location/Qualifiers
             source          1..803
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
                           /cell_type="macrophage"
             sig_peptide     71..133
                           /gene="amac-1"
             CDS              71..340
                           /gene="amac-1"
                           /note="macrophage specific"
                           /codon_start=1
                           /product="CC-chemokine 1"
                           /db_xref="PID:e321838"
                           /db_xref="PID:g2326516"

/translation="MKGLAAALLVLVCTMALCSCAQVGTNKLCCLVYTSWQIPQKFI
              VDYSSETSPQC PKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA"
gene          71..340
               /gene="amac-1"
mat_peptide   134..337
               /gene="amac-1"

BASE COUNT    214 a    213 c    160 g    216 t
ORIGIN

```

```

1 cccgcacgag aggagttgtg agtttccaag cccagctca ctctgaccac ttctctgcct
61 gcccagcatc atgaagggcc ttgcagctgc cctccttgtc ctgctctgca ccatggccct
121 ctgctcctgt gcacaagttg gtaccaacaa agagctctgc tgctctgtct atacctcctg
181 gcagattcca caaaagtcca tagttgacta ttctgaaacc agccccaggt gcccgaagcc
241 aggtgtcatc ctctaacca agagaggccg gcagatctgt gctgacccca ataagaagtg
301 ggtccagaaa tacatcagcg acctgaagct gaatgcctga ggggcctgga agctgcgagg
361 gcccagtcaa cttggtgggc ccaggaggga acaggagcct gagccaggga aatggccctg
421 ccaccctgga ggccacctct tctaagagtc ccatctgcta tgcccagcca cattaactaa
481 ctttaattctt agtttatgca tcatatttca ttttgaattt gatttctatt gttgagctgc
541 attatgaaat tagtattttc tctgacatct catgacattg tctttatcat cctttccctt
601 ttcccttcaa ctcttcgtac attcaatgca tggatcaatc agtgatgata gctttctcag
661 cagacattgt gccatatgta tcaaatgaca aatctttatt gaatggtttt gctcagcacc
721 accttttaat atattggcag tactttattat ataaaaggta aaccagcatt ctactgtga
781 aaaaaaaaaa aaaaaaaaaa aaa

```

```

//
LOCUS       HUMLD78A      3176 bp      DNA
DEFINITION Human LD78 alpha gene.
ACCESSION   D90144
NID         g219905
KEYWORDS    LD78; LD78 alpha; cytokine; inducible gene family; secreted
            peptide.
SOURCE      Human blood lymphocyte DNA, clone Lm LD-3.
ORGANISM    Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
            Hominidae; Homo.
REFERENCE   1 (bases 1 to 3176)
AUTHORS     Nakao,M.; Nomiya,H. and Shimada,K.
TITLE       Structures of human genes coding for cytokine LD78 and their
            expression
JOURNAL     Mol. Cell. Biol. 10 (7), 3646-3658 (1990)
MEDLINE     90287155
COMMENT     These data kindly submitted in computer readable form by:
            Hisayuki

```

```

Nomiya
Department of Biochemistry
Kumamoto University Medical School
2-2-1 Honjo, Kumamoto 860
Japan
Phone: 096-344-2111
Fax: 096-372-6140.
FEATURES             Location/Qualifiers
     source            1..3176
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
     TATA_signal        1041..1045
     exon               1069..1227
                        /number=1
     prim_transcript    1069..2957
                        /note="LD78 alpha mRNA and introns"
     sig_peptide        1155..1220
                        /note="LD78 alpha signal peptide"
     CDS                join(1155..1227,1916..2030,2451..2541)
                        /codon_start=1
                        /product="LD78 alpha precursor"
                        /db_xref="PID:d1014875"
                        /db_xref="PID:g219906"
/translation="MQVSTAALAVLLCTMALCNQFSASLAADTPTACCFSTSRQIPQ
NFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWQKYVSDLELSA"
     mat_peptide        join(1218..1227,1916..2030,2451..2538)
                        /partial
                        /note="LD78 alpha mature peptide"
     intron             1228..1915
     exon               1916..2030
                        /partial
                        /number=2
     intron             2031..2450
     exon               2451..2957
                        /number=3

```

```

BASE COUNT      833 a      741 c      752 g      850 t
ORIGIN
1  acccagggac ctatcacaca aatataagaa ctattcattc ttttaaggcat gtatttccaa
61  gcctttgtat ttttttccat gcttaggggt ggcaagggaat atatatatat ttgtacaaat
121 atatatgtgt atagtacaaa atacatgtat atatatagta aatatatata tatatttgta
181 caattcttca gactttgtag aatttgtata atgtcgtatc ttgtcttttt taaccactga
241 tgttataagc atatttatgc cacttcattc attttagaga ctttaataata aatgatctag
301 tggataaatt atcattccct gatggagaaa aatttagctt tgtttatttt agagtataaa
361 acgatgctgg gtcaggatc tttatgtttg aagatggctc catatttggg ttgtttccac
421 agaactcttt cctagaaatg ctttttctag gttaatggct acagatattt ctaggcacct
481 gacatatgga caccacctc taaagtattt ttatgatcca caactagcgt ttaacacagc
541 gccctagtca ctacatgact aataaataga caaatgactg aaacatgacc tcatgctttc
601 tattctctca gctttcattc agttctttgc ctctgggagg aggaagggtt gtgcagccct
661 ccacagcatc agcccatcaa cctatccctt gtggttatag cagctgagga agcagaattg
721 cagctctgtg ggaaggaaat gggctggaga gttcatgcac agaccagttc ttatgagaag
781 ggactgacta agaatagcct tgggttgaca tatacccttc ttcacactca caggagaaac
841 catttcccta tgaaactata acaagtcacg agttgagagc tgagagttag agaatagtct
901 aaagatgcta ttcttggaata tcctgagccc ctgtgggtcac caggggacctt gagttgtgca
961 acttagcatg acagcatcac tacgcttaaa aatttccctc ctacccctca gattccattt
1021 ccccatccgc cagggtctgc tataaaggag agagctgggt tcagacttca gaaggacacg
1081 ggcagcagac agtggctcagt cctttcttgg ctctgctgac actcgagccc acattccgtc
1141 acctgctcag aatcatgcag gtctccactg ctgcctttgc tgtctctctc tgcaccatgg
1201 ctctctgcaa ccagttctct gcatcacgtg agtctgagtt tcgttggagg tatcaccact
1261 ctctggccat gggttagacca catcaatctt ttcttggggc ctaaaagccc ccaagagaaa
1321 agagaacttc ttaaaggggt cccaacatc ttgggtcttc tctttaagac ttttattttt
1381 atctctagaa ggggtcttag cccctagtc tccaggtagt agaactctag caggggcagg
1441 ggagttacag tcccttttac agatagaaaa acagggttcg aaacgaatca gttagcaaga
1501 ggcagaatcc aggggtctct acttcccagt ggggtatggt gttcactctc cagctcactc
1561 taggtctccc agggagctctg tcccttggat gtcttatgag agatgtccaa ggcttctctt
1621 ggggtggggg atgacttctt gaaccagaca aaattccctg aagagaactg agataagaga
1681 acagtccgtt caggtatctg gatcacacag agaaaacagag aaccacttat gaagagtcaa
1741 ggagaaagaa ggatacagac agaaacaaag agacatttct cagcaaaaat gcccaaatgc
1801 cttccagtc cttgggtctga gcaagcctgc cttctcaac tgctcgggga tcagaagctg
1861 cctggccttt tcttctgagc tgtgactcgg gctcattctc ttcttctctc cacagttgct
1921 gctgacacgc cgaccgcctg ctgcttcagc tacacctccc ggcagattcc acagaatttc
1981 atagctgact actttgagag gagcagccag tgctccaagc cgggtgtcat gtaagtgcc
2041 gtcttctctg tcacctctat ggaggtaggg agggtcaggg ttggggcaga gacaggccag
2101 aaggctatcc tggaaaggcc cagccttcag gagcctatcg gggatacagg acgagggtct
2161 ccgaggtgtg acctgacttg gagctggagt gaggcattgt ttacagagtc aggaagggtc
2221 gccccagccc agaggaaaag gacaggaaga agggagcagc gggacactct gagggccacc
2281 cctactgagt cactgagaga agctctctag acagagatag gcaggggggc cctgaaagag
2341 gagcaagccc tgagctgccc aggcagagaga gcagaatggt gggggccatg tggggccagg
2401 attccccctg tggattcccc agtgcttaac tcttctctcc ttctccacag ctctcctaac
2461 aagcgaagcc ggcaggtctg tgctgacccc agtgaggagt ggggtccaga atatgtcagc
2521 gacctggagc tgagtgcctg aggggtccag aagcttcgag gccagcgac ctcggtgggc
2581 ccagtgggga ggagcaggag cctgagcctt gggaaacatg gtgtgacctc cacagctacc
2641 tcttctatgg actggttgtt gccaaacagc cacactgtgg gactcttctt aacttaaatt
2701 ttaatttatt tatactattt agtttttcta atttatttcc gatttcacag ttgtttgtg
2761 attgtttgct ctgagagttc ccctgtcccc tcccccttcc ctacaccgc gtctggtgac
2821 aaccgagtgg ctgtcatcag cctgtgtagg cagtcatggc accaaaagcca ccagactgac
2881 aaatgtgtat cggatgcttt tgttcagggc tgtgatcggc ctggggaaat aataaagatg
2941 ctctttttaa aggtaaacca gtattgagtt tgggtttgtt tttctggcaa atcaaaatca
3001 ctggttaaga ggaatcatag gcaaagatta ggaagagggt aaatggaggg aaattgggag
3061 agatggggag ggctaccaca gatttatcca ctttacaacg gagacacagt tctggaacat
3121 tgaactacg aatatgttat aactcaaatc ataacatgca tgctctagga gaattc

```

```

//
LOCUS      AF043339      225 bp      mRNA      PRI      23-FEB-1998
DEFINITION Homo sapiens macrophage inflammatory protein 1 alpha (MIP1a)
            mRNA,
            partial cds.
ACCESSION  AF043339
NID        g2905627
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 225)
AUTHORS    Jang, J.S. and Kim, B.E.
TITLE      Direct Submission
JOURNAL    Submitted (15-JAN-1998) Protein Engineering, General Institute

```

of
 Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong,
 Sosa-gu, Bucheon 422-231, Korea
 COMMENT forward primer (5'-tgcgcatcacttgctgctgaca-3')
 reverse primer (5'-cttctggaccctcaggcact-3').
 FEATURES Location/Qualifiers
 source 1..225
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PHA-treated peripheral blood leukocyte"
 gene <1..225
 /gene="MIP1a"
 primer_bind <1..19
 /gene="MIP1a"
 cycles; /PCR_conditions="94C-1min, 50C-1min, 72C-3min, 30
 CDS DeltaCycler II from Ericomp"
 <1..213
 /gene="MIP1a"
 /function="CC chemokine"
 /function="proinflammatory cytokine involved in
 inflammation"
 /note="8-10 kDa"
 /codon_start=1
 /product="macrophage inflammatory protein 1 alpha"
 /db_xref="PID:g2905628"
 /translation="ASLAADTPTACCFSYTSRQIPONFIADYFETSSQCSKPGVIFLT"
 primer_bind KRSRQVCADPSEEWVQKYVSDLELSA"
 complement(205..225)
 /gene="MIP1a"
 BASE COUNT 50 a 68 c 62 g 45 t
 ORIGIN
 1 gcatcacttg ctgctgacac gccgaccgcc tgctgcttca gctacacctc ccggcagatt
 61 ccacagaatt tcatagctga ctactttgag acgagcagcc agtgctccaa gcccggtgtc
 121 atcttcctaa ccaagcgaag ccggcaggtc tgtgctgacc ccagtgagga gtgggtccag
 181 aaatatgtca gcgacctgga gctgagtgcc tgaggggtcc agaag
 //
 LOCUS HUMLD78B 3112 bp DNA PRI 17-JAN-1992
 DEFINITION Human LD78 beta gene.
 ACCESSION D90145
 NID g219907
 KEYWORDS LD78; LD78 beta; cytokine; inducible gene family; secreted
 peptide.
 SOURCE Human placenta DNA, clone Lm LD-1.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae;
 Homo.
 REFERENCE 1 (bases 1 to 3112)
 AUTHORS Nakao,M., Nomiya,H. and Shimada,K.
 TITLE Structures of human genes coding for cytokine LD78 and their
 expression
 JOURNAL Mol. Cell. Biol. 10 (7), 3646-3658 (1990)
 MEDLINE 90287155
 COMMENT These data kindly submitted in computer readable form by:
 Hisayuki
 Nomiya
 Department of Biochemistry
 Kumamoto University Medical School
 2-2-1 Honjo, Kumamoto 860
 Japan
 Phone: 096-344-2111
 Fax: 096-372-6140.
 FEATURES Location/Qualifiers
 source 1..3112
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 repeat_unit 498..797
 /note="Alu repeat"

```

TATA_signal      1078..1082
prim_transcript  1106..2995
                  /note="LD78 beta mRNA and introns"
exon              1106..1267
                  /note="LD78 beta precursor, coding region of exon 1"
                  /number=1
CDS               join(1192..1267,1953..2067,2488..2578)
                  /partial
                  /codon_start=1
                  /product="LD78 beta precursor"
                  /db_xref="PID:d1014876"
                  /db_xref="PID:g219908"

/translation="MQVSTAALAVLLCTMALCNQVLSAPLAADPTACCFSYTSRQIP
              QNFIADYFETSSQCSKPSVIFLTRGRQVCADPSEEWVQKYVSDLELSA"
sig_peptide      1192..1260
                  /partial
                  /note="LD78 beta signal peptide"
mat_peptide       join(1258..1267,1953..2067,2488..2575)
                  /partial
                  /note="LD78 beta mature peptide"
intron            1268..1952
exon              1953..2067
                  /number=2
intron            2068..2487
exon              2488..2955
                  /number=3

BASE COUNT      756 a    775 c    780 g    801 t
ORIGIN
1 ttagagactt aataataaag gatcttgttg ataatttatt attccctgat agagaaaaat
61 ttagctttgc ttatttttaga gttataaatg atgctgggtc aggtatcttt atgtttgaag
121 atggctccat atttgggttg tttccacaga actctttccc agaaatgctt tttctagggt
181 aatggctaca catatttcta ggcacctgac atactgacac ccacctctaa agtattttta
241 tgatccacaa cttagcgttta acacagcgcc ccagtcactc cgagactaat aaatagacaa
301 atgactgaaa cgtgacctca tgctttctat tcctccagct ttcattgagt tcctttccct
361 tgggaggact ggggggttgc tagccctcca cagcatcagc ccattgaccc tatccttggt
421 gttatagcag ctgaggaagc agaattacag ctctgtggga aggaatgggg ctggagagtt
481 catgcataga ccaattcttt tttttttttt tttttgagat ggagtttcc ttttgttgcc
541 caggctggag tgcaatggca tgatctcagc tcaccacagc cccacacctc tgggttcaag
601 cgattctcct gccctcagcc tcccgagtag ctgggattac aggcattgtc caccacgctt
661 gactactttt gtatttttag tagagatgga gtttctcttt cttggtcagg ttggtctcaa
721 actcctgacc tcaggtgata cgcagcctcg gcctcccaaa gtgttgggat tacaggtgtg
781 agcgaccatg cctggctgca tagaccagtt cttatgagaa gggatcaact aagaatagcc
841 ttgggttgac acacaccctt cttcacactc acaggagaaa ccccatgaag ctgaaaccag
901 tcatgagttg agagctgaga gttagagagt agctcagaga tgctatctt ggatctctg
961 agccctctgt gtcaccaggg accctgagtt gtgcaactac cagcatgaca gcatcactac
1021 acttaaaaat ttcctcctc acccccagat tccatttccc catccgccag ggctgcttat
1081 aaagaggaga gatggcttca gacatcagaa ggacgcaggc agcaaagagt agtcagtccc
1141 ttcttggttc tgetgacact cgagcccaca ttccatcacc tgctcccaat catgcaggtc
1201 tccactgctg cccttgccgt cctcctctgc accatggctc tctgcaacca ggtcctctct
1261 gcaccagtg agtccatggt gttgttgttg gtatcaccac tcttgggcca tggttagacc
1321 acatcagttc ttttttgctg cctgagagcc ccgaagagaa aagaaggaag ttcttaagc
1381 gctgccaaac accttggtct tttctttcac aacttttatt tttatctcta gaaggggtct
1441 tagccctcct agtctccagg tatgagaatc taggcagggg caggggagtt acagtcctt
1501 gtacagatag aaaaacaggg ttcaaaacga atcagtttgc aagaggcaga atccagggtt
1561 gcttacttcc cagtggggtc tgtgtttcac tctccagctc accctagggt tcccaggagc
1621 cctgtccctt ggtgtcttta tgagagatgt ccagggtctc tcttgggctg gggatgact
1681 tcttgaaccg acaaaattcc atgaagagag ctaagagaac agtccattca ggtatctgga
1741 tcacatagag aaacagagaa cccactatga agagtcaagg ggaaagagga atatagacag
1801 aaacaaagag acatttctct gcaaaaaccc ccaaatgcct tgcagtcact tggctctgagc
1861 aagcctgccc tcctcaacca ctcagggtat agaagctgcc tggccttttc tctgagctg
1921 tgactcgggc ttattctctc ctttctccgc agttgctgct gacacgccga ccgctgtctg
1981 cttcagctac acctcccgac agattccaca gaatttcata gctgactact ttgagacgag
2041 cagccagtg cccaagccca gtgtcatgta agtgccagtc tctctgctca ccttaggga
2101 ggtaggaggt gtcagggtgg gggcagaaac aggccagaag gccatcttgg aaaggccag
2161 ccttcaggag cctatcgggg atacaggagc cagggcactg aggtgtgacc tgacttgggg
2221 ctggagtgag gtgggtgtta cagagtcagg aagggtgtcc ccaggccaga ggaaaggaac
2281 aggaagaagg aggcagcagg acactctgag ggcccccttg cctggagtc ctgagagaag
2341 ctctctagac ggagataggg agggggcccc tgagagagga gcaggccttg agctgccag
2401 gacagagagc aggatgtcag gccatggttg gcccaggatt ccccggtctg attccccagt
2461 gcttaactct tcctcccttc tccacagctt cctaaccaag agaggccggc aggtctgtgc

```



```

2521 tgacccagct gaggagtggg tccagaaata cgtcagtgac ctggagctga gtgcctgagg
2581 gggtccagaag cttcgaggcc cagcgacctc agtggggccca gtgggggagga gcaggagcct
2641 gagccttgagg aacatgcgtg tgacctctac agctacctct tctatggact ggttattgcc
2701 aaacagccac actgtgggac tcttcttaac ttaaatttta atttatttat actatttagt
2761 ttttataatt tatttttgat ttcacagtgt gtttgtgatt gtttgctctg agagtccccc
2821 ctgtcccttc caccctccct cacagtgtgt ctgggtgacga ccgagtggct gtcacggccc
2881 tgtgtaggca gtcattggac caaagccacc agactgacaa atgtgtatca gatgcttttg
2941 ttcagggctg tgatcggcct ggggaaataa taaagatgtt cttttaaacg gtaaaccagt
3001 attgagtttg gttttgtttt tctggcaaat caaaatcact agttaagagg aatcatagga
3061 aaagattagg aagaggtgaa atggagggaa actgggagag atggggagcg ct

```

```

//
LOCUS          HUMACT2A          696 bp      mRNA          PRI          30-OCT-1994
DEFINITION     Human activation (Act-2) mRNA, complete cds.
ACCESSION      J04130
NID            g178017
KEYWORDS       act2 gene; immune activation gene.
SOURCE         Human (Hut-102B2 library) activated T cells, cDNA to mRNA.
ORGANISM       Homo sapiens
               Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
               Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 (bases 1 to 696)
AUTHORS        Lipes,M.A., Napolitano,M., Jeang,K.T., Chang,N.T. and
Leonard,W.J.
TITLE          Identification, cloning, and characterization of an immune
               activation gene
JOURNAL        Proc. Natl. Acad. Sci. U.S.A. 85 (24), 9704-9708 (1988)
MEDLINE        89071764
COMMENT        Draft entry and computer-readable sequence [1] kindly submitted
               by
               W.Leonard, 09-JAN-1989.

```

```

FEATURES             Location/Qualifiers
    source             1..696
                       /organism="Homo sapiens"
                       /db_xref="taxon:9606"
                       /map="Unassigned"
    mRNA               <1..696
                       /note="act-2 mRNA"
    sig_peptide        109..177
                       /gene="LAG2"
                       /note="act-2 protein signal peptide"
    gene               109..387
                       /gene="LAG2"
    CDS                109..387
                       /gene="LAG2"
                       /note="act-2 protein precursor"
                       /codon_start=1
                       /db_xref="GDB:G00-127-452"
                       /db_xref="PID:g178018"
    /translation="MKLCVTVLSSLMLVA AFCSPALSAPMGSDPPTACCFSTARKLP
    mat_peptide        178..384
                       /gene="LAG2"
                       /note="act-2 protein"

```

```

BASE COUNT      157 a      203 c      139 g      197 t
ORIGIN           Unreported.

```

```

1  tccccccccc cccccccccc ccccgcccca gcacaggaca cagctggggt ctgaagcttc
61  tgagttctgc agcctcacct ctgagaaaac ctcttttcca ccaataccat gaagctctgc
121 gtgactgtcc tgtctctcct catgctagta gctgccttct gctctccagc gctctcagca
181 ccaatgggct cagaccctcc caccgcctgc tgcttttctt acaccgcgag gaagcttctt
241 cgcaactttg tggtagatta ctatgagacc agcagcctct gctcccagcc agctgtggta
301 ttccaaacca aaagaagcaa gcaagtctgt gctgatccca gtgaatcctg ggtccaggag
361 tacgtgtatg acctggaact gaactgagct gctcagagac aggaagtctt cagggaaggt
421 caccctgagcc cggatgcttc tccatgagac acatctcttc catactcagg actcctctcc
481 gcagtctctg tcccttctct taatttaate ttttttatgt gccgtgttat tgtattaggt
541 gtcatttcca ttatttatat tagtttagcc aaaggataag tgctctatgg ggaatggcca
601 ctgtcactgt ttctctgctg ttgcaaatat atggataaca catttgattc tgtgtgtttt
661 ccataataaa acttttaaat aaaatgcaga cagtta

```

```

//
LOCUS          AF031587          481 bp      mRNA          PRI          02-JAN-1998
DEFINITION     Homo sapiens MIP-1 delta mRNA, complete cds.

```

ACCESSION AF031587
 NID g2739163
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 481)
 AUTHORS Wang, W.
 TITLE Molecular cloning and characterization of a new CC chemokine
 MIP-1
 delta
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 481)
 AUTHORS Wang, W.
 TITLE Direct Submission
 JOURNAL Submitted (27-OCT-1997) Immunobiology, DNAX Research Institute,
 901 California Ave, Palo Alto, CA 94304, USA
 FEATURES
 source Location/Qualifiers
 1..481
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="17"
 CDS 1..342
 /note="CC or beta chemokine"
 /codon_start=1
 /product="MIP-1 delta"
 /db_xref="PID:g2739164"
 /translation="MKVSVAALSCMLMLVAVLGSQAQFINDAETELMMSKLPLENPVVL
 NSFHFAADCCTSYISQSIPLCSLMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"
 BASE COUNT 140 a 112 c 100 g 129 t
 ORIGIN
 1 atgaaggtct cctgtgctgc cctctcctgc ctcatgcttg ttgctgtcct tggatcccag
 61 gccagttca taaatgatgc agagacagag ttaatgatgt caaagcttcc actggaaaat
 121 ccagtagttc tgaacagctt tcactttgct gctgactgct gcacctccta catctcacia
 181 agcatcccggt gttcactcat gaaaagttat tttgaaacga gcagcggagt ctccaagcca
 241 ggtgtcatat tcctcaccaa gaaggggagg caagtctgtg ccaaaccag tgggtccggga
 301 gttcaggatt gcatgaaaaa gctgaagccc tactcaatat aataataaag agacaaaaga
 361 gggcagccac ccacctccaa cacctcctgt gagtttcttg gtctgaaata cttaaaaaat
 421 atatatattg ttgtgtctgg taatgaaagt aatgcatcta ataaagagta ttcaattttt
 481 t
 //
 LOCUS AF043340 234 bp mRNA PRI 23-FEB-1998
 DEFINITION Homo sapiens macrophage inflammatory protein 2 alpha (MIP2a)
 mRNA,
 partial cds.
 ACCESSION AF043340
 NID g2905629
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 234)
 AUTHORS Jang, J.S. and Kim, B.E.
 TITLE Direct Submission
 JOURNAL Submitted (15-JAN-1998) Protein Engineering, General Institute
 of Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong,
 Sosa-gu, Bucheon 422-231, Korea
 COMMENT forward primer (5'-tgcgcacccttgccactgaactg-3')
 reverse primer (5'-ccttcctctgtcagttgga-3').
 FEATURES
 source Location/Qualifiers
 1..234
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PHA-treated peripheral blood leukocyte"

```

gene          <1..234
               /gene="MIP2a"
primer_bind   <1..21
               /gene="MIP2a"
               /PCR_conditions="94C-1min, 50C-1min, 72C-3min, 30
cycles;
               DeltaCycler II from Ericomp"
CDS           <1..222
               /gene="MIP2a"
               /function="CXC chemokine"
               /function="proinflammatory cytokine involved in
inflammation"
               /note="8-10 kDa"
               /codon_start=1
               /product="macrophage inflammatory protein 2 alpha"
               /db_xref="PID:g2905630"

/translation="APLATELRQCQLQTLOGIHLKNIQSVKVKSPGPHCAQTEVIATL
               KNGQKACLNPASPMVKKIIIEKMLKNGKSN"
primer_bind   complement(214..234)
               /gene="MIP2a"
BASE COUNT    74 a      70 c      54 g      36 t
ORIGIN
    1 gcacccttg ccaactgaact gcgctgcccag tgcttgccaga ccctgcaggg aattcacctc
   61 aagaacatcc aaagtgtgaa ggtgaagtcc cccggacccc actgcgcca aaccgaagtc
  121 atagccacac tcaagaatgg gcagaaagct tgtctcaacc ccgcatcgcc catggttaag
  181 aaaatcatcg aaaagatgct gaaaaatggc aaatccaact gaccagaagg aagg

//
LOCUS          HSU77035      764 bp      mRNA                      PRI      23-JAN-1997
DEFINITION     Human macrophage inflammatory protein 3 alpha (MIP-3a) mRNA,
complete cds.
ACCESSION      U77035
NID            g1790924
KEYWORDS
SOURCE         human.
ORGANISM       Homo sapiens
               Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
               Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 (bases 1 to 764)
AUTHORS        Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
               Zlotnik,A.
TITLE          Identification through bioinformatics of two new macrophage
proinflammatory human chemokines: MIP-3alpha and MIP-3beta
JOURNAL        J. Immunol. 158 (3), 1033-1036 (1997)
MEDLINE        97166046
REFERENCE      2 (bases 1 to 764)
AUTHORS        Rossi,D.L. and Zlotnik,A.
TITLE          Direct Submission
JOURNAL        Submitted (31-OCT-1996) Immunology, DNAX Research Institute,
901
               California Ave., Palo Alto, CA 94304, USA
FEATURES
source         Location/Qualifiers
               1..764
               /organism="Homo sapiens"
               /db_xref="taxon:9606"
               /cell_type="elutriated monocytes activated with
               LPS/IFN-GAMMA"
gene          1..291
               /gene="MIP-3a"
CDS           1..291
               /gene="MIP-3a"
               /note="chemokine"
               /codon_start=1
               /product="macrophage inflammatory protein 3 alpha"
               /db_xref="PID:g1790925"

/translation="MCCTKSLLLAALMSVLLHLGGESEASNFDCCLGYTDRIHLPK
               FIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTVWKYIVRLLSKVKNM"
BASE COUNT    235 a      121 c      146 g      260 t      2 others
ORIGIN
    1 atgtgctgta ccaagagttt gctcctggct gctttgatgt cagtgtgct actccacctc

```

```

61 tgcggcgaat cagaagcagc aagcaacttt gactgctgtc ttggatacac agaccgtatt
121 cttcatccta aattttattgt gggcttcaca cggcagctgg ccaatgaagg ctgtgacatc
181 aatgctatca tcttttcacac aaagaaaaag ttgtctgtgt gcgcaaatcc aaaacagact
241 tgggtgaaat atattgtgcg tctcctcagt aaaaaagtca agaaccatgta aaaactgtgg
301 cttttctgga atggaattgg acatagccca agaacagaaa gaaccttgct ggggttggag
361 gtttcacttg cacatcatgg aggggttagt gcttatctaa tttgtgcctc actggacttg
421 tccaattaat gaagttgatt catattgcat catagtttgc tttgtttaag catcacatta
481 aagttaaact gtattttatg ttatttatag ctgtagggtt tctgtgttta gctatttaac
541 actaattttc cataagctat tttgggttag tgcaaagtat aaaattatat ttggggggga
601 ataagattat atggactttt ttgcaagcaa caagctattt tttaaaamma actatttaac
661 attcttttgt ttatattgtt ttgtctccta aattgttgta attgcattat aaaataagaa
721 aaatattaat aagacaaata ttgaaaataa agaaacaaaa agtt

```

```

//
LOCUS      HSU77180      545 bp      mRNA      PRI      23-JAN-1997
DEFINITION Human macrophage inflammatory protein 3 beta (MIP-3beta) mRNA,
complete cds.
ACCESSION  U77180
NID        g1791002
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 545)
AUTHORS    Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
            Zlotnik,A.
TITLE      Identification through bioinformatics of two new macrophage
            proinflammatory human chemokines: MIP-3alpha and MIP-3beta
JOURNAL     J. Immunol. 158 (3), 1033-1036 (1997)
MEDLINE     97166046
REFERENCE  2 (bases 1 to 545)
AUTHORS    Vicari,A. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL     Submitted (01-NOV-1996) Immunology, DNAX Research Institute,
901         California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source      1..545
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /cell_type="macrophages activated with LPS or IFNg"
                        /chromosome="9"
            gene        1..297
                        /gene="MIP-3beta"
            CDS          1..297
                        /gene="MIP-3beta"
                        /function="chemokine"
                        /codon_start=1
                        /product="macrophage inflammatory protein 3 beta"
                        /db_xref="PID:g1791003"

```

/translation="MALLLALLSLVLWTSPAPTLSGTNDACCLSVTQKPIPGYIVR

NFHYLLIKDGCRVPAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMKRRSS"

BASE COUNT 125 a 160 c 153 g 107 t

```

ORIGIN
1 atggccctgc tactggccct cagcctgctg gttctctgga cttccccagc cccaactctg
61 agtggcacca atgatgctga agactgctgc ctgtctgtga cccagaaacc catccctggg
121 tacatcgtga ggaacttcca ctaccttctc atcaaggatg gctgcagggt gctgctgta
181 gtgttcacca cactgagggg ccgccagctc tgtgcacccc cagaccagcc ctgggtagaa
241 cgcacatccc agagactgca gaggacctca gccaaagatga agcgcgcgag cagttaacct
301 atgaccgtgc agagggagcc cggagtccga gtcaagcatt gtgaattatt acctaacctg
361 gggaaaccgag gaccagaagg aaggaccagg cttccagctc ctctgcacca gacctgacca
421 gccaggacag ggcctggggg gtgtgtgagt gtgagtgtga gcgagagggt gagtgtggtc
481 tagagtaaag ctgctccacc ccagattgac aatgctacca ataaagccgc ctggtgttta
541 caact

```

```

//
LOCUS      HUMTCSM      1160 bp      mRNA      PRI      15-JUN-1989
DEFINITION Human T cell-specific protein (RANTES) mRNA, complete cds.
ACCESSION  M21121
NID        g339420

```

KEYWORDS Alu repeat; T-cell-specific protein.
 SOURCE Human peripheral blood (T lymphocyte) cell line AH2, cDNA to mRNA, clone 228.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1160)
 AUTHORS Schall, T.J., Jongstra, J., Dyer, B.J., Jorgensen, J., Clayberger, C., Davis, M.M. and Krensky, A.M.
 TITLE A human T cell-specific molecule is a member of a new gene family
 JOURNAL J. Immunol. 141, 1018-1025 (1988)
 MEDLINE 88285659
 COMMENT Draft entry and computer-readable sequence for [1] kindly provided by A.M.Krensky, 24-OCT-1988.

FEATURES
 source Location/Qualifiers
 1..1160
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 27..302
 /note="T cell-specific protein precursor"
 /codon_start=1
 /db_xref="PID:g339421"

/translation="MKVSAARLAVILIATLALCAPASAPYSSDTPCCFAYIARPLPR
 AHIKEYFYTSGKCSNPVVFVTRKNRQVCANPEKKWVREYINSLEMS"

sig_peptide 27..95
 /note="T cell-specific protein signal peptide"

mat_peptide 96..299
 /note="T cell-specific protein"

repeat_region 450..950
 /note="Alu-related repeats"

BASE COUNT 298 a 332 c 295 g 235 t

ORIGIN 276 bp upstream of RsaI site.

```

1 cctccgacag cctctccaca ggtaccatga aggtctccgc ggcacgcctc gctgtcatcc
61 tcattgctac tgcctctgct gctcctgcat ctgctctccc atattcctcg gacaccacac
121 cctgctgctt tgcctacatt gcccgccac tgcctcgtgc ccacatcaag gagtatttct
181 acaccagtgg caagtgtctc aaccagcag tcgtctttgt caccgaaag aaccgccaag
241 tgtgtgccaa cccagagaag aaatgggttc gggagtacat caactctttg gagatgagct
301 aggatggaga gtccttgaac ctgaacttac acaaatttgc ctgtttctgc ttgctcttgt
361 cctagcttgg gaggtctccc ctactatcc taccacaccc gctccttgaa gggcccagat
421 tctgaccacg acgagcagca gttacaaaaa cttcccccag gctggacgtg gtggctcagc
481 cttgtaatcc cagcactttg ggaggccaag gtgggtggat cacttgaggt caggagttcg
541 agacagcctg gccaacatga tgaaacccca tgtgtactaa aaatacaaaa aattagccgg
601 gcgtggtagc ggcgcctgt agtccagct actcgggagg ctgaggcagg agaatggcgt
661 gaacccggga gcggagcttg cagtgcgagc agatcgcgcc actgcactcc agcctgggag
721 acagagcgag actcgtctc aaaaaaaaaa aaaaaaaaaa aaaaaataca aaaattagcc
781 gcgtggtggc ccacgcctgt aatcccagct actcgggagg ctaaggcagg aaaattgttt
841 gaacccagga ggtggaggct gcagtgcgct gagattgtgc cacttcactc cagcctgggt
901 gacaaagtga gactccgtca caacaacaac aacaaaaagc tccccaaact aaagcctaga
961 agagcttctg aggcgtgct ttgtcaaaag gaagtctcta ggttctgagc tctggctttg
1021 ccttggtctt gcaagggctc tgtgacaagg aagggaagtca gcatgcctct agaggcaagg
1081 aagggaggaa cactgcactc ttaagcttcc gccgtctcaa cccctcacag gagcttactg
1141 gcaaacatga aaaatcgggg

```

//

LOCUS HUMTLI309 520 bp mRNA PRI 14-JAN-1995
 DEFINITION Human secreted protein (I-309) mRNA, complete cds.
 ACCESSION M57502
 NID g339728
 KEYWORDS secreted protein.
 SOURCE Human T-cell, cDNA to mRNA.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 520)
 AUTHORS Miller, M.D., Hata, S., De Waal Malefyt, R. and Krangel, M.S.
 TITLE A novel polypeptide secreted by activated human T lymphocytes
 JOURNAL J. Immunol. 143 (9), 2907-2916 (1989)

MEDLINE 90038522

FEATURES

source Location/Qualifiers
1..520
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="T-cell"
/germline
/map="17"

mRNA
1..520
/gene="SCYA1"
/note="G00-118-872"

gene
1..520
/gene="SCYA1"

CDS
51..341
/gene="SCYA1"
/codon_start=1
/db_xref="GDB:G00-118-872"
/product="secreted protein I-309"
/db_xref="PID:g339729"

/translation="MQIITLALVCLLLAGMWPEDVDSKSMQVPFSRCCFSFAEQEIPL
RAILCYRNTSSICSNEGLIFKLKRGKEACALDTVGWVQRHRKMLRHCPSKRK"

BASE COUNT 140 a 137 c 122 g 121 t

ORIGIN

1 accaggctca tcaaagctgc tccaggaagg cccaagccag accagaagac atgcagatca
61 tcaccacagc cctggtgtgc ttgctgctag ctgggatgtg gccggaagat gtggacagca
121 agagcatgca ggtacccttc tccagatgtt gcttctcatt tgcggagcaa gagattcccc
181 tgagggcaat cctgtgttac agaaatacca gctccatctg ctccaatgag ggcttaatat
241 tcaagctgaa gagaggcaaa gaggcctgcg ccttggacac agttggatgg gttcagaggc
301 acagaaaaat gctgaggcac tgcccgtaaa aaagaaaatg agcagatttc tttccattgt
361 gggctctgga aaccacatgg cttcacctgt ccccgaaact accagcccta caccattcct
421 tctgccctgc ttttgctagg tcacagagga tctgcttggt cttgataagc tatgttgttg
481 cactttaaac atttaatta tacaatcatc aaccccaac

//

LOCUS AB000887 687 bp mRNA PRI 05-JUN-1997

DEFINITION Human mRNA for EBI1-ligand chemokine, complete cds.

ACCESSION AB000887

NID g2189952

KEYWORDS EBI1-ligand chemokine; ELC.

SOURCE Homo sapiens fetal tissue_lib:lung cDNA to mRNA.

ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;

Hominidae; Homo.

REFERENCE 1 (bases 1 to 687)

AUTHORS Yoshida,R., Imai,T., Hieshima,K., Kusuda,J., Baba,M.,
Kitaura,M., Nishimura,M., Kakizaki,M., Nomiyama,H. and Yoshie,O.

TITLE Direct Submission

JOURNAL Submitted (05-FEB-1997) to the DDBJ/EMBL/GenBank databases.
Hisayuki Nomiyama, Kumamoto University Medical School,

Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
(E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)

REFERENCE 2 (sites)

AUTHORS Yoshida,R., Imai,T., Hieshima,K., Kusuda,J., Baba,M.,
Kitaura,M., Nishimura,M., Kakizaki,M., Nomiyama,H. and Yoshie,O.

TITLE Molecular cloning of a novel human CC chemokine EBI1-ligand
chemokine that is a specific functional ligand for EBI1, CCR7

JOURNAL J. Biol. Chem. 272 (21), 13803-13809 (1997)

MEDLINE 97298088

FEATURES

source Location/Qualifiers
1..687
/organism="Homo sapiens"
/db_xref="taxon:9606"
/dev_stage="fetal"
/tissue_lib="lung"

gene
139..435
/gene="ELC"

```

CDS          139..435
              /gene="ELC"
              /note="CC chemokine"
              /codon_start=1
              /product="EBI1-ligand chemokine"
              /db_xref="PID:d1021215"
              /db_xref="PID:g2189953"

/translation="MALLLLALLLVLTSPAPTLSGTNDACCLSVTQKPIPGYIVR
NFHYLLIKDGRVPAVVFTTLRGRQLCAPDPQWVERIIQRLQRTSAKMKRRSS"
mat_peptide  202..432
              /gene="ELC"
              /product="EBI1-ligand chemokine"
polyA_signal  657..662
BASE COUNT   154 a    223 c    173 g    137 t
ORIGIN
    1 cattccccagc ctcacatcac tcacaccttg catttcaccc ctgcatccca gtcgccctgc
    61 agcctcacac agatcctgca cacaccaga cagctggcgc tcacacattc accgttggcc
   121 tgctctgttt caccctccat ggccctgcta ctggccctca gcctgtggtt tctctggact
   181 tccccagccc caactctgag tggcaccaat gatgctgaag actgtgacct gtctgtgacc
   241 cagaaaccca tccctgggta catcgtgagg aacttccact accttctcat caaggatggc
   301 tgcagggtgc ctgctgtagt gttcaccaca ctgaggggcc gccagctctg tgcaccccca
   361 gaccagccct gggtagaacg catcatccag agactgcaga ggacctcagc caagatgaag
   421 cgccgcagca gttaacctat gaccgtgcag agggagcccg gagtccgagt caagcattgt
   481 gaattattac ttaacctggg gaaccgagga ccagaaggaa ggaccaggct tccagctcct
   541 ctgcaccaga cctgaccagc caggacaggg cctggggtgt gtgtgagtgt gagtgtgagc
   601 gagagggtga gtgtggtcag agtaaagctg ctccaccccc agattgcaat gctaccaata
   661 aagccgcctg gtgtttacaa ctaattg

//
LOCUS       AB000221          760 bp    mRNA          PRI          31-JUL-1997
DEFINITION  Homo sapiens mRNA for CC chemokine, complete cds.
ACCESSION   AB000221
NID         g2289718
KEYWORDS    CC chemokine; PARC; pulmonary and activation-regulated
            chemokine.
SOURCE      Homo sapiens lung cDNA to mRNA.
ORGANISM    Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE   1 (bases 1 to 760)
AUTHORS    Nomiyama,H.
TITLE      Direct Submission
JOURNAL    Submitted (04-JAN-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki Nomiyama, Kumamoto University Medical School,
Department of Biochemistry, Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
            (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
            Fax:81-96-372-6140)
REFERENCE   2 (sites)
AUTHORS    Hieshima,K., Imai,T., Baba,M., Shoudai,K., Ishizuka,K.,
            Nakagawa,T., Tsuruta,J., Takeya,M., Sakaki,Y., Takatsuki,K.,
            Miura,R., Opdenakker,G., Damme,J., Yoshie,O. and Nomiyama,H.
TITLE      A novel human CC chemokine PARC that is most homologous to
            macrophage-inflammatory protein-lalpha/LD78alpha and
chemotactic for T lymphocytes, but not for monocytes
JOURNAL    J. Immunol. 159 (3), 1140-1149 (1997)
MEDLINE    97376836
FEATURES    Location/Qualifiers
            source          1..760
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /tissue_type="lung"
            gene            64..333
                        /gene="PARC"
            CDS              64..333
                        /gene="PARC"
                        /note="pulmonary and activation-regulated chemokine"

```

```

/codon_start=1
/product="CC chemokine"
/db_xref="PID:d1022520"
/db_xref="PID:g2289719"

/translation="MKGLAAALLVLVCTMALCSAQVGTNKLCLLVYTSWQIPQKFI
VDYSETSPQCPKPGVILLTKRGRQICADFNKKWVQKYISDLKLNA"
BASE COUNT      186 a      208 c      155 g      211 t
ORIGIN
1 gccaggagtt gtgagtttcc aagccccagc tcactctgac cacttctctg cctgcccagc
61 atcatgaagg gccttgacgc tgccctcctt gtccctgctc gcaccatggc cctctgctcc
121 tgtgcacaag ttggtaccaa caaagagctc tgctgcctcg tctatacctc ctggcagatt
181 ccacaaaagt tcatagttga ctattctgaa accagccccc agtgcccca ggcagggtgc
241 atcctcctaa ccaagagagg ccggcagatc tgtgctgacc ccaataagaa gtgggtccag
301 aaatacatca gcgacctgaa gctgaatgcc tgaggggcct ggaagctgcg agggcccagc
361 gaacttggtg ggcccaggag ggaacaggag cctgagccag ggcaatggcc ctgccacctt
421 ggaggccacc tcttctaaga gtcccatctg ctatgcccag ccacattaac taactttaat
481 cttagtttat gcatcatatt tcattttgaa attgatttct attgttgagc tgcattatga
541 aattagtatt ttctctgaca tctcatgaca ttgtctttat catcctttcc cctttccctt
601 caactcttcg tacattcaat gcatggatca atcagtgtga ttagctttct cagcagacat
661 tgtgccatat gtatcaaatg acaaatcttt attgaatggt ttgtctcage accacctttt
721 aatatattgg cagtacttat tatataaaag gtaaacaccg

//
LOCUS      D86955      799 bp      mRNA      PRI      06-MAR-1997
DEFINITION Human mRNA for CC chemokine LARC precursor, complete cds.
ACCESSION  D86955
NID        g1871138
KEYWORDS   CC chemokine LARC precursor.
SOURCE     Homo sapiens cDNA to mRNA.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (sites)
AUTHORS    Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J.,
            Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and
            Nomiyaama,H.
TITLE      Molecular cloning of a novel human CC chemokine liver and
            activation-regulated chemokine (LARC) expressed in liver.
            Chemotactic activity for lymphocytes and gene localization on
            chromosome 2
JOURNAL    J. Biol. Chem. 272 (9), 5846-5853 (1997)
MEDLINE    97190319
REFERENCE  2 (bases 1 to 799)
AUTHORS    Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J.,
            Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and
            Nomiyaama,H.
JOURNAL    Unpublished (1996)
REFERENCE  3 (bases 1 to 799)
AUTHORS    Nomiyaama,H.
TITLE      Direct Submission
JOURNAL    Submitted (08-AUG-1996) to the DDBJ/EMBL/GenBank databases.
            Hisayuki Nomiyaama, Kumamoto University Medical School,
Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
            (E-mail:nomiyaama@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)
FEATURES   Location/Qualifiers
            source          1..799
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="2"
                        /map="q33-37"
            sig_peptide     59..136
                        /gene="LARC"
            CDS             59..349
                        /gene="LARC"
                        /codon_start=1
                        /product="CC chemokine LARC precursor"
                        /db_xref="PID:d1013880"
                        /db_xref="PID:g1871139"

```



```

/translation="MCCTKSLLLAALMSVLLHLHLCGESEAAASNFDCCLGYTDRIHHPK
FIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKVKXNM"
gene          59..349
              /gene="LARC"
mat_peptide   137..346
              /gene="LARC"
              /product="CC chemokine LARC"
BASE COUNT   240 a   138 c   153 g   268 t
ORIGIN
1   cactcccaaa gaactgggta ctcaacactg agcagatctg ttctttgagc taaaaacat
61  gtgctgtacc aagagtttgc tcctggctgc tttgatgtca gtgctgtac tccacctctg
121 cggcgaatca gaagcagcaa gcaactttga ctgctgtctt ggatacacag accgtattct
181 tcctcctaaa tttattgtgg gcttcacacg gcagctggcc aatgaaggct gtgacatcaa
241 tgctatcatc ttccacacaa agaaaaagtt gtctgtgtgc gcaaatccaa aacagacttg
301 ggtgaaatat attgtgcgtc tcctcagtaa aaaagtcaag aacatgtaaa aactgtggct
361 tttctggaat ggaattggac atagcccaag aacagaaaga accttgctgg ggttggagggt
421 ttcaacttgc catcatggag ggtttagtgc ttatctaatt tgtgcctcac tggacttgct
481 caattaatga agttgatcca tattgcatca tagtttgctt tgtttaagca tcacattaaa
541 gttaaaactgt attttatggt atttatagct gtagggtttc tgtgttttagc tatttaatac
601 taattttcca taagctattt tgggttagtg caaagtataa aattatattt gggggggaat
661 aagattatat ggactttctt gcaagcaaca agctattttt taaaaaaact atttaacatt
721 cttttgttta tattgttttg tctcctaaat tgttgtaatt gcattataaa ataagaaaaa
781 cattaataag acaaatatt

//
LOCUS        HUMAR          538 bp      mRNA          PRI          11-SEP-1996
DEFINITION   Human mRNA for chemokine, complete cds.
ACCESSION    D43767
NID          g1536878
KEYWORDS     chemokine, thymus and activation-regulated; chemokine.
SOURCE       Homo sapiens male peripheral blood cDNA to mRNA, clone:D3A.
ORGANISM     Homo sapiens
              Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
              Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
              Hominidae; Homo.
REFERENCE    1 (sites)
AUTHORS      Imai,T., Yoshida,T., Baba,M., Nishimura,M., Kakizaki,M. and
              Yoshie,O.
TITLE        Molecular cloning of a novel T cell-directed CC chemokine
expressed    in thymus by signal sequence trap using Epstein-Barr virus
vector
JOURNAL      J. Biol. Chem. 271 (35), 21514-21521 (1996)
MEDLINE      96355526
REFERENCE    2 (bases 1 to 538)
AUTHORS      Imai,T.
JOURNAL      Unpublished (1996)
REFERENCE    3 (bases 1 to 538)
AUTHORS      Imai,T.
TITLE        Direct Submission
JOURNAL      Submitted (07-DEC-1994) to the DDBJ/EMBL/GenBank databases.
Toshio
Imai, Shionogi Institute for Medical Science; 2-5-1 Mishima,
Settsu, Osaka 566, Japan (Tel:06-382-2612, Fax:06-382-2598)
FEATURES
  source     1..538
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
              /clone="D3A"
              /sex="male"
              /tissue_type="peripheral blood"
  CDS        53..337
              /note="thymus and activation regulated"
              /codon_start=1
              /product="chemokine"
              /db_xref="PID:d1008410"
              /db_xref="PID:g1536879"

/translation="MAPLKMLALVTLLLGASLQHIHAARGTNVGRECCLEYFKGA IPL
RKLKTWYQTS EDCSRDAIVFVTVQGRAICSDPNNKRVKNAV KYLQSLERS"

```

```

BASE COUNT      118 a      168 c      149 g      103 t
ORIGIN
    1 ccctgagcag agggacctgc acacagagac tccctcctgg gctcctggca ccatggcccc
   61 actgaagatg ctggccctgg tcacctcct cctgggggct tctctgcagc acatccacgc
  121 agctcgaggg accaatgtgg gccgggagtg ctgcctggag tacttcaagg gagccattcc
  181 ccttagaaag ctgaagacgt ggtaccagac atctgaggac tgctccaggg atgccatcgt
  241 ttttgtaact gtgcagggca gggccatctg ttcggacccc aacaacaaga gagtgaagaa
  301 tgcagttaaa tacctgcaaa gccttgagag gtcttgaagc ctctcacc cagactcctg
  361 actgtctccc gggactacct gggacctcca cgttggtgt tcaccgcccc caccctgagc
  421 gcctgggtcc aggggaggcc ttccagggac gaagaagagc cacagtgagg gagatcccat
  481 ccccttgctc gaactggagc catgggcaca aaggggccag attaaagtct ttatcctc
//

LOCUS      HUMEOTAXIN      807 bp      mRNA      PRI      25-SEP-1996
DEFINITION Human mRNA for eotaxin, complete cds.
ACCESSION  D49372
NID        g1552240
KEYWORDS   eotaxin; eosinophil-selective CC chemokine; chemoattractant.
SOURCE     Homo sapiens Small intestine, proximal cDNA to mRNA, clone:141.
  ORGANISM Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;
            Homo.
REFERENCE  1 (bases 1 to 807)
AUTHORS   Kitaura,M., Nakajima,T., Imai,T., Harada,S., Combadiere,C.,
            Tiffany,H.L., Murphy,P.M. and Yoshie,O.
TITLE     Molecular cloning of human eotaxin, an eosinophil-selective CC
            chemokine, and identification of a specific eosinophil eotaxin
            receptor, CC chemokine receptor 3
JOURNAL   J. Biol. Chem. 271 (13), 7725-7730 (1996)
MEDLINE   96205964
REFERENCE  2 (bases 1 to 807)
AUTHORS   Yoshie,O.
TITLE     Direct Submission
JOURNAL   Submitted (15-FEB-1995) to the DDBJ/EMBL/GenBank databases.
Osamu
            Yoshie, Shionogi Institute for Medical Science; 2-5-1 Mishima,
            Settsu, Osaka 566, Japan (E-mail:osamu.yoshie@shionogi.co.jp,
            Tel:06-382-2612, Fax:06-382-2598)
COMMENT    On Sep 20, 1996 this sequence version replaced gi:1313900.
FEATURES   Location/Qualifiers
            source          1..807
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /clone="141"
                        /tissue_type="Small intestine, proximal"
            CDS             99..392
                        /codon_start=1
                        /product="eotaxin"
                        /db_xref="PID:d1008966"
                        /db_xref="PID:g1552241"
            /translation="MKVSAALLWLLLLIAAAFSPQGLAGPASVPTTCCFNLANRKIPLQ
            RLESYRRITSGKCPQKAVIFKTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP"
            misc_signal      548..557
                        /note="mRNA destabilization signal"
            polyA_signal     775..780
            polyA_site       807
BASE COUNT      229 a      198 c      147 g      233 t
ORIGIN
    1 gcattttttc aagttttatg atttatttaa cttgtggaac aaaaataaac cagaaccac
   61 cacctctcac gccaaagctc acaccttcag cctccaacat gaaggctctc gcagcacttc
  121 tgtggctgct gctcatagca gctgccttca gcccacagg gctcgctggg ccagctttctg
  181 tcccaaccac ctgctgcttt aacctggcca ataggaagat accccttcag cgactagaga
  241 gctacaggag aatcaccagt ggcaaatgtc ccagaaaagc tgtgatcttc aagaccaaac
  301 tggccaagga tatctgtgcc gaccacaaga agaagtgggt gcaggattcc atgaagtatc
  361 tggacaaaaa atctccaact ccaaagccat aaataatcac catttttgaa accaaaccag
  421 agcctgagtg ttgcctaatt tgtttccctt tcttacaatg cattctgagg taacctcatt
  481 atcagttcaa agggcatggg ttttattata tatatatata tttttttttt aaaaaaaaaa
  541 gtattgcatt taatttatgg aggttttaaa acttatcctc catgaatata agttattttt

```

```

601 aaactgtaaa gctttgtgca gattctttac cccctgggag cccaattcg atccctgtc
661 acgtgtgggc aatgttcccc ctctcctctc ttctccctg gaattctgta aaggctctgg
721 caaagatgat cagtatgaaa atgtcattgt tcttggaac ccaaagtgtg actcattaaa
781 tggaagtaaa tggtgtttta ggaatac

//
LOCUS       HSCCCHM      232 bp      RNA              PRI      10-SEP-1996
DEFINITION  H.sapiens mRNA for CC-chemokine.
ACCESSION   Z69291
NID         g1181148
KEYWORDS    CC-chemokine.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 232)
AUTHORS     Bartels,J.H., Schlueter,C., Richter,E., Christophers,E. and
            Schroeder,J.M.
TITLE       Cloning of a novel human chemokine homologous to human monocyte
            chemoattractant proteins and rodent eotaxins
JOURNAL      Unpublished
REFERENCE   2 (bases 1 to 232)
AUTHORS     Bartels,J.H.
TITLE       Direct Submission
JOURNAL      Submitted (01-FEB-1996) Bartels J. H.,
            Christian-Albrechts-Universitaet zu Kiel,
            Dermatology/Hautklinik,
            Mol.Biol.Lab.609, Schittenhelmstr. 7, Kiel, Schleswig-Holstein,
            Germany, D-24105
REFERENCE   3 (bases 1 to 232)
AUTHORS     Bartels,J., Schluter,C., Richter,E., Noso,N., Kulke,R.,
            Christophers,E. and Schroder,J.M.
TITLE       Human dermal fibroblasts express eotaxin: molecular cloning,
            mRNA
            expression, and identification of eotaxin sequence variants
JOURNAL      Biochem. Biophys. Res. Commun. 225 (3), 1045-1051 (1996)
MEDLINE      96374440
FEATURES             Location/Qualifiers
     source           1..232
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="clones 4(9512),
                     14(9512),15(9512),10(9601),11(9601)"
                     /tissue_type="foreskin"
                     /cell_type="fibroblast"
                     /sex="Male"
     mRNA             <1..>232
                     /citation=[1]
                     /product="CC-chemokine"
     sig_peptide       56..109
                     /citation=[1]
     CDS               56..>232
                     /function="putative chemoattractant protein"
                     /note="sequence homology to human MCP-1, MCP-2 and
MCP-3               and to rodent eotaxins"
                     /citation=[1]
                     /codon_start=1
                     /product="CC-chemokine, preprotein"
                     /db_xref="PID:e221070"
                     /db_xref="PID:g1181149"
                     /db_xref="SWISS-PROT:P50877"
/translation="MKVSAALLWLLLIAAFSPQGLAGPASVPTCCFNLANRKIPLQ
               RLESYRRITSGKCPQ"
     mat_peptide       110..>232
                     /citation=[1]
                     /function="putative chemoattractant protein"
                     /product="CC-chemokine"
BASE COUNT        55 a      82 c      50 g      42 t      3 others
ORIGIN
1 accaaaccag aaaccwccam ytctcagcc aaagctcaca ctttcagcct ccaacatgaa

```

```

61 ggtctccgca gcgttctgtt ggctgtgtct catagcggct gccttcagcc cccaggggct
121 cgctgggcca gcttctgtcc caaccacctg ctgctttaac ctggccaata ggaagatacc
181 ccttcagcga ctagagagct acaggagaat caccagtggc aaatgtcccc ag
//
LOCUS      HSHCC1GEN      4037 bp      DNA      PRI      01-OCT-1995
DEFINITION H.sapiens gene for chemokine HCC-1.
ACCESSION  Z49269
NID        g1004266
KEYWORDS   chemokine.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 4037)
AUTHORS    Pardigol,A., Maegert,H.J., Cieslak,A., Hill,O., Schulz-
Knappe,P.
TITLE      and Forssmann,W.G.
            Nucleotide Sequence of the Gene for the Human Chemokine HCC-1
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 4037)
AUTHORS    Pardigol,A.
TITLE      Direct Submission
JOURNAL    Submitted (18-MAY-1995) Andreas Pardigol, Molecular Biology,
Lower
            Saxony Institute for Peptide Research, Feodor-Lynen-Strasse 31,
            Hannover, Lower Saxon, 30625, Germany
FEATURES   Location/Qualifiers
            source          1..4037
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /clone="ph3b7"
                        /dev_stage="adult"
                        /tissue_type="placenta"
                        /clone_lib="lambda FIX II, Cat.Nr. 946203, Stratagene"
                        /sex="male"
            TATA_signal     727..733
                        /note="putative, determined by consensus rules."
            5'UTR           764..833
                        /note="first base determined by means of consensus
rules"
            exon            764..912
                        /note="first base determined by means of consensus
rules;"
                        base 780 is the first base of cDNA (Z49270)"
                        /number=1
            CDS              join(834..912,3021..3135,3585..3672)
                        /codon_start=1
                        /product="chemokine HCC-1"
                        /db_xref="PID:g1004267"
            /translation="MKISVAAIPFFLLITIALGKTESSSRGPYHPSECCFTYTTYKI
PRQRIMDYETNSQCSKPGIVFITKRGHSVCTNP SDKWVQDIKDMKEN"
            intron           913..3020
                        /number=1
            exon            3021..3135
                        /number=2
            intron           3136..3584
                        /number=2
            exon            3585..3817
                        /number=3
            3'UTR           3673..3817
BASE COUNT  1023 a   1048 c   1004 g   962 t
ORIGIN
1 gagctccggtt gggagtcacca tgtttcttta tggcataatg ggtgagaaca cagacttgga
61 agccaaacca cctgaatttg aaccccagtt ccatttacca actgtcaaaa gcttaggctt
121 tgattctaag cctgtttcct caactgctgt tctaaagatt aaataggcta atattcataa
181 ggcaactggg acagtggctt gtgtgtatag caaccattat ataagtgaat tatctactga
241 gcaccacagc acttcttcac tccatgggtg ggtgaccaga atggagatga gacagagaac
301 tgcaggttct gcttcgagtt taagttagga ttcccttga ccaatgagac ctgacttgga
361 ggagtcctgg cctcattcca ttaccccaaa caccctctag tctctagatg aacagatcct
421 gaatgtccag gccccacgtg gcctgttcta aggcctgaga tggaattgga tacaggacac

```

```

481 atccagcctt gagatctttt gctaagtgtg acacagtgcc cccagccctg tgctcatgtt
541 catgcctagg gaaaggcttc tatcaaaaaga gttgaacttc tccccactgg ggaatgaaga
601 ccatttctct ccttaaacct tggctctctcc tgcttctctc aggccaccaa caacacatgt
661 gcaggatatg aaattgtctga ggcattcactg ctttctctact tcccttccaa gtctcagctc
721 ccttattttaa aaaaatattt ggcctcaatg atcatttctc aacaattctct caccgcagga
781 gcctctgaag ctcccaccag gccagctctc ctcccacaac agcttcccac agcatgaaga
841 tctccgtggc tgccattccc ttcttctctc tcatcaccat cgccctaggg accaagactg
901 aatcctcctc acgtgagtgc aatgccttgt cttccttcca acctagagcc tgcagggaaa
961 taagcaggag tgagggtggg gctcagggga agaccaggag cagggactca gaaaggaggg
1021 ctgggtatctt cttgaaattg tgtgtatagc aacattatat aaatgaatta tctactgagc
1081 accacagcac ttcaccccat ggtgtgtgtg gcaggatgga gatgagactt aggactgtag
1141 gttctgtcta agagttaaag ttgggatctt ccagccttga ccaatgagac ttgactggg
1201 agactccagg cttcattcca ctaccccaaa tgcctcttag tctccaaata aacagatcct
1261 gaatctccag gcctcacatg gccttgatct cttatcattg cccccaggga ccagtcctcc
1321 cttgcctcca aggacatgga gtgagaccag cctgcctctc tactccctca atttctctct
1381 ctttgccgct aagcaaaaga gtggcccacc ccatttgggg tatatttctt caggagattt
1441 agggagcagt tcttgagccc ctcaagggca ttttcttatt ggccctctga ggtttgggccc
1501 cagcctgctt ccagcgtcac ctgtgcccag tgagtgcagc attgcttggg tatgggctgg
1561 ggggaaacac gacagtgtgg ggtccatcct agggccctct tctcagctg atttcttaga
1621 ataagctgcc ttttagagata accaaaaacta ttatcactc ttccatttta cctactctcc
1681 ttttcagaaa ctggggggaa accgaagggt gttaaaatac agctaaagt tgggtggtatg
1741 tgcacagttt gacttgccct ctccgatgtc atttgtcagc tcagaggaaac aaggtgggag
1801 agtataggag ctctgactgg gtctcaggaa acaggggccc cttatgccc tctttggatc
1861 gtgaggatgc tgcctggaat ggagctggaa aacaggatga gacccttcca cccagacatc
1921 tggccaccct cagtgcctc tgaggccatt gtgatgcaca tccatgattc tatgaagcag
1981 ggtcacataa catgcacaca cctgatttct ccactccata accacaacat gtgctgtttt
2041 gtacagggct cttggcctac aatgtccttc ctgctacctc tataattcaa gcttgggggtg
2101 gctgctgtca ccttgcttct cctataaaag ccatgaaact tctcaatcag aaaatagatg
2161 aaaaaatcac ccaatccagt gattttttaa acttttttaga ccacaaaacc ttttctcaa
2221 gcaatatctt ccacagaggc ccaatatgta aaacagaaaa aatgggttga gtagggtaca
2281 agacaccact ctcaaatgca gcaaggcctc cacaatagtc cctgaggccc ccagagctca
2341 gtgtaaaaac cactgatgca gtccaagggc ctcatattaca gaggaggaaa cagggggaaa
2401 gtaaaatggc cacagtacac aggaagcaca ggcaagggtta ggttaggatt tgggtgcctc
2461 gactctgtgg cctttgtctc tggggcttgc tgtgggcctc ctgctctctc tgcaggttgt
2521 cggttcaatg gggacatggg caggggtggg cactaggagg ggctggggtt gcatcccaa
2581 atggcatgtc tccaaatccc tattgggatt tcttccaaat attctccta tttggagcac
2641 ctttcccgaa taaggcatga aggcgtgcag atattggcca agtccctagc cttctctgcc
2701 agtcggcccc cagagatggt gtaagaagat ctgagtgtgc tgctcttcaa tcttgaggtt
2761 gaaagtcate caccagtctt tccaagaggg gttgaagaaa aggagggaag gtgattgatg
2821 atgaggagg agaaaaagaa gagcccagga gtaccatgga gaaggagaag agaagatgag
2881 gaaagcctac tctccctccc aagtctgtag gggctgtctc ctcttctct cctcctcca
2941 tgccctcagc ttgcaggagc agccaatggt atggccttta acaaggggcc cctcctcagc
3001 atctgatgct ctctctcag ggggacctta ccacctctca gagtgtgtct tcacctacac
3061 tacctacaag atcccgcgtc agcggattat ggattactat gagaccaaca gccagtgtct
3121 caagcccgga attgtgtagg tggtagacac acatcacact ggggggagag ggagccagca
3181 gggcctcctg gagggagca gggagtgggt gtggaatggg gacccccagc gtacctccca
3241 ggtgtgacta catggggaga ggcagctgag gggcaatctg agcgtcttct ggttgagcc
3301 tgccaggagcc atggggaaac tgaccccatg gatggggaga tgacagagaa gggagaagaa
3361 ggcaagaggg cacttctcca gggggacaca gagactagat ggtcttaggg gtcttaggaa
3421 ccgaagagta tgtctcagag aggagactgg ctctaagctg cctctgtgga agaaaaggaa
3481 agcagtatag gtcagggtgg gaatttagga gggagggaag atgggctgtc tcttccggcc
3541 actgggcccc tcgggtttgt atccttctcc ctcttgtctc acagcttcat caccaaaagg
3601 ggccattccg tctgtaccaa cccagtgac aagtgggtcc aggactatat caaggacatg
3661 aaggagaact gagtgaccca gaaggggtgg cgaaggcaca gctcagagac ataaagagaa
3721 gatgccaaag cccctcctc caccaccgc taactctcag cccagtcac cctctggag
3781 cttccctgct ttgaattaaa gaccactcat gctcttccct ggccctcatc cttctacgg
3841 gatttactca ttggccatgc actgaggaca ccagggtgtg gcacctcgg catcaagct
3901 cgctctgcag aagttttggg ggagcctggt acaaaaaata ggtcaggcct gcaatgcagg
3961 tagtgagaag cagaaagtga gaaagaaaag cagtgtaaag accgtctcct cctcagcagc
4021 aacagtagca gaccccg

```

```

//
LOCUS       HSCC21             925 bp      mRNA              PRI              30-JUN-1998
DEFINITION  H.sapiens mRNA for chemokine CC-2 and CC-1.
ACCESSION  Z70292
NID        g1296608
KEYWORDS   chemokine CC-1; chemokine CC-2.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 925)

```

AUTHORS Pardigol, A., Forssmann, U., Zucht, H.D., Loetscher, P.,
 Schulz-Knappe, P., Baggiolini, M., Forssmann, W.G. and Magert, H.J.
 TITLE HCC-2, a human chemokine: gene structure, expression pattern,
 and biological activity
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 95 (11), 6308-6313 (1998)
 MEDLINE 98263352
 REFERENCE 2 (bases 1 to 925)
 AUTHORS Pardigol, A.
 TITLE Direct Submission
 JOURNAL Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
 Biology,
 Lower Saxony Institute for Peptide Research, Feodor-Lynen-
 Strasse
 31, Hannover, Lower Saxony, 30625, Germany
 FEATURES
 source Location/Qualifiers
 1..925
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /dev_stage="adult"
 /tissue_type="liver"
 /clone_lib="PCR fragments"
 5'UTR 1..55
 CDS 56..397
 /note="putative; first coding region of a bicistronic
 mRNA"
 /codon_start=1
 /product="chemokine CC-2"
 /db_xref="PID:e233855"
 /db_xref="PID:g1296609"
 /db_xref="SWISS-PROT:Q16663"
 /translation="MKVSVAALSCLMLVAVLGSQAQFTNDAETELMMSKLPLENPVVL
 NSFHFAADCCTSYISQSIPLMSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"
 misc_feature 398..498
 /note="spacing region between two coding regions of
 the bicistronic mRNA"
 CDS 499..780
 /codon_start=1
 /evidence=experimental
 /product="chemokine CC-1"
 /db_xref="PID:e233856"
 /db_xref="PID:g1296610"
 /db_xref="SWISS-PROT:Q16627"
 /translation="MKISVAAIPFFLLITIALGKTESSSRGPYHPSECCFTYTTYKI
 PRQRIMDYETNSQCSKPGIVFITKRGHVCTNPDKWVQDYIKDMKEN"
 3'UTR 781..925
 polyA_signal 902..908
 BASE COUNT 240 a 296 c 199 g 190 t
 ORIGIN
 1 ccaggaagca gtgagcccag gtagctctcg ccagccctgc ctgcccacca ggaggatgaa
 61 ggtctccgtg gctgcccctc cctgcctcat gcttgttgct gtccttggat cccaggccca
 121 gttcacaat gatgcagaga cagagttaat gatgtcaaag cttccactgg aaaaaccagt
 181 agttctgaac agcttttact ttgctgctga ctgctgcacc tcctacatct cacaagcat
 241 cccgtgttca ctcatgaaaa gttattttga aacgagcagc gagtgtctca agccagggtg
 301 catattcctc accaagaagg ggcggcaagt ctgtgcaaaa cccagtggtc cgggagtcca
 361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
 421 gccaccacc tccaacacct cctgagcctc tgaagctccc accaggccag cttcctccc
 481 acaacagctt cccacagcat gaagatctcc gtggctgcca ttcccttctt cctcctcctc
 541 accatcgccc tagggaccaa gactgaatcc tcctcacggg gaccttacca cccctcagag
 601 tgctgcttca cctacactac ctacaagatc ccgcgtcagc ggattatgga ttactatgag
 661 accaacagcc agtgctccaa gcccggaatt gtcttcatca ccaaaggagg ccattccgctc
 721 tgtaccaacc ccagtgcaca gtgggtccag gactatatca aggacatgaa ggagaactga
 781 gtgaccacga aggggtggcg aaggcacagc tcagagacat aaagagaaga tgccaaggcc
 841 ccctcctcca cccaccgcta actctcagcc ccagtcaccc tcttgagct tccctgcttt
 901 gaattaaaga ccactcatgc tcttc
 //

LOCUS HSCC23 973 bp RNA PRI 03-MAY-1996
 DEFINITION H.sapiens mRNA for chemokine CC-2 and CC-3.
 ACCESSION Z70293
 NID g1296611
 KEYWORDS Human chemokine CC-2; Human chemokine CC-3.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 973)
 AUTHORS Pardigol, A., Maegert, H.J., Zucht, HD., Forssmann, W.G. and
 Schulz-Knappe, P.
 TITLE Transcription of a Human Tandem Gene results in a Mature
 Bicistronic mRNA encoding two Novel CC-Chemokines
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 973)
 AUTHORS Pardigol, A.
 TITLE Direct Submission
 JOURNAL Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
 Biology,
 Lower Saxony Institute for Peptide Research, Feodor-Lynen-
 Strasse
 31, Hannover, Lower Saxony, 30625, Germany
 FEATURES
 source Location/Qualifiers
 1..973
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /dev_stage="adult"
 /tissue_type="liver"
 /clone_lib="PCR fragments"
 5'UTR 1..55
 CDS 56..397
 /note="putative; first coding region of a bicistronic
 mRNA"
 /codon_start=1
 /product="chemokine CC-2"
 /db_xref="PID:e233857"
 /db_xref="PID:g1296612"
 /translation="MKVSVAALSCMLVAVLGSQAQFTNDAETELMMSKLPLENPVVL
 NSFHFAADCCTSYISQSIPLCSLMKSYFETSSECSKPGVIFLTKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"
 misc_feature 398..498
 /note="spacing region between two coding regions of
 the
 bicistronic mRNA"
 CDS 499..828
 /note="putative"
 /codon_start=1
 /product="chemokine CC-3"
 /db_xref="PID:e233858"
 /db_xref="PID:g1296613"
 /translation="MKISVAAIPFFLLITIALGKTESSSQTGGKPKVVKIQLKLVGG
 PYHPSECCFTYTYKIPIRQIMDYETNSQCSKPGIVFITKRHGSVCTNPSPDKWVQDY
 IKDMKEN"
 3'UTR 829..973
 polyA_signal 950..956
 BASE COUNT 257 a 301 c 215 g 200 t
 ORIGIN
 1 ccaggaagca gtgagcccag gagtcctcgg ccagccctgc ctgcccacca ggaggatgaa
 61 ggtctccgtg gctgccctct cctgcctcat gcttggtgct gtccttggat cccaggccca
 121 gttcacaagt gatgcagaga cagagttaat gatgtcaaag cttccactgg aaaatccagt
 181 agttctgaac agctttcact ttgctgctga ctgctgcacc tcctacatct cacaagcat
 241 cccgtgttca ctcatgaaaa gttattttga aacgagcagc gaggctcca agccagggtg
 301 catattcctc accaagaagg ggcggcaagt ctgtgccaaa cccagtggtc cgggagtcca
 361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
 421 gccacccacc tccaacacct cctgagcctc tgaagctccc accaggccag ctctcctccc

```

481 acaacagctt cccacagcat gaagatctcc gtggctgcca ttcccttctt cctcctcacc
541 accatcgccc tagggaccaa gactgaatcc tcctcacaac ctggggggaa accgaaggtt
601 gttaaaatag agctaaagtt ggtgggggga ccttaccacc cctcagagtg ctgcttcacc
661 tacactacct acaagatccc gcgtcagcgg attatggatt actatgagac caacagccag
721 tgctccaagc ccggaattgt cttcatcacc aaaagggggc attccgtctg taccaccccc
781 agtgacaagt ggggtccagga ctatatcaag gacatgaagg agaactgagt gacccagaag
841 ggggtggcgaa ggcacagctc agagacataa agagaagatg ccaaggcccc ctctccacc
901 caccgctaac tctcagcccc agtcaccctc ttggagcttc cctgctttga attaaagacc
961 actcatgctc ttc

```

//

```

LOCUS      HSU91746      1430 bp      mRNA
DEFINITION Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
cds.
ACCESSION  U91746
NID        g2581780
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Identification of a novel human CC chemokine upregulated by IL-
10
JOURNAL    Blood (1998) In press
REFERENCE  2 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL    Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source          1..1430
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="17"
            gene            1..1430
                        /gene="HCC-4"
            CDS              1..363
                        /gene="HCC-4"
                        /note="CC or beta chemokine family member"
                        /codon_start=1
                        /product="IL-10-inducible chemokine"
                        /db_xref="PID:g2581781"
/translation="MKVSEAAALSLVLILIITSASRSQPKVPEWVNTPTSCCLKYYEK
VLPRLVVGYRKALNCHLPAIFVTKRNRVCTNPDDWVQEIYKDPNLPLLPTRNLS
TVKIIITAKNGQPQLLSQ"
BASE COUNT 401 a      351 c      293 g      385 t
ORIGIN
1 atgaaggctc cagaggtgct cctgtctctc cttgtctctc tccttatcat tacttcggct
61 tctcgcagcc agccaaaagt tcctgagtggt gtgaacaccc catccacctg ctgcctgaag
121 tattatgaga aagtgttgcc aaggagacta gtgggtggat acagaaaggc cctcaactgt
181 cacctgccag caatcatctt cgtcaccaag aggaaccgag aagtctgcac caaccccaat
241 gacgactggg tccaagagta catcaaggat cccaacctac ctttgctgcc taccaggaac
301 ttgtccacgg ttaaaattat tacagcaaag aatggtcaac cccagctcct caactcccag
361 tgatgaccag gctttagtgg aagcccttgt ttacagaaga gaggggtaaa cctatgaaa
421 caggggaagc cttattagtc tgaaactagc cagtcacatt gagagaagca gaacaatgat
481 caaaataaag gagaagtatt tcgaatattt tctcaatctt aggaggaaat accaaagtta
541 agggacgtgg gcagaggtac gctcttttat ttttatattt atatttttat ttttttgaga
601 taggtcttac tctgtcacc aggctggagt gcagtgggtg gatcttggct cacttgatct
661 tggctcactg taacctccac ctcccaggct caagtgatcc tcccccccca gcctcccag
721 tagctgggac tacaggcttg cgccaccaca cctggctaatt tttgtattt ttggtagaga
781 cggtattcta ccatgttgcc caggctggtc tcaaactcgt gtgcccgaagc aatccacctg
841 cctcagcctt ccaaaagtgc tgggattaca ggcgtgagcc accacatccg gccagtgac
901 tcttaataca cagaaaaata tatttcacat ccttctctgt ctctctttca attcctcact
961 tcacaccagt acacaagcca ttctaataac ttagccagtt tccagcttcc cagatgatct
1021 ttgccctctg ggtcttgacc cattaagagc cccatagaac tcttgatttt tctgttccat
1081 ctttatggat tttctggat ctatattttc ttcaattatt ctttcatttt ataattgcaac

```



```

1141 tttttcatag gaagtcgga tgggaatatt cacattaatc atttttgcag agactttgct
1201 agatcctctc atattttgtc ttcctcaggg tggcaggggt acagagagt cctgattgga
1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
1321 ccatgttaag ctttgcagga cagggaaaga aagggtatga gacacggcta ggggtaaact
1381 cttagtccaa aaccaagca tgcaataaat aaaactccct tatttgacaa

```

//

```

LOCUS      AB007454      1503 bp      mRNA                      PRI      09-APR-1998
DEFINITION Homo sapiens mRNA for chemokine LEC precursor, complete cds.
ACCESSION  AB007454
NID        g2723285
KEYWORDS   chemokine LEC precursor.
SOURCE      Homo sapiens liver cDNA to mRNA.
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (sites)
AUTHORS     Shoudai,K., Hieshima,K., Fukuda,S., Iio,M., Miura,R., Imai,T.,
            Yoshie,O. and Nomiyama,H.
TITLE       Isolation of cDNA encoding a novel human CC chemokine NCC-4/LEC
JOURNAL     Biochim. Biophys. Acta 1396 (3), 273-277 (1998)
MEDLINE     98207719
REFERENCE  2 (bases 1 to 1503)
AUTHORS     Nomiyama,H.
TITLE       Direct Submission
JOURNAL     Submitted (19-SEP-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki Nomiyama, Kumamoto University Medical School,
Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860-0811,
Japan
            (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
            Fax:81-96-372-6140)

```

```

FEATURES             Location/Qualifiers
     source            1..1503
                       /organism="Homo sapiens"
                       /db_xref="taxon:9606"
                       /tissue_type="liver"
     sig_peptide       77..145
     CDS                77..439
                       /codon_start=1
                       /product="chemokine LEC precursor"
                       /db_xref="PID:d1024963"
                       /db_xref="PID:g2723286"

```

/translation="MKVSEAAALSLVLILITSASRSQPKVPEWVNTPTCCLKYYEK

VLPRLVVGGRKALNCHLPAIIFVTKRNRVCTNPNDWVQEIYKDPNPLPLPTRNLS

```

mat_peptide 146..436
polyA_signal 560..565
polyA_signal 1485..1490

```

BASE COUNT 417 a 374 c 312 g 400 t

ORIGIN

```

1 gttggcaagc ggaccaccag caacagacaa catcttcatt cggctctccc tgaagctgta
61 ctgcctcgct gagaggatga aggtctccga ggctgccctg tctctccttg tctctacctc
121 tatcattact tcggcttctc gcagccagcc aaaagttcct gagtgggtga acacccatc
181 cacctgctgc ctgaagtatt atgagaaagt gttgccaagg agactagtgg tgggatacag
241 aaaggccctc aactgtcacc tgccagcaat catcttcgtc accaagagga accgagaagt
301 ctgcaccaac cccaatgacg actgggtcca agagtacatc aaggatccca acctaccttt
361 gctgcctacc aggaacttgt ccacgggttaa aattattaca gcaaagaatg gtcaacccca
421 gctcctcaac tcccagtgat gaccaggctt tagtggaagc ccttggttac agaagagagg
481 ggtaaaccta tgaataacag ggaagcctta ttaggctgaa actagccagt cacattgaga
541 gaagcagaac aatgatcaaa ataaaggaga agtatttcga atattttctc aatcttagga
601 ggaataacca aagttaaggg acgtgggcag aggtacgctc ttttattttt atatttatat
661 ttttattttt ttgagatagg gtcttactct gtcacccagg ctggagtgcg gtggtgtgat
721 cttggctcac ttgatcttgg ctactgttaa cctccacctc ccaggctcaa gtgatcctcc
781 caccacagcc tcccagtag ctgggactac aggccttgcc caccacacct ggctaatttt
841 tgtatttttg gtagagacgg gattctacca tggtgccagc gctgggtctc aactcgtgtg
901 cccaagcaat ccacctgcct cagccttcca aaagtgcctg gattacagcg gtgagccacc
961 acatccggcc agtgcactct taatacacag aaaaaatata ttcacatcct tctcctgctc
1021 tctttcaatt cctcacttca caccagtaca caagccattc taaatactta gccagtttcc

```

```

1081 agccttccag atgatctttg cctctgggt cttgacccat taagagcccc atagaactct
1141 tgatttttcc tgtccatctt tatggatttt tctggatcta tattttcttc aattattctt
1201 tcattttata atgcaacttt ttcataaggaa gtccggatgg gaattattcac attaatcatt
1261 tttgcagaga ctttgctaga tcctctcata ttttgcttcc ctcagggtgg caggggtaca
1321 gagatgtcct gattggaaaa aaaaaaaaaa gagagagaga gagaagaaga agaagaagag
1381 acacaaatct ctacctccca tgttaagctt tgcaggacag ggaaagaaag ggtatgagac
1441 acggctaggg gtaaaactctt agtccaaaac ccaagcatgc aataataaaa actcccttat
1501 ttg

```

//

```

LOCUS      AF001979      800 bp      mRNA      PRI      20-NOV-1997
DEFINITION Homo sapiens beta chemokine mRNA, complete cds.
ACCESSION  AF001979
NID        g2624924
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 800)
AUTHORS    Hedrick, J.A. and Zlotnik, A.
TITLE      Identification and characterization of a novel beta chemokine
            containing six conserved cysteines
JOURNAL    J. Immunol. 159 (4), 1589-1593 (1997)
MEDLINE    97400322
REFERENCE  2 (bases 1 to 800)
AUTHORS    Hedrick, J.A. and Zlotnik, A.
TITLE      Direct Submission
JOURNAL    Submitted (01-MAY-1997) Immunobiology, DNAX Research Institute,
901

```

California Ave, Palo Alto, CA 94304, USA

```

FEATURES             Location/Qualifiers
     source            1..800
                       /organism="Homo sapiens"
                       /db_xref="taxon:9606"
     CDS                1..405
                       /note="6Ckine; CC chemokine"
                       /codon_start=1
                       /product="beta chemokine"
                       /db_xref="PID:g2624925"

```

/translation="MAQSLALSLLILVLAFGIPRTQGS DGAQDCCLKYSQRKIPAKV

VRSYRKQEPSLGC SIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPOKPAQG
CRKDRGASKTGKKGKSGCKRTERSQTPKGP"

```

BASE COUNT      203 a      248 c      210 g      139 t
ORIGIN

```

```

1 atggctcagt cactggctct gagcctcctt atcctgggtc tggccttttg aatccccagg
61 acccaaggca gtgatggagg ggctcaggac tgttgctca agtacagcca aaggaagatt
121 cccgccaagg ttgtccgcag ctaccggaag caggaaccaa gcttaggctg ctccatccca
181 gctatcctgt tcttgccccg caagcgctct caggcagagc tatgtgcaga cccaaaggag
241 ctctgggtgc agcagctgat gcagcatctg gacaagacac catccccaca gaaaccagcc
301 cagggctgca ggaaggacag gggggcctcc aagactggca agaaaggaaa gggctccaaa
361 ggctgcaaga ggaactgagc gtcacagacc cctaaagggc catagcccag tgagcagcct
421 ggagccctgg agacccacc agcttcacca gcgcttgaag cctgaaccca agatgcaaga
481 aggaggctat gctcaggggc cctggagcag ccaccccatg ctggccttgc cacactcttt
541 ctctgtcttt aaccacccca tctgcattcc cagctctacc ctgcatggct gagctgcccc
601 cagcaggcca ggtccagaga gaccgaggag ggagagtctc ccaggagca tgagaggagg
661 cagcaggact gtccccttga aggagaatca tcaggaccct ggacctgata cggtcccca
721 gtacaccca cctcttctt gtaaatatga tttataccta actgaataaa aagctgttct
781 gtcttccac ccaaaaaaaa

```

//

```

LOCUS      HSU64197      821 bp      mRNA      PRI      25-JUN-1997
DEFINITION Homo sapiens chemokine exodus-1 mRNA, complete cds.
ACCESSION  U64197
NID        g1778716
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;

```

Hominidae; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Homo.
 REFERENCE 1 (bases 1 to 821)
 AUTHORS Hromas, R., Gray, P.W., Chantry, D., Godiska, R., Krathwohl, M.,
 Fife, K., Bell, G.I., Takeda, J., Aronica, S., Gordon, M.,
 Cooper, S., Broxmeyer, H.E. and Klemsz, M.J.
 TITLE Cloning and characterization of exodus, a novel beta-chemokine
 JOURNAL Blood 89 (9), 3315-3322 (1997)
 MEDLINE 97275143
 REFERENCE 2 (bases 1 to 821)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (17-JUL-1996) Indiana University Medical Center,
 Medicine, 975 W. Walnut St., Indianapolis, IN 46202, USA
 FEATURES Location/Qualifiers
 source 1..821
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="Exodus-1"
 /cell_type="islet"
 /tissue_type="pancreas"
 /dev_stage="adult"
 CDS 43..330
 /function="inhibits proliferation of hematopoietic
 progenitors and HIV"
 /codon_start=1
 /product="chemokine exodus-1"
 /db_xref="PID:g1778717"
 /translation="MCCTKSLLLAALMSVLLHLGGESEASNFDCCLCGYTDRILHPKF
 IVGFTRQLANEGCDINAIIFHTKKLSVCANPKQTWVKYIVRLLSKKVKNM"
 variation 121^122
 encoding /note="insertion of an extra codon GCA at nt 121,
 for an alanine after the alanine at amino acid
 position 26, represents the allelic difference of the
 transcript isolated from macrophages"
 BASE COUNT 258 a 134 c 156 g 273 t
 ORIGIN
 1 ggtactcaac actgagcaga tctgttcttt gagctaaaaa ccatgtgctg taccaagagt
 61 ttgctcctgg ctgctttgat gtcagtgtct ctactccacc tctgcgggca atcagaagca
 121 agcaactttg actgctgtct tggatacaca gaccgtattc ttcatcctaa atttattgtg
 181 ggcttcacac ggcagctggc caatgaaggc tgtgacatca atgctatcat ctttcacaca
 241 aagaaaaagt tgtctgtgtg cgcaaatcca aaacagactt ggggtgaaata tattgtgcgt
 301 ctcttcagta aaaaagtcaa gaacatgtaa aaactgtggc ttttctggaa tggaattgga
 361 catagcccaa gaacagaaaag aaccttgctg gggttggagg ttccacttgc acatcatgga
 421 gggtttagtg cttatctaat ttgtgcctca cctggacttg tccaattaat gaagttgatt
 481 catattgcat catagtttgc tttgtttaag catcacatta aagtgaact gtattttatg
 541 ttattttatag ctgtaggttt tctgtgttta gctatttaac actaattttc cataagctat
 601 tttggtttag tgcaaatgat aaaattatat ttggggggga ataagattat atggactttc
 661 ttgcaagcaa caagctattt tttaaaaaaa actatttaac attcttttgt ttatattgtt
 721 ttgtctccta aattgttgta atgtcattat aaaataagaa aaatattaat aagacaaata
 781 ttgaaaataa agaaacaaaa agtgcttctg ttaaaaaaaa a
 //

LOCUS HSU88320 828 bp mRNA PRI 18-DEC-1997
 DEFINITION Human beta chemokine Exodus-2 mRNA, complete cds.
 ACCESSION U88320
 NID g2196919
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 828)
 AUTHORS Hromas, R., Kim, C.H., Klemsz, M., Krathwohl, M., Fife, K.,
 Cooper, S.,

TITLE Schnizlein-Bick, C. and Broxmeyer, H.E.
 chemokine Isolation and characterization of Exodus-2, a novel C-C
 with a unique 37-amino acid carboxyl-terminal extension
 JOURNAL J. Immunol. 159 (6), 2554-2558 (1997)
 MEDLINE 97444139
 REFERENCE 2 (bases 1 to 828)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (04-FEB-1997) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 FEATURES Location/Qualifiers
 source 1..828
 /organism="Homo sapiens"
 /note="PCR amplified from activated THP-1 cells"
 /db_xref="taxon:9606"
 /clone_lib="Soares human placenta cDNA"
 /cell_line="THP-1"
 /cell_type="monoblast"
 CDS 15..419
 /codon_start=1
 /product="beta chemokine Exodus-2"
 /db_xref="PID:g2196920"
 /translation="MAQSLALSLLILVLAFGIPRTQGS DGGAGQDCCLKYSQRKIPAKV
 VRSYRKQEPSLGC SIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
 CRKDRGASKTGKKGKSGKCKRTERSQTPKGP"
 BASE COUNT 218 a 255 c 216 g 139 t
 ORIGIN
 1 ggacagagggc agacatggct cagtcactgg ctctgagcct cttatcctg gttctggcct
 61 ttggcatccc caggacccaa ggcagtgatg gaggggctca ggactgttgc ctcaagtaca
 121 gccaaaggaa gattcccgcc aaggttgctc gcagctaccg gaagcaggaa ccaagcttag
 181 gctgctccat cccagctatc ctgttcttgc cccgcaagcg ctctcaggca gagctatgtg
 241 cagacccaaa ggagctcttg gtgcagcagc tgatgcagca tctggacaag acaccatccc
 301 cacagaaaacc agcccagggc tgcaggaagg acaggggggc ctccaagact ggcaagaaaag
 361 gaaagggctc caaaggctgc aagaggactg agcggtcaca gaccctaaa gggccatagc
 421 ccagtgaagc gcctggagcc ctggagaccc caccagcctc accagcgctt gaagcctgaa
 481 cccaagatgc aagaaggagg ctatgctcag gggccctgga gcagccaccc catgctggcc
 541 ttgccacact ctttctcctg ctttaaccac cccatctgca ttcccagetc tcaccctgca
 601 tggctgagtc tgcccacagc agggccaggtc cagagagacc gaggagggag agtctccag
 661 ggagcatgag aggaggcagc aggactgtcc ccttgaagga gaatcatcag gaccctggac
 721 ctgatacggc tccccagtac accccacctc ttccttgtaa atatgattta tacctaactg
 781 aataaaaagc tgttctgtct tccccaccaa aaaaaaaaaa aaaaaaaaaa
 //
 LOCUS HSU88321 502 bp mRNA PRI 22-JUN-1998
 DEFINITION Human beta chemokine Exodus-3 mRNA, complete cds.
 ACCESSION U88321
 NID g2196921
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 502)
 AUTHORS Hromas, R.A., Gray, P., Klemsz, M., Fife, K. and Broxmeyer, H.
 TITLE DCCL chemokines represent a novel beta chemokine subfamily
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 502)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (04-FEB-1997) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 REFERENCE 3 (bases 1 to 502)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (22-JUN-1998) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 REMARK Amino acid sequence updated by submitter
 FEATURES Location/Qualifiers
 source 1..502

CDS

```

/organism="Homo sapiens"
/note="PCR amplified from THP-1 cells"
/db_xref="taxon:9606"
/cell_line="THP-1"
/cell_type="monoblast"
/dev_stage="adult"
120..416
/note="Mip-3alpha/ELC/CKbeta11"
/codon_start=1
/product="beta chemokine Exodus-3"
/db_xref="PID:g3243080"

```

```

/translation="MALLLALSLLVLWTSPAPTLSGTNDÆDCCLSVTKPIPGYIVR

```

```

NFHYLLIKDGCVRPAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMKRRSS"
BASE COUNT      113 a      170 c      121 g      98 t
ORIGIN

```

```

1  ctcacacctt gcatttcacc cctgcatccc atgcgcctcg cagcctcaca cagatcctgc
61 acacacccag acagctggcg ctcacacatt caccgttggc ctgcctctgt tcaccctcca
121 tggccctgct actggccctc agcctgctgg ttctctggac ttccccagcc ccaactctga
181 gtggcaccaa tgatgctgaa gactgctgcc tgcctgtgac ccagaaaccc atccctgggt
241 acatcgtaga gaacttcac taccttctca tcaaggatgg ctgcagggtg cctgctgtag
301 tgttcaccac actgaggggc cgccagctct gtgcaccccc agaccagccc tgggttagaac
361 gcatcatcca gagactgcag aggacctcag ccaagatgaa gcgcccgcag agttaaccta
421 tgaccgtgca gaggagagcc cgagtccgag tcaagcattg tgaattatta ctaactggga
481 acgaggacag aaggaaggac ag

```

//

```

LOCUS      HSU86358      879 bp      mRNA      PRI      11-SEP-1997
DEFINITION Human chemokine (TECK) mRNA, complete cds.
ACCESSION  U86358
NID       g2388626
KEYWORDS
SOURCE    human.
ORGANISM  Homo sapiens
          Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
          Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 879)
AUTHORS   Vicari,A.P., Figueroa,D.J., Hedrick,J.A., Foster,J.S.,
Singh,K.P., Menon,S., Copeland,N.G., Gilbert,D.J., Jenkins,N.A., Bacon,K.B.
and       Zlotnik,A.
TITLE     TECK: a novel cc chemokine specifically expressed by thymic
          dendritic cells and potentially involved in T cell development
JOURNAL   Immunology 7, 291-301 (1997)
REFERENCE 2 (bases 1 to 879)
AUTHORS   Vicari,A.P. and Zlotnik,A.
TITLE     Direct Submission.
JOURNAL   Submitted (21-JAN-1997) Immunology, DNAX Research Institute,
901       California Ave., Palo Alto, CA 94304, USA
FEATURES
          Location/Qualifiers
            source      1..879
                       /organism="Homo sapiens"
                       /db_xref="taxon:9606"
                       /chromosome="4"
            gene        1..879
                       /gene="TECK"
            CDS          1..453
                       /gene="TECK"
                       /codon_start=1
                       /product="chemokine"
                       /db_xref="PID:g2388627"

```

```

/translation="MNLWLLACLVAFLGAWAPAVHTQGVFEDCLAYHYPICWAVLR

```

```

RAWTYRIQEVSGSCNLPAAIFYLPKRHRKVCGNPKSREVQRAMKLLDARNKVFAKLHH
NMQTFQAGPHAVKKLSSGNSKLSKFSNPISSSSKRNVSLISANSGL"
BASE COUNT      191 a      264 c      218 g      206 t

```

ORIGIN

```

1 atgaacctgt ggctcctggc ctgcctgggt gccggcttcc tgggagcctg ggcccccgct
61 gtccacaccc aagggtgtctt tgaggactgc tgcctggcct accactaccc cattgggtgg
121 gctgtgctcc ggcgcgcctg gacttaccgg atccaggagg tgagcgggag ctgcaatctg
181 cctgctgcga tattctacct cccaagaga cacaggaagg tgtgtgggaa ccccaaaagc
241 agggaggtgc agagagccat gaagctcctg gatgctcgaa ataaggtttt tgcaaagctc
301 caccacaaca tgcagacctt ccaagcaggc cctcatgctg taaagaagtt gagttctgga
361 aactccaagt tatcatcatc caagtttagc aatcccatca gcagcagcaa gaggaatgtc
421 tccctcctga tatcagctaa ttcaggactg tgagccggct catttctggg ctccatcggc
481 acaggagggg ccggatcttt ctccgataaa accgtcgccc tacagaccca gctgtcccca
541 cgctctgtc ttttgggtca agtcttaate cctgcacctg agttggctct ccctctgcac
601 ccccaccacc tcctgcccgt ctggcaactg gaaagaagga gttggcctga ttttaacctt
661 ttgccgctcc ggggaacagc acaatcctgg gcagccagt gctctttag agaaaactta
721 ggatacctct ctactttct gtttcttggc gtccaccgg ggccatgcc gttgtcctc
781 tgggtccct ccaaaaatct ggtcattcaa ggatccctc ccaaggctat gcttttctat
841 aacttttaaa taaaccttgg ggggtgaatg gaataaaaa

```

//

```

LOCUS      AB002409      852 bp      mRNA      PRI      15-AUG-1997
DEFINITION Homo sapiens mRNA for SLC, complete cds.
ACCESSION  AB002409
NID        g2335034
KEYWORDS   SLC; mature ELC.
SOURCE      Homo sapiens cDNA to mRNA.
ORGANISM    Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE   1 (bases 1 to 852)
AUTHORS     Nomiya, H.
TITLE        Direct Submission
JOURNAL      Submitted (28-MAR-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki Nomiya, Kumamoto University Medical School,
Department  of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
            (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
            Fax:81-96-372-6140)
REFERENCE   2 (bases 1 to 852)
AUTHORS     Nagira, M., Imai, T., Hieshima, K., Kusuda, J., Ridanpaa, M.,
            Takagi, S., Nishimura, M., Kakizaki, M., Nomiya, H. and Yoshie, O.
TITLE        Molecular Cloning of a Novel Human CC Chemokine Secondary
            Lymphoid-Tissue Chemokine (SLC) That is an Efficient
            Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13
JOURNAL      Unpublished (1997)
FEATURES    Location/Qualifiers
            source          1..852
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
            CDS              59..463
                        /codon_start=1
                        /product="SLC"
                        /db_xref="PID:d1022673"
                        /db_xref="PID:g2335035"

```

/translation="MAQSLALSLLILVLAFGIPRTQGS DGGGAQDCCLKYSQRKIPAKV

```

VRSYRKQEPSLGCIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
CRKDRGASKTGKKGKSGCKRTERSQTPKGP"

```

```

mat_peptide <107..460
            /product="mature ELC"
polyA_site   823..828

```

BASE COUNT 205 a 279 c 217 g 151 t

ORIGIN

```

1 cttgcagctg cccacctcac cctcagctct ggctcttac tcacctctta ccacagacat
61 ggctcagtc ctggtctctga gctccttat cctggttctg gcctttggca tccccaggac
121 ccaaggcagt gatggagggg ctcaggactg ttgcctcaag tacagccaaa ggaagattcc
181 cgccaagggt gtccgcagct accggaagca ggaaccaagc ttaggctgct ccatcccagc
241 taccctgttc ttgccccgca agcgtcttca ggagagacta tgtgcagacc caaaggagct
301 ctgggtgcag cagctgatgc agcatctgga caagacacca tccccacaga aaccagccca

```

```

361 gggctgcagg aaggacaggg gggcctccaa gactggcaag aaaggaaagg gtcctcaaagg
421 ctgcaagagg actgagcggg cacagacccc taaagggcc tagccagtg agcagcctgg
481 agccctggag accccaccag cctcaccaac gcttgaagcc tgaacccaag atgcaagaag
541 gaggctatgc tcaggggccc tggagcagcc accccatgct ggccttgcca cactctttct
601 cctgctttta ccaccccatc tgcattccca gctctaccct gcatggctga gctgcccaca
661 gcaggccagg tccagagaga ccgaggagg agagtctccc agggagcatg agaggaggca
721 gcaggactgt ccccttgaag gagaatcatc aggaccctgg acctgatacg gctccccagt
781 acacccacc tcttccttgt aaatatgatt tatacctaac tgaataaaaa gctgttctgt
841 ctccccacc gc

```

//

```

LOCUS      AF055467      1481 bp      mRNA                      PRI      06-AUG-1998
DEFINITION Homo sapiens monotactin-1 mRNA, complete cds.
ACCESSION  AF055467
NID        g3395775
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1481)
AUTHORS    Youn,B.S., Zhang,S., Broxmeyer,H.E., Antol,K., Fraser,M.J. Jr.,
            Hangoc,G. and Kwon,B.S.
TITLE      Isolation and characterization of LMC, a novel lymphocyte and
            monocytic chemoattractant human CC chemokine, with
myelosuppressive
            activity
JOURNAL     Biochem. Biophys. Res. Commun. 247 (2), 217-222 (1998)
MEDLINE     98308096
REFERENCE  2 (bases 1 to 1481)
AUTHORS     Youn,B.S. and Kwon,B.S.
TITLE      Direct Submission
JOURNAL     Submitted (24-MAR-1998) Microbiology and Immunology, Indiana
            University, School of Medicine, 605 Barnhill Dr. Medical
Science     Bldg., Indianapolis, IN 46202, USA
FEATURES
            Location/Qualifiers
            source          1..1481
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
                           /chromosome="17"
            5'UTR          1..34
            CDS             35..397
                           /note="Mtn-1; LMC; lymphocyte and monocytic
                           chemoattractant
                           CC chemokine"
                           /codon_start=1
                           /product="monotactin-1"
                           /db_xref="PID:g3395776"

```

/translation="MKVSEAALSLVLILIITSASRSQPKVPEWVNTPTSCCLKYEEK

VLPRRLVVGYRKALNCHLPAIFVTKRNREVCTNPNDWVQEYIKDPNLPPLPTRNLS
TVKIITAKNGQPQLLSQ"

3'UTR 398..1481
BASE COUNT 412 a 362 c 302 g 405 t
ORIGIN

```

1 gcacgagctg aagctgtact gcctcgctga gaggatgaag gtctccgagg ctgccctgtc
61 tctccttgct ctcacccctta tcattacttc ggcttctcgc agccagccaa aagttcctga
121 gtgggtgaac accccatcca cctgctgcct gaagtattat gagaaagtgt tgccaaggag
181 actagtgggt ggatacagaa aggccctcaa ctgtcacctg ccagcaatca tcttcgtcac
241 caagaggaac cgagaagtct gcaccaaccc caatgacgac tgggtccaag agtacatcaa
301 ggatcccaac ctacctttgc tgctaccag gaacttgctc acggttaaaa ttattacagc
361 aaagaatggt caacccacgc tcctcaactc ccagtgtatg ccaagcttta gtggaagccc
421 ttgtttacag aagagagggg taaactatga aaacagggga agccttatta ggctgaaact
481 agccagtcac attgagagaa gcagaacaat gatcaaaata aaggagaagt atttcgaata
541 tttttcfaat cttaggagga aataccaaag ttaaggagac tgggcagagg tacgtctttt
601 tatttttata tttatatatt tatttttttg agatagggtc ttactctgtc acccaggctg
661 gagtgcagtg gtgtgatctt ggctcacttg atcttggtc actgtaacct ccacctccca
721 ggctcaagtg atcctccac cccacctccc cgagtacgtg gactacagg ctgtgcacc
781 cacacctggc taatttttgt attttttgga gagacgggat tctaccatgt tgcccaggct

```

```

841 ggtctcaaac tcgtgtgccc aagcaatcca cctgcctcag ccttccaaaa gtgctgggct
901 tacaggcgctg agccaccaca tccggccagt ccactcttaa tacacagaaa aatatatttc
961 acatccttct cctgtctctt ttcaattcct cacttcacac cagtacacaa gccattctaa
1021 atacttagcc agtttccagc cttccagatg atctttgccc tctgggtctt gaccattaa
1081 gagccccata gaactcttga ttttctctgt ccactcttat gggatttttc tggatctata
1141 ttttcttcaa ttattctttc attttataat gcaacttttt cataggaagt ccggtaggga
1201 atattcacat taatcatttt tgcagagact ttgctagatc ctctcatatt ttgtcttcct
1261 caggggtggca ggggtacaga agtgcttgat tgggtttttt tttttttgag agagagagag
1321 aagaagaaga agaagagaca caaatctcta cctcccatgt taagctttgc aggacaggga
1381 aagaaagggt atgagacacg gctagggtaa actcttagtc caaaacccaa gcatgcaata
1441 aataaaactc cttatttga caaaaaaaaa aaaaaaaaaa a

```

//

```

LOCUS      HSRNAATAC      557 bp      RNA      PRI      06-JUL-1995
DEFINITION H.sapiens mRNA for ATAC protein.
ACCESSION  X86474
NID        g895846
KEYWORDS   ATAC gene.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 557)
AUTHORS    Muller,S., Dorner,B., Korthauer,U., Mages,H.W., D'Apuzzo,M.,
            Senger,G. and KroczeK,R.A.
TITLE      Cloning of ATAC, an activation-induced, chemokine-related
molecule  exclusively expressed in CD8+ T lymphocytes
            Eur. J. Immunol. 25 (6), 1744-1748 (1995)
JOURNAL    95339892
MEDLINE    95339892
REFERENCE  2 (bases 1 to 557)
AUTHORS    KroczeK,R.A.
TITLE      Direct Submission
JOURNAL    Submitted (20-APR-1995) R.A. KroczeK, Molecular Immunology,
            Robert-Koch-Institute, Nordufer 20, 13353 Berlin, FRG
FEATURES   Location/Qualifiers
            source      1..557
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /tissue_type="peripheral blood"
                        /cell_type="lymphocyte"
                        /chromosome="1"
                        /map="q23"
            gene        25..369
                        /gene="ATAC"
            CDS          25..369
                        /gene="ATAC"
                        /codon_start=1
                        /product="CD8+T cell specific protein"
                        /db_xref="PID:g895847"
                        /db_xref="SWISS-PROT:P47992"

```

/translation="MRLILALLGICSLTAYIVEGVGSEVSDKRTCVSLLTQRLPVSR

IKTYTITEGSLRAVIFITKRLKVCADPQATWVRDVVRSMDRKSNTNRNMIQTKPTGT

QQSTNTAVTLTG

polyA_signal 469..474

polyA_signal 534..539

BASE COUNT 157 a 139 c 112 g 149 t

ORIGIN

```

1 gcacagctca gcaggacctc agccatgaga cttctcatcc tggccctcct tggcatctgc
61 tctctcactg catacattgt ggaagggtga gggagtgaag tctcagataa gaggacctgt
121 gtgagcctca ctaccagcgc actgccgggt agcagaatca agacctacac catcagcgaa
181 ggctccttga gagcagtaat ttttattacc aaacgtggcc taaaagtctg tgctgatcca
241 caagccacat ggggtgagaga cgtggtcagg agcatggaca ggaaatccaa caccagaaat
301 aacatgatcc agaccaagcc aacagggaacc cagcaatcga ccaatacagc tgtgactctg
361 actggctagt agtctctggc accctgtccg tctccagcca gccagctcat ttcactttac
421 acgctcatgg actgagttta tactgcctt ttatgaaagc actgcatgaa taaaattatt
481 cttttgtatt tttactttta aatgtcttct gtattcactt atatgttcta attaataaat
541 tatttattat taagaat

```

//

LOCUS HSU85767 563 bp mRNA PRI 01-APR-1997
 DEFINITION Human myeloid progenitor inhibitory factor-1 MPIF-1 mRNA, complete
 cds.
 ACCESSION U85767
 NID g1916249
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 563)
 AUTHORS Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T., Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D., Gentz,R. and Garotta,G.
 TITLE Molecular and functional characterization of two novel human C-chemokines as inhibitors of two distinct classes of myeloid progenitors
 J. Exp. Med. (1997) In press
 REFERENCE 2 (bases 1 to 563)
 AUTHORS Li,H. and Patel,V.P.
 TITLE Direct Submission
 JOURNAL Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences, 9410 Keywest Ave., Rockville, MD 20850, USA
 FEATURES
 source Location/Qualifiers
 1..563
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 31..393
 /note="myeloid progenitor inhibitory factor-1"
 /codon_start=1
 /product="MPIF-1"
 /db_xref="PID:g1916250"
 /translation="MKVSVAAALSCLMLVLTALGSQARVTKDAETEFMMSKLPLENPVLL
 DRFHATSADCCISYTPRSIPCSLLESYFETNSECSKPGVIFLTKKGRRFCANPSDKQV
 QVCMRMLKLDTRIKTRKN"
 BASE COUNT 164 a 143 c 117 g 139 t
 ORIGIN
 1 ctccagccagc cctgcctgcc caccaggagg atgaagggtct ccgtggctgc cctctcctgc
 61 ctcatgcttg ttactgccct tggatcccag gcccggtgca caaaagatgc agagacagag
 121 ttcatgatgt caaagcttcc attggaaaat ccagtacttc tggacagatt ccatgctact
 181 agtgctgact gctgcatctc ctacacccca cgaagcatcc cgtgttact cctggagagt
 241 tactttgaaa cgaacagcga gtgctccaag ccgggtgtca tcttcctcac caagaagggg
 301 cgacgtttct gtgccaaacc cagtataaag caagttcagg ttgcatgag aatgctgaag
 361 ctggacacac ggatcaagac caggaagaat tgaacttgtc aaggtgaagg gacacaagtt
 421 gccagccacc aactttcttg cctcaactac ctctctgaat tattttttta agaagcattt
 481 attcttgtgt tctggattta gagcaattca tctaataaac agtttctcac ttttaaaaaa
 541 aaaaaaaaaa aaaaaaaaaa aaa
 //

LOCUS HSU85768 360 bp mRNA PRI 01-APR-1997
 DEFINITION Human myeloid progenitor inhibitory factor-1 MPIF-2 mRNA, complete
 cds.
 ACCESSION U85768
 NID g1916251
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 360)
 AUTHORS Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T., Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D., Gentz,R. and Garotta,G.
 TITLE Molecular and functional characterization of two novel human C-

C

chemokines as inhibitors of two distinct classes of myeloid progenitors
 J. Exp. Med. (1997) In press
 REFERENCE 2 (bases 1 to 360)
 AUTHORS Li, H. and Patel, V.P.
 TITLE Direct Submission
 JOURNAL Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences, 9410
 Keywest Ave., Rockville, MD 20850, USA
 FEATURES Location/Qualifiers
 source 1..360
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 1..360
 /note="myeloid progenitor inhibitory factor-2"
 /codon_start=1
 /product="MPIF-2"
 /db_xref="PID:g1916252"
 /translation="MAGLMTIVTSLFLGVCAHHIIPGTVVIPSPPCMFFVSKRIPE
 NRVVSYQLSSRSTCLKGGVIFTTKKGQQFCGDPKQEWVQRYMKNLDAKQKKASPRARA
 VAVKGFPVQRYPGNQVTC"
 BASE COUNT 85 a 106 c 96 g 73 t
 ORIGIN
 1 atggcaggcc tgatgacat agtaaccagc cttctgttcc ttggtgtctg tgcccaccac
 61 atcatcccta cgggctctgt ggtcataccc tctccctgct gcatgttctt tgtttccaag
 121 agaattcctg agaaccgagt ggtcagctac cagctgtcca gcaggagcac atgcctcaag
 181 ggaggagtga tcttcaccac caagaagggc cagcagttct gtggcgaccc caagcaggag
 241 tgggtccaga ggtacatgaa gaacctggac gccaagcaga agaaggcttc ccctagggcc
 301 agggcagtggt ctgtcaaggg ccctgtccag agatatcctg gcaaccaaac cacctgctaa
 //
 LOCUS HUMSDF1A 1847 bp mRNA PRI 26-DEC-1996
 DEFINITION Human pre-B cell stimulating factor homologue (SDF1a) mRNA,
 complete cds.
 ACCESSION L36034
 NID g1220363
 KEYWORDS intercrine; intercrine CXC subfamily; pre-B cell stimulating
 factor
 SOURCE homologue; alpha-chemokine.
 human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1847)
 AUTHORS Shirozu, M., Nakano, T., Inazawa, J., Tashiro, K., Tada, H.,
 Shinohara, T. and Honjo, T.
 TITLE Structure and chromosomal localization of the human stromal
 cell-derived factor 1 (SDF1) gene
 JOURNAL Genomics 28 (3), 495-500 (1995)
 MEDLINE 96039262
 FEATURES Location/Qualifiers
 source 1..1847
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="h5"
 /cell_line="FLEB14-14"
 sig_peptide 80..142
 /gene="SDF1a"
 CDS 80..349
 /codon_start=1
 /product="pre-B cell stimulating factor homologue"
 /db_xref="PID:g1220364"
 /translation="MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANV
 KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNK"
 gene 80..346
 /gene="SDF1a"
 mat_peptide 143..346

```

/ gene="SDF1a"
/ product="pre-B cell stimulating factor homologue"
BASE COUNT      459 a      471 c      417 g      500 t
ORIGIN
1  tctccgctcag ccgcattgcc cgctcggcgt ccggcccccg acccgtgctc gtccgccccg
61  ccgccccgcc gcccgcgcca tgaacgcca ggtcgtggtc gtgctgggtc tcgtgctgac
121  cgcgctctgc ctcagcgacg ggaagcccg cagcctgagc tacagatgcc catgccgatt
181  ctctcgaaagc catgttgcca gagccaacgt caagcatctc aaaattctca acactccaaa
241  ctgtgccctt cagattgtag cccggctgaa gaacaacaac agacaagtgt gcattgaccc
301  gaagctaaag tggattcagg agtacctgga gaaagcttta aacaagtaag cacaacagcc
361  aaaaaggact ttccgctaga cccactcgag gaaaactaaa accttgtag agatgaaagg
421  gcaaagacgt gggggagggg gccttaacca tgaggaccag gtgtgtgtgt ggggtgggca
481  cattgatctg ggatcggggc tgaggtttgc agcatttaga ccctgcatt atagcatacg
541  gtatgatatt gcagcttata ttcattcatg ccctgtacct gtgcagttg gaacttttat
601  tactgggggt tttctaagaa agaaattgta ttatcaacag cattttcaag cagttagttc
661  cttcatgac atcacatca tcatcattct cattctcatt ttttaaatca acgagtactt
721  caagatctga atttggcttg tttggagcat ctctctgct cccctgggga gtctgggac
781  agtcaggtgg tggcttaaca gggagctgga aaaagtgtcc tttcttcaga cactgaggct
841  cccgcagcag cgccctccc aagaggaagg cctctgtggc actcagatac cgactggggc
901  tggggcgccg ccactgcctt caccctctct tcaaacctc agtgattggc tctgtgggt
961  ccattgtaga gccactatta ctgggactgt ctcagagacc cctctcccag ctattctctac
1021  tctctcccc actccgagag catgcttaat ctgtctctg ctctctcatt ctgtagcctg
1081  atcagcgccg caccagccgg gaagagggtg attgctgggg ctgctgcctt gcacccctc
1141  cctcccaggg cctgccccac agctcggggc ctctgtgaga tccgtctttg gcctctccca
1201  gaatggagct ggcctctctc tggggatgtg taatggtccc cctgcttacc cgcaaaagac
1261  aagtcctttac agaatacaat gcaattttaa atctgagagc tcgcttgagt gactgggttt
1321  gtgattgcct ctgaagccta tgtatgcat ggaggcacta acaaaccttg aggtttccga
1381  aatcagaagc gaaaaaatca gtgaataaac catcatcttg ccactacccc ctctgaagc
1441  cacagcaggg gttcagggtt caatcagaac tgttggaag gtgacatttc catgcataga
1501  tgcgatccac agaaggtcct ggtggtatgt gtaacttttt gcaaggcatt ttttatata
1561  tattttttgtg cacatttttt ttacgattc tttagaaaac aaatgtattt caaaatatat
1621  ttatagtcga acaagtcata tatatgaatg agagccatat gaatgtcagt agtttatact
1681  tctctattat ctcaaacctac tggcaatttg taaagaaata tatatgatata ataatgtga
1741  ttgcagcttt tcaatgttag ccacagtgtg ttttttcaact tgtactaaaa ttgtatcaaa
1801  tgtgacatta tatgcactag caataaaatg ctaattgttt catggtg
//

```

```

LOCUS      HUMSDF1B      3524 bp      mRNA
DEFINITION Human pre-B cell stimulating factor homologue (SDF1b) mRNA,
              complete cds.
ACCESSION  L36033
NID        g1220365
KEYWORDS   intercrine; intercrine CXC subfamily; pre-B cell stimulating
              factor
SOURCE      homologue; alpha-chemokine.
              human.
ORGANISM    Homo sapiens
              Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
              Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 3524)
AUTHORS     Shirozu, M., Nakano, T., Inazawa, J., Tashiro, K., Tada, H.,
              Shinohara, T. and Honjo, T.
TITLE       Structure and chromosomal localization of the human stromal
              cell-derived factor 1 (SDF1) gene
JOURNAL      Genomics 28 (3), 495-500 (1995)
MEDLINE      96039262
FEATURES
    source          Location/Qualifiers
                    1..3524
                    /organism="Homo sapiens"
                    /db_xref="taxon:9606"
                    /clone="h17"
                    /cell_line="FLEB14-14"
    sig_peptide      80..142
                    /gene="SDF1b"
    CDS              80..361
                    /codon_start=1
                    /product="pre-B cell stimulating factor homologue"
                    /db_xref="PID:g1220366"

```

```

/translation="MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPFRFFESHVARANV
              KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNKRFRKM"

```

```

gene      80..358
          /gene="SDF1b"
mat_peptide 143..358
          /gene="SDF1b"
          /product="pre-B cell stimulating factor homologue"
BASE COUNT   903 a   886 c   793 g   942 t
ORIGIN
1   tctccgtcag ccgcattgcc cgctcggcgt ccggcccccg acccgtgctc gtccgcccg
61  cgcgcgcgcc gccgcgcgca tgaacgccaa ggtcgtggtc gtgctggtcc tcgtgctgac
121 cgcgctctgc ctccagcgag ggaagcccg cagcctgagc tacagatgcc catgccgatt
181 cttcgaaagc catgttgcca gagccaacgt caagcatctc aaaattctca acactccaaa
241 ctgtgccctt cagattgtag cccggctgaa gaacaacaac agacaagtgt ccattgaccc
301 gaagctaaag tggattcagg agtacctgga gaaagcttta aacaagaggt tcaagatgtg
361 agagggtcag acgcctgagg aacctttaca gtaggagccc agctctgaaa ccagtgttag
421 ggaaggccct gccacagcct cccctgccag ggcagggccc caggcatgce caagggcttt
481 gttttgcaca ctttgccata ttttcaccat ttgattatgt agcaaaatac atgacattta
541 tttttcattt agtttgatta ttcagtgtca ctggcgacac gtagcagctt agactaaggc
601 cattattgta cttgccttat tagagtgtct tccacggag ccactcctct gactcagggc
661 tcctgggttt tgtattctct gagctgtgca ggtggggaga ctgggctgag ggagcctggc
721 cccatggtca gccctagggt ggagagccac caagagggag gcctgggggt gccaggacca
781 gtcaacctgg gcaaacctta gtgaaggctt ctctctgtgg gatgggatgg tggagggcca
841 catgggaggg tcacccctct ctccatccac atgggagccg ggtctgcctc ttctgggagg
901 gcagcagggc taccctgagc tgaggcagca gtgtgaggcc agggcagagt gagaccagc
961 cctcatcccg agcacctcca catctccac gttctgctca tcattctctg tctcatcat
1021 catcatgtgt gtccacgact gtctccatgg ccccgcaaaa ggactctcag gaccaaagct
1081 ttcattgtaa ctgtgcacca agcaggaaat gaaaatgtct tgtgttacct gaaaacactg
1141 tgcacatctg tgtcttgtgt ggaatattgt ccattgtcca atcctatggt tttgttcaaa
1201 gccagcgtcc tcctctgtga ccaatgtctt gatgcatgca ctgttcccc ttgtgcagccg
1261 ctgagcgagg agatgtcctt tgggcccctt gagtgcagtc ctgatcagag ccgtgttctt
1321 ttggggtgaa ctaccttggg tccccactg atcacaaaaa catggtgggt ccatgggcag
1381 agcccaaggg aattcgggtg gcaccagggt tgacccaga ggattgtctg cccatcagtg
1441 ctccctcaca tgtcagtacc ttcaactag ggccaagccc agcactgctt gaggaataca
1501 agcattcaca acttgtttt gggtttttaa acccagttca caaaataacc aatcttggac
1561 atgaagattc tttcccaatt cacatctaac ctcatcttct tcaccatttg tagcaagctt
1621 catctcctgc ctctcctctg ggccctctct gctctgcgtg tcacctgtgc ttcgggcccct
1681 tccacagga cattttctta agagaacaat gtgctatgtg aagagtaagt caacctgcct
1741 gcacatttga gtgttccct cccactgagg gcagtcgata gagctgtatt aagccactta
1801 aatgtttcac ttttgacaaa ggcaagcact tgtgggtttt tgttttgttt ttcattcagt
1861 cttacgaata cttttgccct ttgattaaag actccagtta aaaaaatttt taatgaagaa
1921 agtggaatac aaggaagtca aagcaaggaa actatgtaac atgtaggaag taggaagtaa
1981 attatagtga tgtaatcttg aattgttaact gttcgtgaat ttaataatct gtagggtaat
2041 tagtaacatg tgttaagat tttcataagt atttcaaat ggagcttcat ggcagaaggg
2101 aaacccatca acaaaaattg tcccttaaac aaaaattaaa atcctcaatc cagctatgtt
2161 atattgaaaa aatagagcct gagggatctt tactagttaa aaagatacag aactcttcca
2221 aaaccttttg aaattaacct ctactatac cagtataatt gagttttcag tggggcagtc
2281 attatccagg taatccaaga tattttaaaa tctgtcacgt agaacttgga gtactctgcc
2341 cccaatccat gaaccaagac cattgaattc ttggttgagg aaacaaacat gaccctaaat
2401 cttgactaca gtcaggaaaag gaatcatttc tatttctcct ccatgggaga aaatagataa
2461 gagtagaaac tgcagggaat attatttgca taacaattcc tctactaaca atcagctcct
2521 tcctggagac tgcccagcta aagcaatatg catttaaata cagtcttcca tttgcaaggg
2581 aaaagtctct tgtaatccga atctcttttt gctttcgaa tgctagtcaa gtgctccac
2641 gagctgttta ctagggatcc ctcatctgtc cctcgggac ctggtgctgc ctctacctga
2701 cactcccttg ggctccctgt aacctcttca gaggccctcg ctgccagctc tgtatcagga
2761 cccagaggaa ggggccagag gctcgttgac tggctgtgtg ttgggatgga gtctgtgcca
2821 cgtgtatgtg ctgtggtgtg tccccctctg tccaggcact gagataccag cgaggaggct
2881 ccagagggca ctctgcttgt tattagagat tacctcctga gaaaaaagct tccgcttgga
2941 gcagaggggc tgaatagcag aagggtgcac ctcccccaac cttagatggt ctaagtcttt
3001 ccattggatc tcattggacc cttccatggt gtgatcgtct gactgggtgt atcaccgtgg
3061 gctccctgac tgggagttga tcgcttttcc cagggtgtac acccttttcc gctggatga
3121 gaatttgagt gctctgatcc ctctacagag ctccctgac tcattctgaa ggagcccat
3181 tcctgggaaa tattccctag aaacttccaa atccccctag cagaccactg ataaaaccat
3241 gtgaaaaatt tgttattttg caacctcgct ggactctcag tctctgagca gtgaatgatt
3301 cagtgttaaa tgtgatgaat actgtatttt gtattgtttc aagtgcactc cccagataat
3361 gtgaaaaatg tccaggagaa ggccaattcc tatacgagc gtgctttaa aataaataa
3421 gaaacaactc tttgagaaac aacaatttct actttgaagt cataccaatg aaaaaatgta
3481 tatgcactta taattttcct aataaagttc tgtactcaa tgta

```

//

```

LOCUS      HSJ002211      663 bp      mRNA      PRI      11-MAR-1998
DEFINITION Homo sapiens cDNA for a CXC chemokine.
ACCESSION  AJ002211

```

NID g2832410
 KEYWORDS CXC chemokine.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 663)
 AUTHORS Legler, D.F., Loetscher, M., Roos, R.S., Clark-Lewis, I.,
 Baggiolini, M.
 TITLE B cell-attracting chemokine 1, a human CXC chemokine expressed
 in lymphoid tissues, selectively attracts B lymphocytes via
 BLR1/CXCR5
 JOURNAL J. Exp. Med. 187 (4), 655-660 (1998)
 MEDLINE 98130629
 REFERENCE 2 (bases 1 to 663)
 AUTHORS Moser, B.
 TITLE Direct Submission
 JOURNAL Submitted (05-NOV-1997) Moser B., University of Bern, Theodor
 Kocher Institute, Freiestrasse 1, CH-3012 Bern, SWITZERLAND
 FEATURES
 source 1..663
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PBL"
 sig_peptide 35..100
 /gene="BCA-1"
 CDS 35..364
 /gene="BCA-1"
 /codon_start=1
 /product="CXC chemokine"
 /db_xref="PID:e1249325"
 /db_xref="PID:g2832411"
 /translation="MKFISTSLLLMLLVSSLSPVQGVLEVYYTSLRCRCVQESSVFIP"
 RRFIDRIQILPRNGCPRKEIIWKNKNSIVCVDPQAEWIQRMMEVLRKRSSSTLPVP
 VFKRKIP
 gene 35..364
 /gene="BCA-1"
 mat_peptide 101..361
 /gene="BCA-1"
 BASE COUNT 176 a 136 c 145 g 198 t 8 others
 ORIGIN
 1 cagagctcaa gtctgaactc tacctccaga cagaatgaag ttcattctga catctctgct
 61 tctcatgctg ctggtcagca gcctctctcc agtccaaggt gttctggagg tctattacac
 121 aagcttgagg tgtagatgtg tccaagagag ctcatgtctt atccctagac gcttcattga
 181 tcgaattcaa atcttgcccc gtgggaatgg ttgtccaaga aaagaaatca tagtctggaa
 241 gaagaacaag tcaattgtgt gtgtggaccc tcaagctgaa tggatacaaa gaatgatgga
 301 agtattgaga aaaagaagtt cttcaactct accagttcca gtgtttaaga gaaagattcc
 361 ctgatgctga tatttccact aagaacacct gcattcttcc cttatccctg ctctgggatt
 421 ttagttttgt gcttagttaa atcttttcca gggagaaaga acttcccat acaataaagg
 481 catgaggact atgtaaaaat aaccttgacg gagctggatg gggggccaaa ctcaagcttc
 541 tttcactcca caggcacctt attntacact tgggggtttt gcnttctttn tttctcagg
 601 gggggggaaa gtttcttttg gaaantagtt nttccagttt ttaggtatta cagggttntt
 661 ttt
 //
 LOCUS HSHUMIG 2545 bp RNA PRI 16-NOV-1993
 DEFINITION H. sapiens Humig mRNA.
 ACCESSION X72755 S60728
 NID g311375
 KEYWORDS chemokine; cytokine; Humig gene; secreted protein.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 2545)
 AUTHORS Farber, J.M.
 TITLE Direct Submission
 JOURNAL Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School

of

USA Medicine, Ross 1147, 720 Rutland Avenue, Baltimore, MD 21205,
 REFERENCE 2 (bases 1 to 2545)
 AUTHORS Farber, J.M.
 TITLE HuMig: a new human member of the chemokine family of cytokines
 JOURNAL Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
 MEDLINE 93236577
 FEATURES Location/Qualifiers
 source 1..2545
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /germline
 /dev_stage="child"
 /tissue_type="leukaemia"
 /cell_type="monocyte"
 /cell_line="THP-1"
 /clone_lib="THP-1/IFN-gamma cDNA"
 /clone="H-1-3"
 misc_feature 13..19
 /note="cis-acting element; putative"
 gene 40..417
 /gene="Humig"
 CDS 40..417
 /gene="Humig"
 /codon_start=1
 /db_xref="PID:g311376"
 /db_xref="SWISS-PROT:Q07325"

/translation="MKKSGVLFLLGIILLVLIGVQGTTPVVRKGRCSISTNQGTIHLQ

SLKDLKQFAPSPSCEKIEIIATLKNVQTCNLNPDSDVKELIKKWEKQVSQKKKQKNG
KKHQKKKVLKVRKSQRSRQKKT"

BASE COUNT	755 a	581 c	457 g	752 t
ORIGIN				

```

1 atccaataca ggagtgactt ggaactccat tctatcacta tgaagaaaag tgggtgttctt
61 ttctctcttg gcatcatctt gctgggtctg attggagtgc aaggaacccc agtagtgaga
121 aagggtcgct gttcctgcac cagcaccaac caagggacta tccacctaca atccttgaaa
181 gaccttaaac aatttgcccc aagcccttcc tgcgagaaaa ttgaaatcat tgctacactg
241 aagaatggag ttcaaactatg tctaaaccca gattcagcag atgtgaagga actgattaaa
301 aagtgggaga aacagggtcag ccaaaagaaa aagcaaaaaga atgggaaaaa acatcaaaaa
361 aagaaagtgc tgaaagtctg aaaatctcaa cgttctctgc aaaagaagac tacataagag
421 accacttcac caataagtat tctgtgttaa aaatgttcta ttttaattat accgctatca
481 ttccaaagga ggatggcata taatacaaa gcttattaat ttgactagaa aatttaaaac
541 attactctga aattgtaact aaagtttagaa agttgatttt aagaatccaa acgttaagaa
601 ttgttaaagg ctatgattgt cttgttctct ctaccaccca ccagttgaaat ttcacatgc
661 ttaaggccat gatttttagca ataccatgt ctacacagat gttcacccaa ccacatccca
721 ctccacaacag ctgcctggaa gagcagccct aggtctccac gtactgcagc ctccagagag
781 tatctgaggc acatgtcagc aagtcctaa gctgttagca tgcgtgtgag caagcagtt
841 tgaattgag ctggacctca ccaagctgct gtggccatca acctctgtat ttgaatcagc
901 ctacaggcct cacacacaat gtgtctgaga gattcatgct gattgttatt gggatatcacc
961 actggagatc accagtgtgt ggctttcaga gcctccttcc tggccttggga agccatgtga
1021 ttccatcttg cccgctcagg ctgaccactt tatttctttt tgttcccttt tgcttcatte
1081 aagtcagctc ttctccatcc taccacaatg cagtgccctt ctctctccca gtgcacctgt
1141 catatgctct gatttatctg agtcaactcc ttctcatct tgtccccaac accccacaga
1201 agtgctttct tctcccaatt catctcact cagtcagct tagttcaagt cctgcctctt
1261 aaataaacct ttttgacac acaaatattc ttaaaactcc tgtttcactt ggttcagtac
1321 cacatgggtg aacactcaat ggttaactaa ttcttgggtg tttatcctat ctctccaaac
1381 agattgtcag ctccctgagg gcaagagcca cagtataatt cctgtttct tccacagtgc
1441 ctaataatac tgtggaacta ggttttaata attttttaat tgatgttgtt atgggcagga
1501 tggcaaccag accattgtct cagagcaggt gctggctctt tcctggctac tccatgttgg
1561 ctagcctctg gtaacctctt acttattatc ttacaggacac tcaactacag gaccagggat
1621 gatgcaacat ccttgtcttt ttatgacagg atgtttgtct agcttctcca acaataagaa
1681 gcacgtggta aaacacttgc ggatattctg gactgttttt aaaaaatata cagtttaccg
1741 aaaatcatat aatcttaca tgaaaaggac tttatagatc agccagtgac caacctttc
1801 ccaaccatac aaaaattcct ttcccgagg gaaaagggtt ttctcaataa gcctcagctt
1861 tctaagatct aacaagatag ccaccgagat ccttatcgaa actcatatta ggcaaatatg
1921 agttttattg tccgtttact tgtttcagag ttgtattgt gattatcata taccacacca
1981 tctcccatga agaaaggga cggtgaagta ctaagcgcta gaggaagcag ccaagtcggt
2041 tagtggaagc atgattgggtg cccagttagc ctctgcagga tgtggaaacc tcttccagg
2101 ggaggttcag tgaattgtgt aggagaggtt gtctgtggcc agaatttaaa cctatactca

```

```

2161 ctttcccaaa ttgaatcact gctcacactg ctgatgattt agagtgtgtt cgggtggaga
2221 tcccaccgga acgtcttatt taatcatgaa actccctagt tccttcatgt aacttccttg
2281 aaaaatctaa gtgtttcata aatttgagag tctgtgaccc acttaccttg catctcacag
2341 gtagacagta tataactaac aaccaagac tacatattgt cactgacaca caggttataa
2401 tcatttatca tatatataca tacatgcata cactctcaaa gcaataaatt tttcacttca
2461 aaacagtatt gacttgata ccttgtaatt tgaaatattt tctttgttaa aatagaatgg
2521 tatcaataaa tagaccatta atcag

```

//

```

LOCUS      HSHUMIG      2545 bp      RNA      PRI      16-NOV-1993
DEFINITION H.sapiens Humig mRNA.
ACCESSION  X72755 S60728
NID        g311375
KEYWORDS   chemokine; cytokine; Humig gene; secreted protein.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 2545)
AUTHORS    Farber, J.M.
TITLE      Direct Submission
JOURNAL    Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School
of         Medicine, Ross 1147, 720 Rutland Avenue, Baltimore, MD 21205,
USA
REFERENCE  2 (bases 1 to 2545)
AUTHORS    Farber, J.M.
TITLE      HuMig: a new human member of the chemokine family of cytokines
JOURNAL    Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
MEDLINE    93236577
FEATURES   Location/Qualifiers
            source          1..2545
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /germline
                        /dev_stage="child"
                        /tissue_type="leukaemia"
                        /cell_type="monocyte"
                        /cell_line="THP-1"
                        /clone_lib="THP-1/IFN-gamma cDNA"
                        /clone="H-1-3"
            misc_feature    13..19
                        /note="cis-acting element; putative"
            gene            40..417
                        /gene="Humig"
            CDS             40..417
                        /gene="Humig"
                        /codon_start=1
                        /db_xref="PID:g311376"
                        /db_xref="SWISS-PROT:Q07325"

```

/translation="MKKSGVLFLLGIILLVLIGVQGTTPVVRKGRCSISTNQGTIHLQ

SLKDLKQFAPSPSCEKIEIIATLKNVQTCNLPDSADVKELIKKEKQVSQKKKQKNG
KKHQKKKKVLKVRKSQRSRQKKTT

```

BASE COUNT      755 a      581 c      457 g      752 t
ORIGIN

```

```

1 atccaataca ggagtgcatt ggaactccat tctatcacta tgaagaaaag tgggtgttctt
61 ttcctcttgg gcatcatctt gctggttctg attggagtgc aaggaacccc agtagtgaga
121 aagggtcgct gttcttgcac cagcaccaac caagggacta tccacctaca atccttgaaa
181 gaccttaaac aatttgcccc aagcccttcc tgcgagaaaa ttgaaatcat tgctacactg
241 aagaatggag ttcaaacatg tctaaaccca gattcagcag atgtgaagga actgattaaa
301 aagtgggaga aacaggtcag ccaaaagaaa aagcaaaaga atgggaaaaa acatcaaaaa
361 aagaaagttc tgaaagttcg aaaatctcaa cgttctcgtc aaaagaagag tacataagag
421 accacttcac caataagtat tctgtgttaa aaatgttcta ttttaattat accgctatca
481 ttccaaagga ggatggcata taatacaaaag gcttattaat ttgactagaa aatttaaaac
541 attactctga aattgtaact aaagtttagaa agttgatttt aagaatccaa acgttaagaa
601 ttgttaaagg ctatgattgt ctttgttctt ctaccaccca ccagttgaat ttcatcatgc
661 ttaaggccat gatttttagca ataccatgt ctacacagat gtccacccaa ccacatccca
721 ctcaaacag ctgcctggaa gagcagccct aggttccac gtactgcagc ctccagagag
781 tatctgagga acatgtcagc aagtcctaag cctgttagca tgctgggtgag ccaagcagtt

```

```

841 tgaattgag ctggacctca ccaagctgct gtggccatca acctctgtat ttgaatcagc
901 ctacaggcct cacacacaat gtgtctgaga gattcatgct gattgttatt gggatcacc
961 actggagatc accagtggtg ggctttcaga gcctccttcc tggcttttga agccatgtga
1021 ttccatcttg cccgctcagg ctgaccactt tatttctttt tgttccccct tgcttcattc
1081 aagtcagctc ttctccatcc taccacaatg cagtgccttt ctctctcca gtgcacctgt
1141 catatgctct gatttatctg agtcaactcc ttctcatct tgtcccaac accccacaga
1201 agtgctttct tctcccaatt catcctcact cagtccagct tagttcaagt cctgcctctt
1261 aaataaacct ttttgacac acaaattatc ttaaaactcc tgtttcactt ggttcagtag
1321 cacatgggtg aacactcaat ggtaactaa ttcttgggtg ttatctctat ctctccacc
1381 agattgtcag ctccctgagg gcaagagcca cagtataatt ccctgtttct tccacagtgc
1441 ctaataatac tgtggaacta ggttttaata atttttaat tgatgtgtt atgggcagga
1501 tggcaaccag accattgtct cagagcaggt gctggctctt tcttggctac tccatgttgg
1561 ctagcctctg gtaacctctt acttattatc ttcaggacac tctactacag gaccagggat
1621 gatgcaacat ccttgtcttt ttatgacagg atgtttgtct agcttctcca acaataagaa
1681 gcacgtggta aaacacttgc ggatattctg gactgttttt aaaaaatata cagtttaccg
1741 aaaatcatat aatcttaca tgaaaaggac ttatagatc agccagtgac caaccttttc
1801 ccaaccatac aaaaattcct ttcccgaag gaaaagggtt ttctcaataa gcctcagctt
1861 tctaagatct aacaagatag ccaccgagat cttatcgaa actcatttta ggcaaatatg
1921 agttttattg tccgtttact tgtttcagag ttgtattgt gattatcaat taccacacca
1981 tctcccatga agaaagggaa cgggtgaagta ctaagcgcta gaggaagcag ccaagtcggt
2041 tagtggaagc atgattggtg cccagttagc ctctgcagga tgtggaacc tcttccagg
2101 ggaggttcag tgaattgtgt aggagaggtt gtctgtggcc agaattttaa cctatactca
2161 ctttcccaaa ttgaatcact gctcacactg ctgatgattt agagtgtgt cgggtggaga
2221 tcccacccga acgtcttact taatcatgaa actccctagt tcttcatgt aacttccctg
2281 aaaaatctaa gtgtttcata aatttgagag tctgtgaccc acttaccttg catctcacag
2341 gtagacagta tataactaac aaccaagac tacatattgt cactgacaca cagttataa
2401 tcatttatca tatatataca tacatgcata cactctcaa gcaataaatt tttcacttca
2461 aaacagtatt gacttgata ccttgaatt tgaaatattt tctttgttaa aatagaatgg
2521 tatcaataaa tagaccatta atcag

```

//

```

LOCUS      AF002985      995 bp      mRNA      PRI      01-NOV-1997
DEFINITION Homo sapiens putative alpha chemokine (H174) mRNA, complete
cds.
ACCESSION  AF002985
NID        g2580585
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 995)
AUTHORS    Jacobs,K.A., Collins-Racie,L.A., Colbert,M., Duckett,M.,
            Golden-Fleet,M., Kelleher,K., Kriz,R., LaVallie,E.R.,
            Merberg,D.,
            Spaulding,V., Stover,J., Williamson,M.J. and McCoy,J.M.
TITLE      A genetic selection for isolating cDNAs encoding secreted
proteins
JOURNAL    Gene 198 (1-2), 289-296 (1997)
MEDLINE    98036061
REFERENCE  2 (bases 1 to 995)
AUTHORS    Jacobs,K.A., Collins-Racie,L.A., Colbert,M., Duckett,M.,
            Golden-Fleet,M., Kelleher,K., Kriz,R., LaVallie,E.R.,
            Merberg,D.,
            Spaulding,V., Stover,J., Williamson,M.J. and McCoy,J.M.
TITLE      Direct Submission
JOURNAL    Submitted (07-MAY-1997) Genetics Institute, 87 Cambridge Park
            Drive, Cambridge, MA 02140, USA
FEATURES   Location/Qualifiers
            source          1..995
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /cell_type="PHA and PMA activated human peripheral
blood
                        mononuclear cells"
            gene            1..995
                        /gene="H174"
            CDS              88..372
                        /gene="H174"
                        /codon_start=1
                        /product="putative alpha chemokine"

```


/db_xref="PID:g2580586"

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQVAD
IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIKKVERKNF"

BASE COUNT 382 a 170 c 194 g 249 t
ORIGIN
1 gaattcggcc aaaggagcct acttccaaga agagcagcaa agctgaagta gcagcaacag
61 caccagcagc aacagcaaaa aacaaacatg agtggtgaagg gcatggctat agccttggct
121 gtgatattgt gtgtctacagt tgttcaaggc ttcccatgt tcaaaagagg acgctgtctt
181 tgcataaggcc ctggggtaaa agcagtgaaa gtggcagata ttgagaaagc ctccataatg
241 tacccaagta acaactgtga caaaatagaa gtgattatta ccctgaaaga aaataaagga
301 caacgatgcc taaatcccaa atcgaagcaa gcaaggctta taatcaaaaa agttgaaaga
361 aagaattttt aaaaaatca aaacatatga agtcctggaa aagggcatct gaaaaacctt
421 gaacaagttt aactgtgact actgaaatga caagaattct acagtaggaa actgagactt
481 ttctatggtt ttgtgacttt caacttttgt acagttatgt gaaggatgaa aggtgggtga
541 aaggacccaa aacagaaata cagtcttctt gaatgaatga caatcagaat tccactgccc
601 aaaggagtc aacaattaaa tggatttcta ggaaaagcta ccttaagaaa ggctgggtac
661 catcggagtt tacaaagtgc ttacacgttc ttacttgttg tattatacat tcattgattt
721 ctaggctaga gaaccttcta gatttgatgc ttacaactat tctgttgga ctatgagaac
781 atttctgtct ctagaagtta tctgtctgta ttgatcttta tgctatatta ctatctgtgg
841 ttacagtggg gacattgaca ttattactgg agtcaagccc ttataagtca aaagcaccta
901 tgtgtcgtaa agcattcttc aaacatttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
961 aaaaaaaaaa aaaaaaaaaa aaaaaaagcg gccgc

//

LOCUS AF030514 1371 bp mRNA PRI 17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant precursor, mRNA, complete cds.
ACCESSION AF030514
NID g3219692
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1371)
AUTHORS Cole, K.E., Strick, C.A., Paradis, T.J., Ogborne, K.T., Loetscher, M., Gladue, R.P., Lin, W., Boyd, J.G., Moser, B., Wood, D.E., Sahagan, B.G. and Neote, K.
TITLE Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3
J. Exp. Med. 187 (12), 2009-2021 (1998)
MEDLINE 98290735
REFERENCE 2 (bases 1 to 1371)
AUTHORS Cole, K.E., Strick, C.A. and Sahagan, B.G.
TITLE Direct Submission
JOURNAL Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc., Eastern Point Road, Groton, CT 06340, USA
FEATURES
source Location/Qualifiers
1..1371
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="4"
/cell_type="astrocytes"
sig_peptide 70..132
CDS 70..354
/note="chemokine; I-TAC"
/codon_start=1
/product="interferon stimulated T-cell alpha chemoattractant precursor"
/db_xref="PID:g3219693"
/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQVAD
IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIKKVERKNF"
mat_peptide 133..351
/evidence=not_experimental

/product="interferon stimulated T-cell alpha
chemoattractant"

BASE COUNT	487 a	228 c	244 g	411 t	1 others
ORIGIN					
1	ctccttccaa	gaagagcagc	aaagctgaag	tagcagcaac	agcaccagca gcaacagcaa
61	aaaacaaaca	tgagtgtgaa	gggcatggct	atagccttgg	ctgtgatatt gtgtgctaca
121	gttgttcaag	gcttccccat	gttcaaaaaga	ggacgctgtc	tttgcatagg ccttggggta
181	aaagcagtga	aagtggcaga	tattgagaaa	gcctccataa	tgtaccaag taacaactgt
241	gacaaaatag	aagtgattat	tacctgaaa	gaaaataaag	gacaacgatg cctaaatccc
301	aaatcgaagc	aagcaaggct	tataatcaaa	aaagttgaaa	gaaagaattt ttaaaaaat
361	caaaacatat	gaagtcctgg	aaaagggcat	ctgaaaaacc	tagaacaagt ttaactgtga
421	ctactgaaat	gacaagaatt	ctacagtagg	aaactgagac	ttttctatgg ttttgtgact
481	ttcaactttt	gtacagttaa	gtgaaggatg	aaagtggtgt	gaaaggacca aaaacagaaa
541	tacagtcttc	ctgaatgaat	gacaatcaga	attccactgc	ccaaaggagt ccagcaatta
601	aatggatttc	taggaaaagc	taccttaaga	aaggctgggt	accatcggag ttacaaaagt
661	gcttttcacgt	tcttacttgt	tgtattatac	attcatgcat	ttctaggcta gagaaccttc
721	tagatttgat	gcttacaact	attctgttgt	gactatgaga	acatttctgt ctctagaagt
781	tatctgtctg	tattgatctt	tatgctatat	tactatctgt	ggttacagtg gagacattga
841	cattattact	ggagtcaagc	ccttataagt	caaaagcatc	tatgtgtcgt aaagcattcc
901	tcaaacattt	tttcatgcaa	atacacaytt	ctttccccaa	atatcatgta gcacatcaat
961	atgtagggaa	acattcttat	gcatcatttg	gtttgtttta	taaccaattc attaaatgta
1021	attcataaaa	tgtactatga	aaaaaattat	acgctatggg	atactggcaa cagtgcacat
1081	atttcataac	caaattagca	gcaccgggtc	taatttgatg	tttttcaact ttatttcatt
1141	gagatgtttt	gaagcaatta	ggatatgtgt	gtttactgta	cttttgtgtt tttatccgttt
1201	gtataaatga	tagcaatata	ttggacacat	ttgaaataca	aaatgttttt gtctacaaa
1261	gaaaaatgtt	gaaaaataag	caaatgtata	cctagcaatc	acttttactt tttgtaattc
1321	tgtctcttag	aaaaatacat	aatctaata	aaaaaaaaa	aaaaaaaaa a

//

LOCUS AF030514 1371 bp mRNA PRI 17-JUN-1998

DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant precursor, mRNA, complete cds.

ACCESSION AF030514

NID g3219692

KEYWORDS

SOURCE human.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1371)

AUTHORS Cole, K.E., Strick, C.A., Paradis, T.J., Ogborne, K.T., Loetscher, M., Gladue, R.P., Lin, W., Boyd, J.G., Moser, B., Wood, D.E., Sahagan, B.G. and Neote, K.

TITLE Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3

JOURNAL J. Exp. Med. 187 (12), 2009-2021 (1998)

MEDLINE 98290735

REFERENCE 2 (bases 1 to 1371)

AUTHORS Cole, K.E., Strick, C.A. and Sahagan, B.G.

TITLE Direct Submission

JOURNAL Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc., Eastern Point Road, Groton, CT 06340, USA

FEATURES

Location/Qualifiers

source 1..1371

/organism="Homo sapiens"

/db_xref="taxon:9606"

/chromosome="4"

/cell_type="astrocytes"

sig_peptide 70..132

CDS 70..354

/note="chemokine; I-TAC"

/codon_start=1

/product="interferon stimulated T-cell alpha chemoattractant precursor"

/db_xref="PID:g3219693"

/translation="MSVKGMALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQAD
IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIKKVERKNF"
mat_peptide 133..351
/evidence=not_experimental
/product="interferon stimulated T-cell alpha
chemoattractant"

BASE COUNT 487 a 228 c 244 g 411 t 1 others
ORIGIN
1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
121 gttgttcaag gcttcccat gttcaaaaaga ggacgctgtc tttgcatagg ccctggggta
181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtaccgaag taacaactgt
241 gacaaaatag aagtgtattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaatatt ttaaaaaatat
361 caaacatat gaagtcctgg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagtagg aaactgagac tttctatgg ttttgtgact
481 ttcaactttt gtacagttat gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
601 aatggatttc taggaaaagc taccttaaga aaggctgggt accatcggag tttacaaagt
661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc
721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
781 tatctgtctg tattgatctt tatgctatat tactatctgt ggttacagtg gagacattga
841 cattattact ggagtcaagc ccttataagt caaaagcatc tatgtgtcgt aaagcattcc
901 tcaaacattt tttcatgcaa atacacaytt ctttccccc aaatcatgta gcacatcaat
961 atgtaggga acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta
1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
1081 atttcataac caaattagca gcaccgtct taatttgatg tttttcaact tttattcatt
1141 gagatgtttt gaagcaatta ggatatgtgt gtttactgta cttttgtgtt tgatccgttt
1201 gtataaatga tagcaatcatt ttggacacat ttgaaataca aaatgttttt gtctaccaaa
1261 gaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
1321 tgtctcttag aaaaatacat aatctaataca aaaaaaaaaa aaaaaaaaaa a

//

LOCUS AF030514 1371 bp mRNA PRI 17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant
precursor, mRNA, complete cds.
ACCESSION AF030514
NID g3219692
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1371)
AUTHORS Cole, K.E., Strick, C.A., Paradis, T.J., Ogborne, K.T.,
Loetscher, M., Gladue, R.P., Lin, W., Boyd, J.G., Moser, B., Wood, D.E.,
Sahagan, B.G. and Neote, K.
TITLE Interferon-inducible T cell alpha chemoattractant (I-TAC): a
novel non-ELR CXC chemokine with potent activity on activated T cells
through selective high affinity binding to CXCR3
JOURNAL J. Exp. Med. 187 (12), 2009-2021 (1998)
MEDLINE 98290735
REFERENCE 2 (bases 1 to 1371)
AUTHORS Cole, K.E., Strick, C.A. and Sahagan, B.G.
TITLE Direct Submission
JOURNAL Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
Eastern Point Road, Groton, CT 06340, USA
FEATURES
source Location/Qualifiers
1..1371
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="4"
/cell_type="astrocytes"
sig_peptide 70..132
CDS 70..354
/note="chemokine; I-TAC"
/codon_start=1

```

/product="interferon stimulated T-cell alpha
chemoattractant precursor"
/db_xref="PID:g3219693"

/translation="MSVKGMALAVILCATVVQGFPMFKRGRLCIGPGVKAVKVAD
IEKASIMYPNNCDKIEVIIITLKENKGQRCCLNPKSKQARLIKKVERKNF"
mat_peptide 133..351
/evidence=not_experimental
/product="interferon stimulated T-cell alpha
chemoattractant"
BASE COUNT 487 a 228 c 244 g 411 t 1 others
ORIGIN
1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
121 gttgttcaag gcttcccat gttcaaaaga ggacgctgtc tttgcatagg ccttggggta
181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtacccaag taacaactgt
241 gacaaaatag. aagtgattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
361 caaacatat gaagtccctg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
481 ttcaactttt gtacagttat gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
601 aatggatttc taggaaaagc taccttaaga aaggctgggt accatcgag tttacaaagt
661 gctttcacgt tcttacttgt tgtattatac attcatgcac ttttaggcta gagaaccttc
721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
781 tatctgtctg tattgatctt tatgtctat tactatctgt ggttacagtg gagacattga
841 cattattact ggagtcaagc ccttataagt caaaagcatc tatgtgtcgt aaagcattcc
901 tcaaacattt tttcatgcaa atacacaytt ctttcccaa atatcatgta gcacatcaat
961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta
1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
1081 atttcataac caaattagca gcaccggtct taatttgatg tttttcaact tttattcatt
1141 gagatgtttt gaagcaatta ggatatgtgt gtttactgta ctttttgttt tgatccgttt
1201 gtataaatga tagcaatata ttggacacat ttgaaataca aaatgttttt gttaccacaa
1261 gaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
1321 tgtctcttag aaaaatacat aatctaata caaaaaaaaa aaaaaaaaaa a
//

LOCUS HSMDNCF 1560 bp RNA PRI 31-MAR-1995
DEFINITION Human mRNA for MDNCF (monocyte-derived neutrophil chemotactic
factor).
ACCESSION Y00787
NID g34518
KEYWORDS cytokine.
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1. (bases 1 to 1560)
AUTHORS Matsushima,K.
TITLE Direct Submission
JOURNAL Submitted (03-MAY-1988) Matsushima K., National Cancer
Institute,,
Bldg 560, Rm 31-19, Frederick, MD 21701
REFERENCE 2 (bases 1 to 1560)
AUTHORS Matsushima,K., Morishita,K., Yoshimura,T., Lavu,S.,
Kobayashi,Y.,
Lew,W., Appella,E., Kung,H.F., Leonard,E.J. and Oppenheim,J.J.
TITLE Molecular cloning of a human monocyte-derived neutrophil
chemotactic factor (MDNCF) and the induction of MDNCF mRNA by
interleukin 1 and tumor necrosis factor
J. Exp. Med. 167 (6), 1883-1893 (1988)
JOURNAL MEDLINE 88258376
COMMENT for overlapping sequence see M17016 - M17017.
FEATURES
source Location/Qualifiers
1..1560
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="monocyte"
/clone_lib="lambda gt10"
sig_peptide 102..182
/note="signal peptide (AA -27 to -1)"

```

```

CDS
102..401
/codon_start=1
/product="MDNCF precursor (AA -27 to 72)"
/db_xref="PID:g34519"
/db_xref="SWISS-PROT:P10145"

/translation="MTSKLAVALLAAFLISAALCEGAVLPRSAKELRCQCIKTYSKPF
HPKFIKELRVIESGPHCANTEIIIVKLSGRELCLDPKENWVQRVVEKFLKRAENS"
mat_peptide 183..398
/note="mat. MDNCF (AA 1 - 72)"
BASE COUNT 526 a 247 c 281 g 506 t
ORIGIN
1 cttcataagg cacaacttt cagagacagc agagcacaca agcttctagg acaagagcca
61 ggaagaaacc accggaagga accatctcac tgtgtgtaaa catgacttcc aagctggccc
121 tggctctctt ggcagccttc ctgatttctg cagctctgtg tgaagggtgca gttttgcca
181 ggagtgctaa agaacttaga tgtcagtgcg taaagacata ctccaaacct tccacccca
241 aatttatcaa agaactgaga gtgattgaga gtggaccaca ctgcgccaac acagaaatta
301 ttgtaaagct ttctgatgga agagagctct gtctggaccc caaggaaaac tgggtgcaga
361 ggggttggtg gaagtttttg aagagggctg agaattcata aaaaaattca ttctctgtg
421 tatccaagaa tcagtgaaga tgccagtga aactcaagca aatctacttc aacacttcat
481 gtattgtgtg ggtctgttgt agggttgcca gatgcaatc aagattctct gttaaatttg
541 aatttcagta aacaatgaat agtttttcat tgtaccatga aatatccaga acatacttat
601 atgtaaagta ttattttatt gaattctaca aaaacaacaa ataattttta aatataagga
661 ttttcctaga tattgcacgg gagaatatac aaatagcaaa attgggcca aaggccaagag
721 aatatccgaa ctttaatttc aggaattgaa tgggtttgct agaattgtat atttgaagca
781 tcacataaaa atgatgggac aataaatttt gccataaagt caaatttagc tggaaatcct
841 ggattttttt ctgttaaatc tggcaaccct agtctgctag ccaggatcca caagtctctg
901 ttccactgtg ccttggtttc tcctttattt ctaagtggaa aaagtattag ccaccatctt
961 acctcacagt gatgtgtgga ggacatgtgg aagcacttta agttttttca tcataacata
1021 aattattttc aagtgttaact tattaacctt tttattattt atgtatttat ttaagcatca
1081 aatattttgt caagaatttg gaaaaataga agatgaatca ttgattgaat agttataaag
1141 atgttatagt aaattttatt tatttttagat attaaatgat gttttattag ataaatttca
1201 atcagggttt ttagattaaa caaacaacaa attgggtacc cagttaaatt ttcatctcag
1261 atatacaaca aataattttt tagtataagt acattattgt ttatctgaaa ttttaattga
1321 actaacaatc ctagtttgat actcccagtc ttgtcattgc cagctgtgtt ggtagtgcgt
1381 tgttgaatta cggaataatg agttagaact attaaaacag ccaaaactcc acagtcaata
1441 ttgttaattt cttgctgtgt gaaacttggt tattatgtac aaatagattc ttataatatt
1501 atttaaatga ctgcattttt aaatacaagg ctttatattt ttaactttta aaaaaaccgg

```

```

//
LOCUS      HSINFGFR      1172 bp      RNA      PRI      21-MAR-1995
DEFINITION Human mRNA for gamma-interferon inducible early response gene
(with      homology to platelet proteins).
ACCESSION  X02530 M17752
NID        g33917
KEYWORDS   interferon response; signal peptide.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1172)
AUTHORS    Luster,A.D., Unkeless,J.C. and Ravetch,J.V.
TITLE      Gamma-interferon transcriptionally regulates an early-response
gene
            containing homology to platelet proteins
JOURNAL     Nature 315 (6021), 672-676 (1985)
MEDLINE     85240552
REFERENCE  2 (bases 1 to 1172)
AUTHORS     Luster,A.D.
TITLE      Direct Submission
JOURNAL     Submitted (29-JUL-1986) to the EMBL/GenBank/DBJ databases
COMMENT     Data kindly reviewed (29-JUL-1986) by Luster A.D.
FEATURES
            Location/Qualifiers
            source          1..1172
                        /organism="Homo sapiens"
                        /strain="(U 937 histiocytic lymphoma cell line)"
                        /db_xref="taxon:9606"
            misc_RNA        1
                        /note="cap site"

```

sig_peptide 67..129
 /note="pot. signal peptide (aa-21 to -1)"
 CDS 67..363
 /note="early response precursor polypeptide (aa-21 to 77)"
 /codon_start=1
 /db_xref="PID:g33918"
 /db_xref="SWISS-PROT:P02778"

/translation="MNQTALICCLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRS

LEKLEIIPASQFCPRVEIIATMKKKGEKRCINPESKAIKNLLKAVSKEMSKRSP"

mat_peptide 130..360
 /note="mature early response polypeptide (aa 1-77)"
 old_sequence 1138..1141
 /note="uga was uga in [1]"
 /citation=[1]
 old_sequence 1146..1148
 /note="caa was ca in [1]"
 /citation=[1]
 misc_feature 1155..1160
 /note="pot. polyA signal"
 polyA_site 1172
 /note="polyA site"

BASE COUNT 384 a 231 c 208 g 349 t
 ORIGIN

```

1 gagacattcc tcaattgctt agacatattc tgagcctaca gcagaggaac ctccagtctc
61 agcaccatga atcaaactgc gattctgatt tgctgcctta tctttctgac tctaagtggc
121 attcaaggag tacctctctc tagaaccgta cgctgtacct gcatacagcat tagtaatcaa
181 cctgttaatc caagggtctt agaaaaactt gaaattattc ctgcaagcca atttgtcca
241 cgtgttgaga tcattgctac aatgaaaaag aagggtgaga agagatgtct gaatccagaa
301 tcgaaggcca tcaagaattt actgaaagca gttagcaagg aaatgtctaa aagatctcct
361 taaaaccaga ggggagcaaa atcgatgcag tgcttccaag gatggaccac acagaggctg
421 cctctcccat cacttcccta catggagtat atgtcaagcc ataattgttc ttagtttgca
481 gttacactaa aagggtgacca atgatgggtc ccaaatcagc tgctactact cctgtaggaa
541 gggttaatgt catcatccta agctattcag taataactct accctggcac tataatgtaa
601 gctctactga ggtgctatgt tcttagtgga tgtctgacc ctgcttcaaa tattccctc
661 acctttccca tcttccaagg gtactaagga atctttctgc tttgggggtt atcagaattc
721 tcagaatctc aaataactaa aagggtatgca atcaaatctg ctttttaaa aatgctctt
781 acttcatgga ctccactgc catcctccca aggggcccac attctttcag tggctaccta
841 catacaattc caaacacata caggaaggta gaaatatctg aaatgtatg tgtaagtatt
901 cttatttaat gaaagactgt acaaggtata agtcttagat gtatatatt cctatatgt
961 tttcagtgt catggaataa catgtaatta agtactatgt atcaatgagt aacaggaaaa
1021 ttttaaaaat acagatagat atatgtcttg catgttacat aagataaatg tgctgaatgg
1081 ttttcaata aaaatgaggt actctcctgg aaatattaag aaagactatc taaatgttga
1141 aagatcaaaa ggttaataaa gtaattataa ct
  
```

//

LOCUS SYNRP4A 225 bp DNA SYN 15-JUN-1989
 DEFINITION Human recombinant platelet factor 4 (PF4) gene, complete cds.
 ACCESSION M20901
 NID g209285
 KEYWORDS platelet factor; platelet factor 4.
 SOURCE Synthetic oligonucleotide DNA, clone pIN-III-ompA-2.
 ORGANISM artificial sequence
 artificial sequence.
 REFERENCE 1 (bases 1 to 225)
 AUTHORS Barone,A.D., Ghrayeb,J., Hammerling,U., Zucker,M.B. and Thorbecke,G.J.
 TITLE The expression in Escherichia coli of recombinant human
 platelet factor 4, a protein with immunoregulatory activity
 JOURNAL J. Biol. Chem. 263, 8710-8715 (1988)
 MEDLINE 88243725
 FEATURES Location/Qualifiers
 source 1..225
 /organism="artificial sequence"
 /db_xref="taxon:29278"
 CDS <1..>225
 /note="recombinant platelet factor 4"
 /codon_start=2

```

/transl_table=11
/db_xref="PID:g209286"

/translation="ASMEAEDGDLQCLCVKTTSOVRPRHITSLEVIKAGPHCPTAQL
IATLKDGRKICLDLQAPLYKKIIKLLESGS"
BASE COUNT      59 a      59 c      51 g      56 t
ORIGIN          HindIII site.
      1 agcttctatg gaagctgaag aagacggtga cctgcagtgc ctgtgcgtta aaactacttc
     61 tcagggttcgt ccgcgtcata tcacttctct ggaagttatc aaagctggtc cgcattgccc
    121 gactgctcag ctgatcgcta ctctcaaaga cggtcgtaaa atctgcctgg acctgcaggc
    181 tccgctgtac aaaaaaatca tcaaaaaact gctggaatct ggatc
//

LOCUS          HUMGRO          1050 bp      mRNA          PRI          11-JUN-1993
DEFINITION      Human gro (growth regulated) gene.
ACCESSION      J03561
NID            gl83622
KEYWORDS        gro gene; tumor cell.
SOURCE          Human bladder tumor cell (T24) cDNA to mRNA.
ORGANISM        Homo sapiens
                Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
                Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 (bases 1 to 1050)
AUTHORS        Anisowicz,A., Bardwell,L. and Sager,R.
TITLE          Constitutive overexpression of a growth-regulated gene in
                transformed Chinese hamster and human cells
JOURNAL         Proc. Natl. Acad. Sci. U.S.A. 84, 7188-7192 (1987)
MEDLINE        88041072
COMMENT        Draft entry and computer-readable sequence kindly submitted by
                R.Sager (20-NOV-1987).
FEATURES        Location/Qualifiers
                source          1..1050
                                /organism="Homo sapiens"
                                /db_xref="taxon:9606"
                sig_peptide     54..140
                                /note="signal peptide (put.); putative"
                CDS             54..377
                                /note="gro protein"
                                /codon_start=1
                                /db_xref="PID:g306806"

/transl_table="MARAALSAAPSNPRLLRVALLLLLLVAAGRRAAGASVATELRQ
CLQTLQGIHPKNIQSVNVKSPGPHCAQTEVIATLKNGRKACLNPAPIVKKIIEKMLN
SDKSN"
mat_peptide     141..374
                /note="gro mature protein (put.); putative"
BASE COUNT      270 a      246 c      239 g      295 t
ORIGIN          52 bp upstream of NcoI site.
      1 ctgccagct cttccgtcc tctcacagcc gccagaccgc cctgctgagc cccatggccc
     61 gcgctgtct ctcgcgcgc cccagcaatc cccggctcct gcgagtggca ctgctgctcc
    121 tgctcctgt agccgctggc cggcgcgag caggagcgtc cgtggccact gaactgcgct
    181 gccagtgtt gcagaccctg cagggaattc accccaagaa catccaaagt gtgaacgtga
    241 agtcccccg accccactgc gcccaaaccg aagtcatagc cacactcaag aatgggcgga
    301 aagcttgct caatcctgca tcccccatag ttaagaaaat catcgaaaag atgctgaaca
    361 gtgacaaatc caactgacca gaagggagga ggaagctcac tgggtgctgt tcctgaagga
    421 ggccctgccc ttataggaac agaagaggaa agagagacac agctgcagag gccacctgga
    481 ttgtgcctaa tgtgtttgag catcgcttag gagaagtctt ctatttattt atttattcat
    541 tagttttgaa gattctatgt taatatttta ggtgtaaaat aattaagggg atgattaact
    601 ctacctgcac actgtcctat tatattcatt ctttttgaaa tgtcaacccc aagttagttc
    661 aatctggatt catatttaat ttgaaggtag aatgttttca aatgtttctc agtcattatg
    721 ttaatathtt tgaggagcct gcaacatgcc agccactgtg atagaggctg gcggatccaa
    781 gcaaatggcc aatgagatca ttgtgaaggc aggggaatgt atgtgcacat ctgttttgta
    841 actgtttaga tgaatgtcag ttgtatttta ttgaaatgat ttcaagtggt gtggtcaaca
    901 tttctcatgt tgaacttta agaactaaaa tgttctaaat atcccttgga cattttatgt
    961 ctttcttgta aggcatactg cttgttttaa tggtagtttt acagtgtttc tggcttagaa
   1021 caaaggggct taattattga tgttttcgga
//

LOCUS          HUMGROB5          1110 bp      mRNA          PRI          07-MAR-1995
DEFINITION      Human cytokine (GRO-beta) mRNA, complete cds.

```

ACCESSION M36820
 NID g183628
 KEYWORDS cytokine.
 SOURCE Human lymphocyte, cDNA to mRNA, clone GRO-beta.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1110)
 AUTHORS Haskill, S., Peace, A., Morris, J., Sporn, S.A., Anisowicz, A.,
 Lee, S.W., Smith, T., Martin, G., Ralph, P. and Sager, R.
 TITLE Identification of three related human GRO genes encoding
 cytokine functions
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
 MEDLINE 91017578
 COMMENT Draft entry and computer-readable sequence for [Proc. Natl.
 Acad. Sci. U.S.A. (1990) In press] kindly submitted
 by S.Haskill, 20-JUL-1990.
 FEATURES
 source Location/Qualifiers
 1..1110
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GRO-beta"
 /tissue_type="monocyte and lymphocyte"
 gene 75..398
 /gene="GRO-beta"
 CDS 75..398
 /gene="GRO-beta"
 /codon_start=1
 /product="cytokine gro-beta"
 /db_xref="PID:g183629"

/translation="MARATLSAAPSNPRLRLVALLLLLLVAASRRRAAGAPLATELRQC

CLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATLKNQKACLNPASPMVKKIIIEKMLK
 NGKSN"

BASE COUNT	300 a	247 c	247 g	316 t			
ORIGIN	1	gacagagccc	gggccacgga	gctccttgcc	agctctctc	ctcgcacagc	cgctcgaacc
	61	gcctgctgag	ccccatggcc	cgcgccacgc	tctccgccgc	ccccagcaat	ccccggctcc
	121	tgcgggtggc	gctgctgctc	ctgctcctgg	tggccgccag	ccggcgcgca	gcaggagcgc
	181	ccctggccac	tgaactgcgc	tgccagtgtc	tcagaccct	gcagggaatt	cacctcaaga
	241	acatccaaag	tgtgaagggtg	aagtcctccg	gacccactg	cgcccaaacc	gaagtcatag
	301	ccacactcaa	gaatgggcag	aaagcttgct	tcaacccgc	atcgcccatg	gttaagaaaa
	361	tcacgaaaaa	gatgctgaaa	aatggcaaat	ccaactgacc	agaaggagg	aggaagctta
	421	ttggtggctg	ttcctgaagg	aggccctgcc	ttacaggaac	agaagaggaa	agagagacac
	481	agctgcagag	gccacctggc	ttgcgcctaa	tgtgtttgag	catacttagg	agaagtcttc
	541	tatttattta	tttatttatt	tatttgtttg	ttttagaaga	ttctatgtta	atattttatg
	601	tgtaaaataa	ggttatgatt	gaatctactt	gcacactctc	ccattatatt	tattgtttat
	661	tttaggtcaa	acccaagtta	gttcaatcct	gattcatatt	taatttgaag	atagaaggtt
	721	tgcagatatt	ctctagtcac	ttgttaatat	ttcttcgtga	tgacatatca	catgtcagcc
	781	actgtgatag	aggctgagga	atccaagaaa	atggccagta	agatcaatgt	gacggcaggg
	841	aaatgtatgt	gtgtctatgt	tgtaactgta	aagatgaatg	tcagttgtta	tttattgaaa
	901	tgatttcaca	gtgtgtgggc	aacatttctc	atgttgaagc	tttaagaact	aaaatgttct
	961	aaatatccct	tggcatttta	tgtctttctt	gtaagatact	gccttgttta	atgttaatta
	1021	tgcagtggtt	ccctctgtgt	tagagcagag	aggtttcgat	atattattgat	gttttcacaa
	1081	agaacaggaa	aataaaatat	ttaaaaaatat			

//

LOCUS HUMGROG5 1064 bp mRNA PRI 07-MAR-1995
 DEFINITION Human cytokine (GRO-gamma) mRNA, complete cds.
 ACCESSION M36821
 NID g183632
 KEYWORDS cytokine.
 SOURCE Human lymphocyte, cDNA to mRNA, clone GRO-gamma.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1064)
 AUTHORS Haskill, S., Peace, A., Morris, J., Sporn, S.A., Anisowicz, A.,

TITLE Lee, S.W., Smith, T., Martin, G., Ralph, P. and Sager, R.
 cytokine Identification of three related human GRO genes encoding
 functions
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
 MEDLINE 91017578
 COMMENT Draft entry and computer-readable sequence for [Proc. Natl.
 Acad. Sci. U.S.A. (1990) In press] kindly submitted
 by S.Haskill, 20-JUL-1990.

FEATURES
 source Location/Qualifiers
 1..1064
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GRO-gamma"
 /tissue_type="lymphocyte and monocyte"
 gene 78..398
 /gene="GRO-gamma"
 CDS 78..398
 /gene="GRO-gamma"
 /codon_start=1
 /product="cytokine GRO-gamma"
 /db_xref="PID:g183633"

/translation="MAHATLSAAPSNPRLRLVALLLLLLVGSRRRAAGASVVTELRQCQ
 LQTLQGIHLKNIQSVNVRSPGPHCAQTEVIATLKNGKKACLNPASPMVQKIIIEKILNK
 GSTN"

BASE COUNT	281 a	237 c	239 g	305 t	2 others
ORIGIN	1	61	121	181	241
	cacagccggg	tcgcaggcac	ctccccngcc	agctctcccg	cattctgcac
	61	cgctctgct	gagcccatg	gcccacgcca	cgctctccgc
	121	tcctgcccgt	ggcgctgctg	ctcctgtctc	tggtgggag
	181	ccgtgggtcac	tgaactgcgc	tgccagtgtc	tgacagacact
	241	acatccaaag	tgtgaatgta	aggtcccccg	gaccccaactg
	301	ccacactcaa	gaatgggaag	aaagcttgct	tcaaccccg
	361	tcacgaaaa	gatactgaac	aaggggagca	ccaactgaca
	421	tcagcgtatc	attgacactt	cctgcagggt	ggctccctgcc
	481	aaaagagaac	agcagctttc	tagggacagc	tgaaaaggga
	541	cttacgagg	ttctacttat	ttatgtat	atttttgaaa
	601	catgctgtta	tttaaagatg	tgagtgtgtt	tcacaaaaca
	661	aattggaata	tgatgggttt	taaaatgtgtc	attaaactaa
	721	tgtgtcagcc	accttgataa	atgacagggt	ggggaactgg
	781	caagcaatta	gtggatcact	gttagggtaa	gggaatgtat
	841	cttttttttt	taaaaaagaa	tgtagttgt	tatttattca
	901	tcaacatttt	tatgctgaag	tttcccttag	acattttatg
	961	gccttggtta	atgtccattc	tgacgcgttt	ctctttccct
	1021	tactgttaca	tttgtacaaa	tgacatgata	ataaaagt

//

LOCUS HUMCTAP3 673 bp mRNA PRI 06-MAR-1995
 DEFINITION Human connective tissue activation peptide III mRNA, complete
 cds.
 ACCESSION M54995 M38441
 NID g181175
 KEYWORDS connective tissue activating peptide-III; platelet basic
 protein;
 thromboglobulin.
 SOURCE Human platelet, cDNA to mRNA, clone lambda-c[1,2].
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 673)
 AUTHORS Wenger, R.H., Wicki, A.N., Walz, A., Kieffer, N. and Clemetson, K.J.
 TITLE Cloning of cDNA coding for connective tissue activating peptide
 III
 from a human platelet-derived lambda gt11 expression library
 JOURNAL Blood 73 (6), 1498-1503 (1989)
 MEDLINE 89229374
 FEATURES
 source Location/Qualifiers
 1..673

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/tissue_type="platelet"
/clone="lambda-cl"
/cell_type="platelet"
/tissue_type="blood"
/tissue_lib="lambda-gt11"
/map="4p13-q21"
gene 67..453
sig_peptide 67..168
CDS 67..453
/translation="MSLRDTPSCNSARPLHALQVLLLLSLLLTALASSTKGQTKRN
LAKGKEESLSDLYAELRCMCIKTTSGIHPKNIQSLEVIGKTHCNQVEVIATLKDGR
mat_peptide 196..450
mat_peptide 208..450
polyA_site 673
BASE COUNT 202 a 149 c 139 g 183 t
ORIGIN
1 gggcaactca ccctcactca gaggtcttct ggttctggaa acaactctag ctccagcttc
61 tccaccatga gcctcagact tgataccacc ccttcctgta acagtgcgag accacttcat
121 gccttgacag tgctgctgct tctgtcattg ctgctgactg ctctggcttc ctccaccaa
181 ggacaaacta agagaaactt ggcgaaaggc aaaggaggaa gtctagacag tgacttgat
241 gctgaactcc gctgcatgtg tataaagaca acctctggaa ttcaccccaa aaacatccaa
301 agtttggaag tgatcgggaa aggaacccat tgcaaccaag tcgaagtgat agccacactg
361 aaggatggga ggaaaatctg cctggaccca gatgctccca gaatcaagaa aattgtacag
421 aaaaaattgg caggtgatga atctgctgat taattgttc tgtttctgcc aaacttcttt
481 aactcccagg aagggtagaa ttttgaaacc ttgattttct agagttctca ttatttcagg
541 atacctattc ttactgtatt aaaatttgga tatgtgttct attctgtctc aaaaatcaca
601 ttttattctg agaagggttg ttaaaagatg gcagaaagaa gatgaaaata aataagcctg
661 gtttcaaccc tct

```

```

//
LOCUS HUMENA78A 2177 bp DNA PRI 31-JAN-1996
DEFINITION Homo sapiens neutrophil-activating peptide 78 (ENA-78) gene,
complete cds.
ACCESSION L37036 246254
NID g607030
KEYWORDS ENA-78 gene; homologue; neutrophil-activating factor;
neutrophil-activating peptide 78.
SOURCE Homo sapiens DNA.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 2177)
AUTHORS Walz,A., Burgener,R., Car,B., Baggiolini,M., Kunkel,S.L. and
Strieter,R.M.
TITLE Structure and neutrophil-activating properties of a novel
inflammatory peptide (ENA-78) with homology to interleukin 8
J. Exp. Med. 174 (6), 1355-1362 (1991)
JOURNAL 92078844
MEDLINE
REFERENCE 2 (bases 1 to 2177)
AUTHORS Walz,A.

```

TITLE Direct Submission
 JOURNAL Submitted (14-OCT-1994) A. Walz, University of Bern, Theodor
 Kocher
 Institute, Freiestr. 1, Bern, Switzerland 3012
 REFERENCE 3 (bases 1 to 2177)
 AUTHORS Corbett, M.S., Schmitt, I., Riess, O. and Walz, A.
 TITLE Characterization of the gene for human neutrophil-activating
 peptide 78 (ENA-78)
 JOURNAL Biochem. Biophys. Res. Commun. 205 (1), 612-617 (1994)
 MEDLINE 95091791

FEATURES
 source Location/Qualifiers
 1..2177
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="lymphoblastoid cells"
 /clone="4H2, 178C11, 106C1"
 /chromosome="4"
 /clone_lib="Chromosome 4 cosmid library of Riess et

al.
 gene 539..1747
 /gene="ENA-78"
 CAAT_signal 539..547
 /gene="ENA-78"
 TATA_signal 675..681
 /gene="ENA-78"
 exon <803..911
 /gene="ENA-78"
 /number=1
 CDS join(803..911,1046..1178,1289..1372,1729..1747)
 /gene="ENA-78"
 /note="homologue to interleukin-8"
 /codon_start=1
 /product="neutrophil-activating peptide 78"
 /db_xref="PID:g607031"

/translation="MSLLSSRAARVPGPSSSLCALLVLLLLLTQPGPIASAGPAAAVL

RELRCVCLQTTQGVHPKMISNLQVFAIGPQCSKVEVVASLKNKGKEICLDPEAPFLKKV

intron IQKILDGGNKEN
 912..1045
 /gene="ENA-78"
 /number=1
 exon 1046..1178
 /gene="ENA-78"
 /number=2
 intron 1179..1288
 /gene="ENA-78"
 /number=2
 exon 1289..1372
 /gene="ENA-78"
 /number=3
 intron 1373..1728
 /gene="ENA-78"
 /number=3
 exon 1729..>1747
 /gene="ENA-78"
 /number=4

BASE COUNT 539 a 512 c 496 g 630 t
 ORIGIN

```

1 gaattctcag taagcggact taccaaagta ggtgatctgt aggggagtta acaaaattca
61 gtggtccttt caggccactg acttcaagtg gcaagagaca agggctctct gttatcatgt
121 tatcttggtt tccaaagctg gttgaagtcc agagattcat aaagtcattc aagaaaacct
181 gaatgacctg cctgcaagaa gacaggaagg actttcagtt tatagcaatt caaacatgaa
241 taacatttcc tgattaatag taataataat tagaaaggat tgactttcag aaatttttct
301 caaatcaagg ctctgtttac tttggttcca ccttttctct ctagaaggag aggaggagca
361 tctcccagat gctgcgtgct ccagaaaagc cggcatccct agcccgtctt ggcacaggcc
421 atgaggcgct gctgaatcct gctgaatagc tactcccttc tagctggagc cacagctccc
481 tccaccgcgg aacagggtta caacgtccct ctcggtagag gtgcacgcag ctctctctgg
541 ccaccctccc caccagtccc cattgtctgg ccccccctcc ccaacctctt ctttccacac
601 tgccccatga gttcaggga tttccccagc atcccaaagc ttgagtttcc tgtcagtggg
661 gagagatgag tgtagataaa aggagtgcag aaggaacgag gaagccacag tgctccggat

```

```

721 cctccaatct tcgtcctccc aatctccgct cctccacca gttcaggaac ccgcgaccgc
781 tcgcagcgct ctcttgacca ctatgagcct cctgtccagc cgcgcggccc gtgtccccgg
841 tccttcgagc tccttggtgcg cgctgttggt gctgctgctg ctgctgacgc agccagggcc
901 catcgccagc ggtgagagcg catggcgcg cggacgcact cgcactcggg cacagagggtg
961 catcccagcc tctgcggggt cgctgcgttc cagggaaactc tcccagcaac ctgcccctata
1021 aaggggtgtct ctctttcttc cccagctggt cctgcccgtg ctgtgttgag agagctgcgt
1081 tgcgtttgtt tacagaccac gcaaggagtt catcccaaaa tgatcagtaa tctgcaagtg
1141 ttgcgcatag gccacacagt cccaagggtg gaagtgtgtt aagtctgtg ctgctgtgtc
1201 cgctgtgacc ttggcaagag agaaatcccc cagcctgggt cttcaacctt ggtatctcat
1261 gagtgtatct tctttttctt tccttcagag cctccctgaa gaacgggaag gaaatttgtc
1321 ttgatccaga agcccttttt ctaaagaaag tcatccagaa aattttggac gggtagctgt
1381 cactttgatc tttgtggttt ctaaatctga tctagggaga ccatagactt cacaaggctt
1441 ttattctctg tacgatttaa gtaacacttt tcatgtttag aattaaaagg ttgttgtaatt
1501 gggaaagtgt ttctggattg tcctgggaaa atataccaat cttacatgta attacttgag
1561 caattacaca cagcttgatc ctaagttatg ttttttggtt acccattgct tttattgatt
1621 tttgtattct ccttttttac caaacatcat aaacgctgag ttttgacaag ggtggagtag
1681 aaaggagtgt gaaaaatggt taaactaata taacatTTTT ctcaacagtg gaaacaagga
1741 aaactgatta agagaaatga gcacgcattg aaaagtttcc cagtcttcag cagagaagtt
1801 ttctggaggt ctctgaaccc agggagagaa agaaggaaag attttgttgt tgtttgttta
1861 tttgtttttc cagtgttag cttcttctct ggattcctca ctttgaagag tgtgaggaaa
1921 acctatgttt gccgcttaag ctttcagctc agctaagtaa gtgtttagca tagtacctct
1981 gctatttgcg gttattttat ctgctatgct attgaagttt tggcaattga ctatagtgtg
2041 agccaggaaat cactggctgt taatctttca aagtgtcttg aattgtaggt gactattata
2101 tttccaagaa atattcctta agatattaac tgagaaggct gtggatttaa tgtggaaatg
2161 atgtttcata agaattc

```

//

LOCUS HSGCP2 254 bp RNA PRI 04-MAR-1997
 DEFINITION H.sapiens mRNA for granulocyte chemotactic protein.
 ACCESSION Y08770
 NID gl769436
 KEYWORDS cell surface receptor; CXC chemokine; GCP-2 gene; granulocyte chemotactic protein.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 254)
 AUTHORS Froyen,G., Proost,P., Ronsse,I., Mitera,T., Haelens,A., Wuyts,A.,
 TITLE Opdenakker,G., Van Damme,J. and Billiau,A.
 of Cloning, bacterial expression and biological characterization
 and recombinant human granulocyte chemotactic protein-2 and differential expression of granulocyte chemotactic protein-2
 epithelial cell-derived neutrophil activating peptide-78 mRNAs
 JOURNAL Eur. J. Biochem. 243 (3), 762-769 (1997)
 MEDLINE 97210779
 REFERENCE 2 (bases 1 to 254)
 AUTHORS Froyen,G.F.V.
 TITLE Direct Submission
 JOURNAL Submitted (10-OCT-1996) G.F.V. Froyen, Rega Institute,
 University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
 FEATURES
 source Location/Qualifiers
 1..254
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /haplotype="diploid"
 /tissue_type="embryonic"
 /rearranged
 /cell_type="fibroblast"
 /cell_line="E6SM (embryonic strain - skin and muscle)"
 gene 1..254
 /gene="GCP-2"
 exon <1..131
 /gene="GCP-2"
 /number=2
 CDS <1..234
 /gene="GCP-2"

```

/codon_start=1
/product="granulocyte chemotactic protein"
/db_xref="PID:e283124"
/db_xref="PID:g1769437"

/translation="GPVSAVLTELRCTCLRVTLRVNPKTIGKLQVFPAGPQCSKVEVV
              ASLKNGKQVCLDPEAPFLKKVIQKILDSGNKKN"
      exon      132..215
                /gene="GCP-2"
                /number=3
      exon      216..254
                /gene="GCP-2"
                /number=4
      3'UTR      235..254
                /gene="GCP-2"

BASE COUNT      66 a      64 c      70 g      54 t
ORIGIN
    1 ggtcctgtct ctgctgtgct cacggagctg cggtgcactt gtttacgcgt tacgctgaga
    61 gtaaacccca aaacgattgg taaactgcag gtgttccccg caggcccgca gtgctccaag
   121 gtggaagtgg tagcctccct gaagaacggg aagcaagttt gtctggacct ggaagccct
   181 tttctaaaga aagtcattca gaaaattttg gacagtggaa acaagaaaaa ctgagtaaca
   241 gtcgacgcgg ccgc

//

LOCUS      D63789      5669 bp      DNA      PRI      27-DEC-1996
DEFINITION Human DNA for SCM-1beta precursor, complete cds.
ACCESSION  D63789
NID        g1754608
KEYWORDS   SCM-1beta; SCM-1beta precursor.
SOURCE     Homo sapiens placenta DNA, clone:hg44.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (sites)
AUTHORS    Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
TITLE      Molecular cloning of a novel C or gamma type chemokine, SCM-1
JOURNAL    FEBS Lett. 360 (2), 155-159 (1995)
MEDLINE    95180438
REFERENCE  2 (sites)
AUTHORS    Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
Yaoi,T.    and Yoshie,O.
TITLE      Structure and expression of two highly related genes encoding
            SCM-1/human lymphotactin
JOURNAL    FEBS Lett. 395 (1), 82-88 (1996)
MEDLINE    97002294
REFERENCE  3 (bases 1 to 5669)
AUTHORS    Yoshida,T.
JOURNAL    Unpublished (1995)
REFERENCE  4 (bases 1 to 5669)
AUTHORS    Yoshida,T.
TITLE      Direct Submission
JOURNAL    Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
Tetsuya    Yoshida, Shionogi Institute for Medical Science; 2-5-1,
Mishima,   Settsu, Osaka 566, Japan (E-
            mail:teyoshid@fl.lab.shionogi.co.jp.
            Tel:06-382-2612, Fax:06-382-2598)
FEATURES   Location/Qualifiers
            source      1..5669
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="1"
                        /clone="hg44"
                        /map="1q23"
                        /tissue_type="placenta"
            TATA_signal  2154..2158
            exon         2197..2278

```

```

        /number=1
prim_transcript 2197..5349
gene            2218..5230
                /gene="SCM-1beta"
CDS             join(2218..2278,4075..4189,5062..5230)
                /gene="SCM-1beta"
                /codon_start=1
                /product="SCM-1beta precursor"
                /db_xref="PID:d1010504"
                /db_xref="PID:g1754609"

/translation="MRLILALLGICSLTAYIVEGVGSEVSHRRTCVSLTTQRLPVSR
IKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDVRSMDRKSNTNRNMIQTKPTGT
        intron      QQSTNTAVTLTG"
        2279..4074
        /gene="SCM-1beta"
        /number=1
        exon        4075..4189
        /gene="SCM-1beta"
        /number=2
mat_peptide      join(4077..4189,5062..5227)
        /gene="SCM-1beta"
        intron      4190..5061
        /gene="SCM-1beta"
        /number=2
        exon        5062..5349
        /number=3
BASE COUNT      1702 a   1058 c   1248 g   1661 t
ORIGIN
1  ggatccagga ggataacaag ggaatctect actctcaaag agtctgccat ctagtgggag
61  acgcaggaat gtaattgagt aggagaacac aatgagattc gttgcagaac agccatgaga
121 acagaacaaa gttctaagag agcataaagg ggtggcacia cttaatttta tcaaaaaaat
181 tcaggaaaac ttatacagag aggaggagtt tacaagtaac tatgtaggga gctgtcatgg
241 gtattccagt taaaggaaac atgtgaggag cataaagag gctggcccat tgggttggtc
301 gcacatgtat gtgtttgtta aggtttggga gtgtgtgagt gaatggtgga aggtgagctc
361 gaaaggaaag cagtactaga tcttgagcat tcttatatat cacaatgaaa gatttgaat
421 acatcctgta ggcattggaa gttagcaaaa gaggttctca gtagggaat ggcatgatta
481 gattgaggct ttacagtgat taccctggca aagctgcaga gaacagactg agaggaggcc
541 ctggtctggg taaccagtta gtccactgta atttgcctaa catttgagca gtgtggggag
601 aaaggaggac acatctcaaa ggactaccta gaaggtatac ttagtccagt ttggttgaga
661 atgacatgta ggtggatagc aatgagctca agatgatccc tatatatcag tatttggaaa
721 ttagatggaa gagaacacat tgctccatgc taaggactaa tatgaggaga agcagtttga
781 atagaagatg tgtccagtgt tcaaggagtg atttgcagc aaggtagaga tcattaaaga
841 gccagtttga agtttagaat gaagtctggg tgaaaaatca aatgcgatta gtgggaagtc
901 tcttagaggt taacctatac tttttatgaa aacataggaa tttattttca tattccctaa
961 tagcaaaagga cttttaacta cacatatatt taataaatac attttataga tacctatgta
1021 aaataaaagaa caaccaccac acaacaaact cagtggcaga aaagtctcag tgcaatcagt
1081 atattttaat tctactgggg gtattgcaaa tcaaatttac attttgggag actatattggc
1141 aatataataat aagagctata aagatgatca tatcattttt cccagtaatc ctactcctgg
1201 ttattaaagg gaagtaattc agtgatatatt aatgaaatcg acctatagt tctgatcttt
1261 ataataagtt ataagaaaat ggtttaactt gtatgtgtat atatttactc gaagtagaaa
1321 tatgaaggct aaaaaaatgg gaagatatatt aaattggtgt taaaacagca tttaaaatta
1381 ccacaattat gagaacacat gtatgccaat gcagattcac tggaaaaata ttgaaaatga
1441 aaactgtcag atggtaagat tataatttta tttctttttt aatttgaat aaattggtaa
1501 cagcacagct tttcaaaagc ttctataaat gtgtatgtta agttgtaata aagcaaacac
1561 atgcatgtaa gacatgctta aacagttatt taattgtttc ttgggtacct ggggagatgg
1621 ggtgaagaaa ggggggtgac ttgaatgaag gtggaggaga aaaaatgagaa ccaagaaagc
1681 aaaggatcga gaagctcagt gtggcagcag cctctcttcc cctcctgaga gactcaaagg
1741 gtggcatcag ggactcatga tccatggttg tggaaagcctc atgtcacact ggaatgcaca
1801 tgaggtggga tggaaacacag tgaccacccc acctcatttc ctttacagct tccgtggggg
1861 ccatggcagt gaacagcctt caggcatgtc tacgggtggaa gatctgaatt caggctgggtg
1921 gcaggagaca acacaaccac gttttctttt atgcatgcat ttggtttaat tgacacatta
1981 accacagaca aaggggtaaa ggccacaagg cgaataggtta gtatgaacag ggaaggggac
2041 attttttttt ttttaagaaa ataaaagcat cagtattgca aagactttcc atgatcctat
2101 acccacctcg aaagccccct ctcaccacag gaagtgcact gaccattgga ggcataaaag
2161 agatcctcaa agagcccgat cctcactctc cctgcacagc tcagcgggac ctcagccatg
2221 agacttctca tctgtgccct ccttggcatc tgcctcttca ctgcatacat tgtggaaggt
2281 aagtggagaa gctgtctgtg agataaagaa tagggaggca aggcaggtgg gcacacattt
2341 tgggtttgac tcgggttttg actggactaa actgctgtct ccaggggagc cttaaacttc
2401 ccatgtgcaa gaaaggaatg atgattttga ctgtagaggg cttcgtaaac ttccaaaaca

```

```

2461 gggagaattt gattagatc tgggctccta cttttcctaa ttgggtaatt tcaggtaaat
2521 tccttaacca ctcagggcct gtgcttattt atgtataaac tgaatagaat aagagacatg
2581 atcacctgag attaagatta aataaatatt atgggttatt taataacatc agatttcctt
2641 acaagcagta attttttgat taatgttagc tatggattag aggtgatgat tataaatgca
2701 tttgtagggt ttgcccattt aatatatagt ttgataaatt atcaaaatct tagagagttc
2761 agttacaata tggggatgca ccagaggatg tatgttcttg agcaaatcaa tgttttcaat
2821 acaaaacctg tgtgaaggcg acagtagtgc ttgctgtgga ctggatgtcc cagtcttgcc
2881 ttccttcccc ttgataatgc aataagggac ccccatTTta ggacgcagga caggcagaaa
2941 gataaccagc ttgatggggt ccacaccatg tgcaatcact accagctgag acttcttggt
3001 ttccagcaag gtggtgatga tgttaacccc tgctcaaaaga acaggtgatt tccttagtgg
3061 gacaacccct ttgctagcag ctttcttctc agcctgggcc aacagtctct gcttcttctc
3121 ttgctttgtc tctggtcagt acttgtggat cagcttaagt ggctgagtag ctgtttgggg
3181 gtctaaggct tgggtgaact ggtaaatggc agaaggcatt ttcagctgct tatagaggat
3241 agctctttgc agctggaacc agatatagcg gggccatttc acaaagcagt ggaggtctct
3301 tttgggctgg atgtcctgtc caatgcctgc ctaagaaaac tcttaggctt tttctcacac
3361 agcgggttca tcactttctt agcctcctgc ttcttcacga cggcagggac tggggcacct
3421 tctttccttt ggccttcttt cttttcagca tcttaggcag ctgacagaga gggaaatttg
3481 accatTTaaa aagggaaca cctttattta ctcagtcaaa agcatgcttc ctccctcac
3541 tgaatgttgc cttgcctaga gtactcttca cgcattactc tgtcatctca cttatggtac
3601 tgtaacatgt tgcactattt gaaatgatct tttctgtttg cctgtctgct gcctggctcc
3661 ctcatgagaa gatatgtctt atgaaaacag ggataatgtc tgtcttaata aaacatgtgg
3721 gacacaacag gcaccattgt ataaatgaat gaatgcgtgt cactggggca tttgctagcc
3781 gtcccaaatg tctaagtga aatatacaca gagacgggat aacatcttgt tatttctct
3841 cagcatgaaa ttcctgaaac aattctgttg attgagtttt taaattagtc aaattttac
3901 taagaatctg tgacgggcaa gagattcggg atgcctatca gtctctctct ccccaaaaaa
3961 gcaaatggcc ttatattctc acaacattct cagagtaatt taacagacga ttgttctctg
4021 gatctgggta attgtcttat ttttaattgt ctgttgtttt tttttctca tcagggtgag
4081 ggagtgaagt ctacatagg aggacctgtg tgagcctcac taccacgca ctgccagtta
4141 gcagaatcaa gacctacacc atcacggaag gctccttgag agcagtaatg tgagtctgcc
4201 tcctcagaag ttgggctggg tgggtaccta gaggtataga aatacactct atagaaatgc
4261 tgccatcctc aggaaaagta ggtcagcata gaggaacacc tcaacttaac caaaaacctc
4321 tttagttttc cttatcaacc atgtctttct gcagcccaac cgaatagcga ttattgcaga
4381 aattgggctg ccaaagaaag aatagaagtc ctctctattt tgtcttagtg gaagagtctg
4441 ttgaatactg tgcacagctc tgagatctgg gtttagagat ggctgggtca tgtcagggtt
4501 tccctgcaag cctcactgga gttgggggat cttagggttg agttaggcag agtcccatc
4561 tttatcagtt gccatatctt aagaaaatga gtcaatgcac aacctacatg gtccctttct
4621 tctaccagaa tctcattttt agaagtaata actcttccca atacatttg caagctttgc
4681 tctaaagaat gaaaatgtaa aaatcacctt tttaaaaaaa ataagatgag tattttcaaa
4741 tttgaaaagg aagaggttat ataataatgg aactagatgg cctcaaatgt ctttttgta
4801 caacatttgg tgacatggat gagaagaaag gctgtgaaat tatggtgaac aaaggggctg
4861 gatactactt gcagatatct ctcctttatg ttaaaataga tggcagaaga aggggtgctc
4921 tttatgatct catggctctg aaagactatt tcttgcaagta atttctgcac aagatctctt
4981 catgtctgcc ctgatcttaa ctcctgacce tgaggctttg agaactgctc taactctc
5041 tgtcttttcc ttgctgttaca gttttattac caaacgtggc ctaaaagtct gtgctgatcc
5101 acaagccacg tgggtgagag acgtggtcag gagcatggac aggaaatcca acaccagaaa
5161 taacatgacg cagaccaagc caacaggaac ccagcaatcg accaatagc cgtgacctt
5221 gactggctag tagtctctgg caccctgtcc gtctccagcc agccagctca tttcacttta
5281 caccctcatg gactgagatt atactcacct tttatgaaag cactgcatga ataaaattat
5341 tcttttgtat ttttactttt aaatgtcttc tgtattcact tatatgttct aattaataaa
5401 ttatttatta ttaagaatag ttccctagtc tattcattat atttagggaa aggtagtgtg
5461 tcattgttgt ttgatttctg acctgttacc tctctttgat ggtaaccata atggaagaga
5521 ttctgggctag tgtctatcag agtgaaaagc tatatcgatc actcttagag tccagcttgt
5581 aatggttctt tacacatcag tcacaagtta cagctgtgac aatggcaaca atttgagatc
5641 tatttcaact tgtctctata atagaattc

```

//

```

LOCUS      D63790          5660 bp      DNA          PRI          27-DEC-1996
DEFINITION Human DNA for SCM-1alpha precursor, complete cds.
ACCESSION  D63790
NID        G1754610
KEYWORDS   SCM-1alpha precursor; SCM-1 alpha.
SOURCE     Homo sapiens placenta DNA, clone:hg40.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (sites)
AUTHORS   Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
TITLE     Molecular cloning of a novel C or gamma type chemokine, SCM-1
JOURNAL   FEBS Lett. 360 (2), 155-159 (1995)

```

MEDLINE 95180438
REFERENCE 2 (sites)
AUTHORS Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
Yaoi,T.
and Yoshie,O.
TITLE Structure and expression of two highly related genes encoding
SCM-1/human lymphotactin
JOURNAL FEBS Lett. 395 (1), 82-88 (1996)
MEDLINE 97002294
REFERENCE 3 (bases 1 to 5660)
AUTHORS Yoshida,T.
JOURNAL Unpublished (1995)
REFERENCE 4 (bases 1 to 5660)
AUTHORS Yoshida,T.
TITLE Direct Submission
JOURNAL Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
Tetsuya
Yoshida, Shionogi Institute for Medical Science; 2-5-1,
Mishima, Settsu, Osaka 566, Japan (E-
mail:teyoshid@f1.lab.shionogi.co.jp,
Tel:06-382-2612, Fax:06-382-2598)
FEATURES Location/Qualifiers
source 1..5660
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="1"
/clone="hg40"
/map="1q23"
/tissue_type="placenta"
TATA_signal 640..644
exon 683..764
/number=1
prim_transcript 683..5340
CDS join(704..764,4064..4178,5053..5221)
/codon_start=1
/product="SCM-1alpha precursor"
/db_xref="PID:d1010505"
/db_xref="PID:g1754611"
/translation="MRLILALLGICSLTAYIVEGVGSEVSDKRTCVSLLTQRLPVSR
IKTYTITEGSLRAVIFITKRLKVCADPQATWVRDVRSMDRKSNTNRNMIQTKPTGT
QQSTNTAVTLTG"
intron 765..4063
/number=1
exon 4064..4178
/number=2
mat_peptide join(4066..4178,5053..5218)
/note="SCM-1alpha mature peptide"
intron 4179..5052
/number=2
exon 5053..5340
/number=3
BASE COUNT 1623 a 1139 c 1175 g 1723 t
ORIGIN
1 aagcttctat aaatgtgtat gtttaagttgt aataaagcaa acacatgcat gtagacatgc
61 ttaaaccagt atttaattgt ttcttgggta cctggggaga tgggggtgaag aaaggggggt
121 gacttgaaag aagggtggagg agaaaaatga gaaccaagaa agcaaaggat cgagaagctc
181 agtgtggcag cagctctctt cccctctctga gagagtcaaa ggggtggcatc agggactcat
241 gatccatggt tgtggaagcc tcatgtcaca ctggatgtca catgaggtgg gatggaacac
301 agtgaccacc ccacctcatt tcctttacag ctccgtggt gggccatggc agtgaacacc
361 ttcaggcatg tctacggcgg aatatctgaa ttcaggctgg tggcaggaga caacacaacc
421 acgttttctt ttatgcatgc atttgggtta attgacacat taaccacaga caaaggggta
481 aaggccacaa ggcgttaggt tagtatgaac agggaaaagg gacttttttt ttttttttta
541 agaaaaataa aagcatcagt attgcaaaaga ctttccatga tcctacaccc acctcgaaag
601 cccctctctc ccacaggaag tgcactgacc actggaggca taaaagaggt cctcaaagag
661 cccgatcctc actctccttg cacagctcag caggacctca gccatgagac ttctcatcct
721 ggccctcctt ggcattctgt ctctcactgc atacattgtg gaaggtaagt ggagaagctg
781 tctgtgagat aaagaacagg gaggcaaggc aggtgggcac acattttggg ttgactcag
841 gttatgactg gactaatctg ctttccccag gggagcctta aacttcccat gtgcaagaaa

901 ggaatgatga ttttgactgt agagggcttc gtaaaacttc aaaacaggga gaatttgatt
 961 agtatctggg ctcctacttt tcttaattgg gtaatttcag gtaatttcct taaccactca
 1021 gggcctgtgc ttattttatgt ataactgaat agtataacag acttgatcac ctgagattaa
 1081 gattaaataa atattatgggt ttattttaata acatcagatt tccttacaag cagtaatttt
 1141 ttgattaatg ttagctatgg attagaggtg atgattataa atgcatttgt aggttttggc
 1201 catttaatat atagtttgat aaattatcaa aatcttagag agttcagtta cgaatgtggg
 1261 atgcaccatt ggatgtatgt tctggagtaa atcaatgttt tcaatacaaa actaagcccc
 1321 aaatgactgg aagttcaaac cttcatgtcc agaaaatcaa tattaccttc aagtacgtgg
 1381 gggactctgt tagtaatgcc atgactatta ctattttatga gaaattttct gttttttaa
 1441 gagaacatac aataataact actaccaaag agatcagcac ctatacaca gttcaataaa
 1501 cctgcaagac acatccaggt aagattcaga tataccgagc ccttacctga gcattcagta
 1561 ggtattttct aaggattgat ttttctatg actggaggtg aatctgtcga ctattttgtg
 1621 ttctagttgg taggcttatt acttagacta tgatattata acttaataat ggggtcccaa
 1681 ggggttccat gaataaaggt ggctaagtct ggaagtcttt gaaattatgg ataaaaacaa
 1741 aaaatactga tgaacaacaa gagtttgatt actacattag gccacatgtt gctacgtggc
 1801 tggcattttt ctgagacaat gggcatacca tttaggggag actcagatct gagtagggga
 1861 aaggagctct ataagtecca ctgggtgctta gcttcttaca tacaataatg agggaaaaacg
 1921 gtctctgctt tgactcaatt ttgcaacctg agtgaaggtg atattttaaa aaataacaca
 1981 gacactcaaa cattgtctgac aataaggaaa aggtctttgt gtttcaagca taacaggatt
 2041 ccctgagctt taggagtecca ctccagatag ttccacagaga gaaatattgt ttcttaataa
 2101 tgagagaaac agagaaaaaa cccagatttt tctcttttca ttggctacag aaacaattca
 2161 ccactaaaaa taaattggca aaggtagagg atagcaatgt gcagactggc attgagagtg
 2221 aagaaatgat gaagaaaagc acacaatgaa cactctttgt ttagtccctt gctttaaaaa
 2281 atgccttctg atattagcaa cactacagac caatgttggc cattatcagt gggtacttta
 2341 gatgcttttt agctgcctat ttccctggga agcaaaagac agtgtctaca gctaaggaga
 2401 aaatcagcac ttgaaaaact ggatttagatt tcacccaacc cttaacagta ttaattctcc
 2461 caagttattt ttctctatgc aatgtttttt tgattctcta cacttaatag ttaattctct
 2521 ttgggcccatt actattgggg atgcataatt aagggtctgac ttctctttat atatatctta
 2581 cctttttacca tttaataatt ttttggagag tttttattat ttttatgtac agaaaaactca
 2641 acagtgtaca tttaacccag tttagtggca agttctcttg cctttgtctat ttccagcttg
 2701 gcattgtgag ccacagattt tggactcggg acattgcaga tctcatcata tccgtcatgt
 2761 taattttgtc tgatagcttc caccagctta gccaaagctc ctttgtcttc ctggttaact
 2821 tgtgtgaagg ccacagtggt gcttctcttg gactggatgt cccagctctt ccttcttacc
 2881 ccttgataat gcattaaagg acccccattt ttaggacaca ggacagacag aagtttaacc
 2941 agcttgatgg ggtccacacc atgtgcaata ccagctgagc cttctctctt tccagcaagg
 3001 tgggtgatag gttaaccctt gctcaaaaga cagggtgatt cctagtgagg acaacccttt
 3061 tgctagcagc ttcttcttca gcctgggcca acagtctctg cttcttctct tgcattgtct
 3121 ctggtcagta cttgtggatc agcttaagtg gctgagtagc tgtttggggg tctaaggctt
 3181 ggggtgaactg gttaattggca gaaggcactt tcagctgctt atagaggata gctctttgca
 3241 gctggaacca gatatagcgg ggccatttca caaagcagcg gaggtccctt ttgggctgga
 3301 tgtcctgtcc aatgcctgcc taagaaaact cttaggcctt ttctcacaca gcggtttcat
 3361 cactttctta gccctctgct tctcaccgac ggcagggctt ggggccactt tcttctctt
 3421 ggccatcttt cctttcagca tcttaggcag ctgacagaga gagacatttg accattttaa
 3481 aaggagaaca cctttattta gtctgtcaaa agcatgtctt cttccctcac tgaattgtgc
 3541 cttgcctaga gtactcttca cgcattactc tgtcttctca ctatgggtact gtaacatgtt
 3601 gcactatttg aaatgatctt ttctgtttgc ctgtctgctg cctggctcct tcatgagaga
 3661 gatattgctt atgaaaacag gagtaaatgt tgcttagtaa aacatgtggg acacaacagg
 3721 caccatttga taaatgaatg aatgcgtgtc actggggcat ttgctagccg tcccaaatgt
 3781 ctaagtgaat atatacacag agacgggata acatcttggt attttctctc agcatgaaat
 3841 tcttgaataa attctgttga ttgagttttt aaattagtca aatatttact aagaatctgt
 3901 gacgggcaag agattcggga tgccatcag tctctctctt ccccaaaaag caaatggcct
 3961 taaattctca caacattctc agagtaattt aacagatgat tgttctctgt atctggataa
 4021 ttgctttatt ttttaattgtc ttttctctac cagggtgtag gagtgaagtc
 4081 tcagataaga ggacctgtgt gagcctcact acccagcgac tgccgggttag cagaatcaag
 4141 acctacacca tcacggaagg ctctttaga gcagtaatgt gagtctgctt cctcagaagt
 4201 tgtgctgggt ggggtatctag aagtatagaa atacactctg tagaaatgct gccgtctca
 4261 ggaaaagtag gtcagcatag aggaacacct caacttaacc aaaaacctct ttagttttcc
 4321 ttatcaatca tgtctttctg cagcccaacc gaatagcgat tattgcagaa attgggctgc
 4381 caaagaaaga atagaagtcc tctcttattt agcttagtgg aagagtctgt tgaatactgt
 4441 gcacagctct gagacctggg tttagagatg actggcccat gtcagggttt ccttgcaagc
 4501 ctactggag ttgggggagc ttagggttga gtcaggcaga gtccctactt ctaccagaat
 4561 gccatatttc aagaaaatga gtcaatgcac aacctacatg gtccctctct ctctaaaaaa
 4621 ctcattttta gaagttaata actcttctca acatgtaatt gcaagcttta cttctaaaaa
 4681 tgaataatgta aaaatcactt ttatttttaa aaataagatg aatattttta aatttgaaaa
 4741 ggaagaggtt atgtaataat ggaactagtt ggccctcaag tcttttttgt acaacatttg
 4801 gtgacatgga tgagaaaagg accctgtgaa ttattgtgaa caaaggggct ggatactact
 4861 tgcatgattt actcctttat gttaaaatag atggcagaag aagggtactc atttatgatc
 4921 tcatggctct gaaagactat ttcttgcagt aatttctgca caagatctct tcatgtctgc
 4981 cctgatctta actcctgacc ctgaggcttt gagaatgtgg ctaactctgt ctgtcttttc
 5041 cttgcgttac agttttatta ccaaactgtg cctaaaagtc tgtgctgac cacaagccac
 5101 atgggtgaga gacgtggtca ggagcatgga caggaaatcc aacaccagaa ataactgat

```

5161 ccagaccaag ccaacaggaa cccagcaatc gaccaataga gctgtgactc tgactggcta
5221 gtagtctctg gcaccctgtc cgtctccagc cagccagctc atttcacttt acacgctcat
5281 ggactgagtt tatactcacc ttttatgaaa gcactgcatg aataaaatta ttcctttgta
5341 tttttacttt taaatgtctt ctgtattcac ttatatgttc taattaataa attatttatt
5401 attaagaata gttccctagt ctattcatta tatttaggga aaggtagtgt atcattgttg
5461 ttgatttctt gaccttgtag ctctctttga tggtaacatc aatggaagag attctggcta
5521 gtgtctatca gaggtgaaa gctatatcaat ctctcttaga gtccagcttg taatgggtct
5581 ttacacatca gtcacaagtt acagctgtga caatggcaac aatttgagat gtatttcaac
5641 ttgtctctat aatagaattc

```

//

```

LOCUS      HSU91835      1635 bp      mRNA      PRI      21-MAR-1997
DEFINITION Human CX3C chemokine precursor, mRNA, alternatively spliced,
complete cds.
ACCESSION  U91835
NID        g1899258
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1635)
AUTHORS    Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Soo,K., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
TITLE      A new class of membrane-bound chemokine with a CX3C motif
JOURNAL    Nature 385 (6617), 640-644 (1997)
MEDLINE    97177111
REFERENCE  2 (bases 1 to 1635)
AUTHORS    Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
TITLE      Direct Submission
JOURNAL    Submitted (03-MAR-1997) Molecular Biology, DNAX Research
Institute,
            901 California Ave., Palo Alto, CA 94304-1104, USA
FEATURES   Location/Qualifiers
            source          1..1635
                                /organism="Homo sapiens"
                                /db_xref="taxon:9606"
            CDS              80..1273
                                /note="membrane-tethered chemokine module"
                                /codon_start=1
                                /product="CX3C chemokine precursor"
                                /db_xref="PID:g1899259"
            /translation="MAPISLSWLLRLATFCHLTVLLAGQHHGVTKCNITCSKMTSKIP
            VALLIHYQONQASCGKRAIILETRQHRLFCADPKEQWVKDAMQHLDRQAAALTRNGGT
            FEKQIGEVKPRTPPAAGGMDESUVLEPEATGESSSLEPTPSSQEAQRALGTSPELPTG
            VTGSSGTRLPPTPKAQDGGFVGTELFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEA
            PSTQDPSTQASTASSPAPEENAPSEGQRVWGQGQSPRPENSLEREEMGPVPAHTDAFQ
            DWGPGSMAHVSVPVSSEGTPSREPVASGSWTPKAEPIHATMDPQRLGVLITPVPDA
            QAATRRQAVGLLAFLLFCLGVAMFTYQSLQGCPRKMAGEMAEGRLYIPRSCGSNSY
            VLPV"
            sig_peptide       80..151
            mat_peptide       152..1270
                                /product="CX3C chemokine"
            misc_feature       152..379
                                /note="encodes chemokine module"
            misc_feature       380..1102
                                /note="encodes glycosylation stalk"
            misc_feature       1103..1159
                                /note="encodes transmembrane helix"
            misc_feature       1160..1270
                                /note="encodes intracellular domain"
            3'UTR             1274..1635
                                /note="alternatively spliced; long transcript can be

```

found

in GenBank Accession Number U84487

BASE COUNT 338 a 544 c 464 g 289 t

ORIGIN

```

1  ggcacgaggg cactgagctc tgcgcctgg ctctagccgc ctgcctggcc cccgcccggga
61 ctcttgccca cctcagcca tggctccgat atctctgtcg tggctgctcc gcttggccac
121 ctcttgccat ctgactgtcc tgctggctgg acagcaccac ggtgtgacga aatgcaacat
181 caggtgcagc aagatgacat caaagatacc tgtagctttg ctcatccact atcaacagaa
241 ccaggcatca tgcggcaaac gcgcaatcat cttggagacg agacagcaca ggcgtgtctg
301 tgcgcacccg aaggagcaat gggtaagga cgcgatgcag catctggacc gccaggctgc
361 tgcctaact cgaaatggcg gcaccttcga gaagcagatc ggcgaggtga agcccaggac
421 caccctgcc gccgggggaa tggacgagtc tgtggtcctg gagcccgaag ccacaggcga
481 aagcagtagc ctggagccga ctcttcttcc ccaggaagca cagagggccc tggggacctc
541 cccagagctg ccgacgggag tgactggttc ctcagggacc aggcctcccc cgacgcaaaa
601 ggtcaggat ggagggcctg tgggcacgga gcttttcga gtgcctccc tctccactgc
661 cgccacgtgg cagagtctg ctccccacca acctgggccc agcctctggg ctgaggcaaa
721 gacctctgag gcccctgcca cccaggaccc ctccaccagc gcctccactg cgtcctcccc
781 agccccagag gagaatgctc cgtctgaagg ccagcgtgtg tggggtcagg gacagagccc
841 caggccagag aactctctgg agcgggagga gatgggtccc gtgccagcgc acacggatgc
901 cttccaggac tgggggcctg gcagcatggc ccacgtctct gtggtccctg tctcctcaga
961 agggaccccc agcaggggag cagtggcttc aggcagctgg acccctaagg ctgaggaacc
1021 catccatgcc accatggacc cccagaggct gggcgctcct atcactcctg tccctgacgc
1081 ccaggctgcc acccggaggc aggcgtgggg gctgctggcc ttcttggcc tcctctctg
1141 cctgggggtg gccatgttca cctaccagag cctccagggc tggcctcgaa agatggcagg
1201 agagatggcg gagggccttc gctacatccc ccggagctgt ggtagtaatt catatgtcct
1261 ggtgcccgtg tgaactctc tggcctgtgt ctagtgttt gattcagaca gctgcctggg
1321 atccctcatc ctcatacca cccccaccca agggcctggc ctgagctggg atgattggag
1381 gggggagggt ggatcctcca ggtgcacaag ctccaagctc ccaggcattc cccaggaggc
1441 cagccttgac cattctccac cttccaggga cagagggggt ggctctccaa ctaccccag
1501 ccccaaaact ctctctgct gctggctggt tagaggttcc ctttgacgcc atcccagccc
1561 caatgaacaa ttatttatta aatgccagc cccttctgaa aaaaaaaaaa aaaaaaaaaa
1621 aaaaaaaaaa aaaaa

```

//

LOCUS HSU84487 3310 bp mRNA PRI 15-MAR-1997

DEFINITION Human CX3C chemokine precursor, mRNA, alternatively spliced, complete cds.

ACCESSION U84487

NID g1888522

KEYWORDS

SOURCE human.

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 3310)

AUTHORS Bazan, J.F., Bacon, K.B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D.R., Zlotnik, A. and Schall, T.J.

TITLE A new class of membrane-bound chemokine with a CX3C motif

JOURNAL Nature 385 (6617), 640-644 (1997)

MEDLINE 97177111

REFERENCE 2 (bases 1 to 3310)

AUTHORS Bazan, J.F., Bacon, K.B., Hardiman, G., Wang, W., Rossi, D., Greaves, D.R., Zlotnik, A. and Schall, T.J.

TITLE Direct Submission

JOURNAL Submitted (07-JAN-1997) Molecular Biology, DNAX Research Institute,

901 California Ave., Palo Alto, CA 94304-1104, USA

FEATURES

source Location/Qualifiers

1..3310

/organism="Homo sapiens"

/db_xref="taxon:9606"

CDS 80..1273

/note="membrane-tethered chemokine module"

/codon_start=1

/product="CX3C chemokine precursor"

/db_xref="PID:g1888523"

/translation="MAPISLSWLLRLATFCHLTVLLAGQHGVTKCNITCSKMTSKIP

VALLIHYQQNQASCGKRAIILETRQHLRFCDPKEQWVKDAMQHLDRQAAALTRNGGT

FEKQIGEVKPRTPPAAGGMDESVVLEPEATGESSLSLEPTSSQEAQRALGTSPELPTG
 VTGSSGTRLPTPKAQDGGPVGTFLFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEA
 PSTQDPSTQASTASSPAPEENAPSEGQRVWGQGSPPRPNLSLÈREEMGPVPAHTDAFQ
 DWGPGSMAHVSVPVSSEGTSPREPASGSWTPKAEPIHATMDPQRLGVLITPVPDA

QAATRRQAVGLLAFLGLLFLGLVAMFTYQSLQGCPRKMAGEMAEGRLYIPRSCGSNSY

VLVPV"
 sig_peptide 80..151
 mat_peptide 152..1270
 /product="CX3C chemokine"
 misc_feature 152..379
 /note="encodes chemokine module"
 misc_feature 380..1102
 /note="encodes glycosylation stalk"
 misc_feature 1103..1159
 /note="encodes transmembrane helix"
 misc_feature 1160..1270
 /note="encodes intracellular domain"
 3'UTR 1274..3310
 /note="alternatively spliced; short transcript

deposited

as GenBank Accession Number U91835*

BASE COUNT 659 a 1051 c 916 g 682 t 2 others

ORIGIN

```

1  ggacagaggg cactgagctc tgccgcctgg ctctagccgc ctgectggcc cccgccggga
61  ctcttgccca cctcagcca tggtccgat atctctgtcg tggctgctcc gcttggccac
121  cttctgccat ctgactgtcc tgctggctgg acagaccac ggtgtgacga aatgcaacat
181  cacgtgcagc aagatgacat caaagatacc tgtagctttg ctcactcact atcaacagaa
241  ccaggcatca tgcggcaaac gcgcaatcat cttggagacg agacagcaca ggctgttctg
301  tgccgaccgg aaggagcaat ggtcaagga cgcgatgcag catctggacc gccaggctgc
361  tgccctaact cgaaatggcg gcaccttcga gaagcagatc ggcgagggtg agcccaggac
421  caccctgcc gccgggggaa tggacgagtc tgtggtcctg gagccgaag ccacaggcga
481  aagcagtagc ctggagccga ctccctcttc ccaggaagca cagagggccc tggggacctc
541  cccagagctg ccgacggggc tgactggttc ctacgggacc aggtcccccc cgacgcaaaa
601  ggctcaggat ggagggcctg tgggcacgga gcttttcga gtgctcccc tctccactgc
661  cgccacgtgg cagagtcttg ctccccacca acctgggccc agcctctggg ctgaggcaaa
721  gacctctgag gccccgtcca ccaggagccc ctccaccag gcctccactg cgtcctcccc
781  agccccagag gagaatgtc ctctgaagg ccagcgtgtg tggggtcagg gacagagccc
841  caggccagag aactctctgg agcgggagga gatgggtccc gtgccagcgc acacggatgc
901  cttccaggag tgggggcctg gcagcatggc ccacgtctct gtggtccctg tctcctcaga
961  agggaccccc agcaggagag cagtggcttc aggcagctgg acccctaagg ctgaggaaac
1021  catccatgcc accatggacc ccagaggct gggcgctcct atcactctcg tccctgacgc
1081  ccaggctgcc acccgaggag agcggtggg gctgctggcc ttccttggcc tctctctctg
1141  ctggggggtg gccatgttca cctaccagag cctccagggc tgccctcgaa agatggcagg
1201  agagatggcg gagggccttc gctacatccc ccggagctgt ggtagtaatt catatgtcct
1261  ggtgcccgtg tgaactcctc tggcctgtgt ctagtgtgtt gattcagaca gctgcctggg
1321  atccctcatc ctcataccca cccccacca agggcctggc ctgagctggg atgattggag
1381  gggggagggt ggatcctcca ggtgcacaag ctccaagctc ccaggcattc ccaggaggc
1441  cagccttgac cattctccac ctccaggga cagaggggtt ggcctcccaa ctcaccagag
1501  ccccaaaact ctctctgtgt gctggctggt tagaggttcc ctttgacgcc atcccagccc
1561  caatgaacaa ttatttatta aatgcccagc cccttctgac ccagtctgcc ctgtgagtac
1621  tacagtcttc ccattctaca catgagcatc aggccaggcc ctctgccac tccctgcaac
1681  ctgatttgtt ctcttggttc tgctgcagtt gccagtcacc ccggccacct gcggtgctat
1741  ctccccagc cccatcctct gtacagagcc cagccccca ctggtgacat gtctttctct
1801  gcatgaggct agtgtgtgt ttcttgggca ctgcttcag tgaggctctg cccttgggta
1861  ggsatttgtg gaaggggaga taagggtatc tggtagcttt cctctttggt ctacactgtg
1921  ctgagtctga aggtgggtt ctgaccttag ttccaccatc aagccacca cactactcca
1981  tctgtgaaag gaaagaggga ggtaaggaa acctgtcccc ctgacaacac tcattgacct
2041  gaggcccttc tctccagccc ctggatgcag cctcacagtc cttaccagca gagcacctta
2101  gacagtcctt gccaatggac taactgtct ttggacctg agggccagag ggctgcarg
2161  ggagtgagtt gatagcacag acctgcccct gtggggcccc aaatggaaat gggcagagca
2221  gagaccatcc ctgaaggccc cggccaggct tagtcaactg gacagcccg gctctgcttc
2281  ccatacccg ctaagaggga gggagggtc cagacacatg tccaagaagc ccaggaaagg
2341  ctccaggagc agccacattc ctgatgcttc ttcagagact cctgcaggca gccaggccac
2401  aagacccttg tgggtcccac ccacacacgc cagattcttt cctgaggctg ggctcccttc
2461  ccacctctct cactccttga aaacactgtt ctctgcccct caagaccttc tcttccactc
2521  ttgtccccac cgcagacagg accaggggat ttccatgatg ttttccatga gtccccctgt
2581  tgtttctgaa agggacgcta cccgggaagg gggctgggac atgggaaagg ggaagtgtga

```

```

2641 ggcataaagt caggggttcc ctttttttggc tgctgaaggc tcgagcatgc ctggatgggg
2701 ctgcaccggc tggcctggcc cctcagggtc cctgggtggc gctcacctct cccttggatt
2761 gtccccgacc cttgccgtct acctgagggg cctcttatgg gctgggttct acccaggtgc
2821 taggaacact ccttcacaga tgggtgcttg gaggaaggaa acccagctct ggtccataga
2881 gagcaaaacg ctgtgctgcc ctgcccaccc tggcctctgc actcccctgc tgggtgtggc
2941 gcagcatatt caggaagctc agggccctgg ctccaggtgg gtactctgg cagctcagag
3001 aggggtgggag tgggtccaat gcactttgtt ctggctcttc caggctggga gaggctttca
3061 ggggtgggac accctgtgat ggggccctgc ctcccttctg aggaagccgc tggggccagt
3121 tgggtccctt tccatggact ttgttagttt ctccaagcag gacatggaca aggatgatct
3181 aggaagactt tggaaagagt aggaagactt tggaaagact ttccaaccc tcatcacaa
3241 cgtctgtgcc attttgtatt ttactaataa aattttaaag tcttgtgaaa aaaaaaaaaa
3301 aaaaaaaaaa

```

//

```

LOCUS      HSU91746      1430 bp      mRNA      PRI      12-MAR-1998
DEFINITION Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
cds.
ACCESSION  U91746
NID        g2581780
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Identification of a novel human CC chemokine upregulated by IL-
10
JOURNAL    Blood (1998) In press
REFERENCE  2 (bases 1 to 1430)
AUTHORS     Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL    Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source          1..1430
                               /organism="Homo sapiens"
                               /db_xref="taxon:9606"
                               /chromosome="17"
            gene            1..1430
                               /gene="HCC-4"
            CDS              1..363
                               /gene="HCC-4"
                               /note="CC or beta chemokine family member"
                               /codon_start=1
                               /product="IL-10-inducible chemokine"
                               /db_xref="PID:g2581781"

```

/translation="MKVSEAAALLVLILIIITSASRSQPKVPEWVNTFSTCCLKYYEK

VLPRRLVVG YRKALNCHLP AIFVTKRNREVCTNPNDWVQ EYIKDPNLP LPLPTRNLS
TVKIITAKNGQPOLLNSQ"

BASE COUNT 401 a 351 c 293 g 385 t
ORIGIN

```

1 atgaaggtct cagaggtgc cctgtctctc cttgtctctc tccttatcat tacttcggct
61 tctcgcagcc agccaaaagt tcctgagtggt gtgaacaccc catccacctg ctgcctgaag
121 tattatgaga aagtgttgcc aaggagacta gtggtgggat acagaaaggc cctcaactgt
181 cacctgccag caatcatctt cgtcaccaag aggaaccgag aagtctgcac caaccccaat
241 gacgactggg tccaagagta catcaaggat cccaacctac cttgtctgcc taccaggaac
301 ttgtccacgg ttaaaattat tacagcaaag aatggtcaac cccagctcct caactccag
361 tgatgaccag gcttttagtg aagcccttgt ttacagaaga gaggggtaaa cctatgaaaa
421 caggggaagc cttattagc tgaaactagc cagtcacatt gagagaagca gaacaatgat
481 caaaataaag gagaagtatt tcgaatattt tctcaatctt aggaggaaat accaaagtta
541 agggacgtgg gcagaggtac gctcttttat ttttatattt atatttttat ttttttgaga
601 taggtcttac tctgtcacc aggtggagt gcagtgggtg gatcttggct cacttgatct
661 tggctcactg taacctccac ctcccaggct caagtgatcc tcccccca gcctcccgag
721 tagctgggac tacaggcttg cgccaccaca cctggctaatt tttgtattt ttggtagaga
781 cgggattcta ccatgttgcc caggctggte tcaaactcgt gtgcccgaag aatccacctg
841 cctcagcctt ccaaaagtgc tgggattaca ggcgtgagcc accacatccg gccagtgac
901 tcttaataca cagaaaaata tatttcacat ccttctcctg ctctctttca attcctcact

```

961 tcacaccagt acacaagcca ttctaataac ttagccagtt tccagccttc cagatgatct
1021 ttgccctctg ggtcttgacc cattaagagc cccatagaac tcttgatttt tctgtccat
1081 ctttatggat tttctggat ctataatttc ttcaattatt ctttcatttt ataatgcaac
1141 tttttcatag gaagtcgga tgggaatatt cacattaatc attttgcag agactttgct
1201 agatcctctc atattttgtc ttctcaggg tggcaggggt acagagagt cctgattgga
1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
1321 ccatgttaag ctttgcagga cagggaaaga aagggtatga gacacggcta ggggtaaact
1381 cttagtccaa aaccaagca tgcaataaat aaaactcct tatttgacaa

//

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

A. CLASSIFICATION OF SUBJECT MATTER

IPC(b) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,141, 867 A (IVANOFF et al.) 25 August 1992, see entire document.	22-32, 45-55
A	ENG et al. The Stimulatory Effects of Interleukin (IL)-12 On Hematopoiesis Are Antagonized by IL-12-induced Interferon γ In Vivo. J. Exp. Med. May 1995, Vol.181, pages 1893-1898, see entire document.	1-21, 33-44
A	ORANGE et al. Mechanism of Interleukin 12-mediated Toxicities during Experimental Viral Infections: Role of Tumor Necrosis Factor and Glucocorticoids. J. Exp. Med. March 1995, Vol.181, pages 901-914, see entire document.	1-21, 33-44

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

25 MARCH 1999

Date of mailing of the international search report

15 APR 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PREMA MERTZ

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WU et al. Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System. The Journal of Biological Chemistry. 05 April 1987, Vol.252, No. 10, pages 4429-4432, see entire document.	22-32, 45-55

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07K 14/47, 14/52; C12N 15/12, 15/19, 15/63; A61K 38/16, 38/19, 48/00

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAN ONLINE, MEDLINE, CAPLUS

search terms: chemokine, vaccination, immunogenic, antigen, HIV, efficacy, macrophage-derived chemokine, stromal cell-derived factor, monocyte chemotactic protein, composition, administration

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claims 1-21, 33-44, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto.

Group II, claims 22-32, 45-55, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering nucleic acid sequences encoding one or more antigens and nucleic acid sequences encoding one or more chemokines.

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product and method, a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto. Further pursuant to 37

C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.